Corrected on Mar 3, 2022.

Source: the publisher, via Crossref · checked Oct 21, 2026 · Read the notice

Designer drugs: mechanism of action and adverse effects

Dino Luethi, Matthias E. Liechti

Archives of Toxicology · 2020 · Review

Abstract

Psychoactive substances with chemical structures or pharmacological profiles that are similar to traditional drugs of abuse continue to emerge on the recreational drug market. Internet vendors may at least temporarily sell these so-called designer drugs without adhering to legal statutes or facing legal consequences. Overall, the mechanism of action and adverse effects of designer drugs are similar to traditional drugs of abuse. Stimulants, such as amphetamines and cathinones, primarily interact with monoamine transporters and mostly induce sympathomimetic adverse effects. Agonism at μ-opioid receptors and γ-aminobutyric acid-A (GABA A ) or GABA B receptors mediates the pharmacological effects of sedatives, which may induce cardiorespiratory depression. Dissociative designer drugs primarily act as N -methyl- d -aspartate receptor antagonists and pose similar health risks as the medically approved dissociative anesthetic ketamine. The cannabinoid type 1 (CB 1 ) receptor is thought to drive the psychoactive effects of synthetic cannabinoids, which are associated with a less desirable effect profile and more severe adverse effects compared with cannabis. Serotonergic 5-hydroxytryptamine-2A (5-HT 2A ) receptors mediate alterations of perception and cognition that are induced by serotonergic psychedelics. Because of their novelty, designer drugs may remain undetected by routine drug screening, thus hampering evaluations of adverse effects. Intoxication reports suggest that several designer drugs are used concurrently, posing a high risk for severe adverse effects and even death.

Shown for reading. Its publisher allows quoting it, not republishing it.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1The term “designer drugs” was originally introduced to describe novel substances that are derived from clandestine alterations of well-known drugs of abuse, preserving or enhancing pharmacologic effects while remaining outside of legal control (Jerrard ). The term is currently applied more widely to include substances that originate from industrial or academic research but never receive medical approval. Some substances that are referred to as designer drugs may be medically approved in different countries, thus not fitting the classic definition of a designer drug (Bäckberg et al.; Manchester et al.; Owen et al.; Zawilska and Wojcieszak ). The Internet plays a crucial role in the distribution of designer drugs and in the acquisition of information about them (Miliano et al. ). The number of available designer drugs is constantly growing, and trends and patterns of use change over time. This poses a challenge to drug-regulatory authorities and can jeopardize public health. Designer drugs can generally be divided into the same categories as traditional drugs of abuse, namely stimulants, sedatives, dissociatives, cannabinoids, and psychedelics. However, in contrast to traditional drugs of abuse, newly emerging drugs can remain undetected by routine drug screening, and information about associated adverse effects is often scarce. Knowledge of the mechanism of action and potential clinical complications of designer drugs is key for healthcare workers who treat intoxicated patients. The present review provides an overview of the main mechanisms of action and adverse effects of currently available designer drugs.

Stimulants

2Monoaminergic stimulants, such as amphetamine, 3,4-methylenedioxymethamphetamine (MDMA), and cocaine, are among the most popular drugs of abuse. Other stimulants, such as methylphenidate and dextroamphetamine, are widely prescribed for the treatment of attention-deficit/hyperactivity disorder (ADHD). MDMA is currently being investigated as a prescription drug for the treatment of posttraumatic stress disorder (Amoroso and Workman; Mithoefer et al.,; Sharma and Couture ). Stimulants modulate monoaminergic neurotransmission mainly by interacting with norepinephrine, dopamine, and serotonin (5-hydroxytryptamine [5-HT]) transporters (NET, DAT, and SERT, respectively), in addition to interacting with monoaminergic receptors and other targets. At monoamine transporters, monoaminergic stimulants act as either transporter inhibitors or substrates that mediate non-exocytotic monoamine efflux (Fleckenstein et al.; Rothman and Baumann; Sitte and Freissmuth ). Different selectivity (Fig. 1) and potency (Fig. 2) at the different transporters result in different pharmacological effects, different clinical potencies (i.e., the dose that is necessary to induce a psychoactive effect), and different abuse liabilities (Aarde and Taffe; Gannon et al.; Javadi-Paydar et al.; Kuhar et al.; Luethi and Liechti; Ritz et al.; Vandewater et al.; Wee et al.; Wee and Woolverton ). In rats, substances that are selective for DAT vs. SERT facilitate dose-dependent and abuse-related intracranial self-stimulation, indicating high abuse potential. In contrast, substances that are selective for the SERT vs. DAT depress dose-dependent intracranial self-stimulation (Suyama et al. ), indicating a lower risk of abuse. Repeated exposure to substances with similar activity at the DAT and SERT may sustain the expression of DAT-mediated abuse-related effects while developing tolerance to SERT-mediated abuse-limiting effects, thus resulting in a higher abuse potential (Suyama et al. ). The number of available designer stimulants is constantly increasing, and their use can cause various physiological complications and mood disturbances, which are discussed in the subsequent sections for the different classes of designer stimulants.

Amphetamines

3In addition to traditional amphetamines that are used both medically and recreationally, several amphetamine designer drugs without approved medical uses have become available. MDMA is by far the most popular amphetamine designer drug. It was first synthesized by Merck in 1912 as a precursor in a new chemical pathway, but it was not further investigated until many years later (Freudenmann et al. ). In the 1980s, MDMA started to be used in psychotherapy and became popular as a recreational drug under the street name “ecstasy,” which led to a ban of MDMA in most countries soon afterward (Freudenmann et al.; Green et al. ). MDMA has slowly found its way back into psychotherapy as a promising agent for the treatment of posttraumatic stress disorder (Amoroso and Workman; Mithoefer et al., ). Recently, various other, often ring-substituted amphetamine derivatives (Fig. 3) have gained increasing popularity as designer drugs, many of which were initially legally obtainable.

Mechanism of action of amphetamines

4Most amphetamines are substrate-type monoamine releasers (Rothman and Baumann; Simmler et al.,; Sitte and Freissmuth ). In addition to potent effects at the NET, many amphetamines predominantly act at the DAT vs. SERT, resulting in greater reinforcing effects and higher abuse liability (Kuhar et al.; Ritz et al.; Wee et al.; Wee and Woolverton ). In contrast, some amphetamines, including MDMA, have more pronounced effects at the SERT vs. DAT, resulting in an entactogenic effect profile and lower abuse liability (Baumann et al.,; Luethi et al.; Simmler et al. ). Para-substitution at the phenyl ring of amphetamines has been shown to shift their pharmacological profile toward more pronounced activity at the SERT vs. DAT (Luethi et al.,; Rickli et al.; Simmler et al.; Wee et al. ). In addition to their interactions with plasma membrane transporters, amphetamines are substrates at vesicular monoamine transporters (VMATs) and inhibit monoamine oxidases (Fleckenstein et al.; Partilla et al.; Sitte and Freissmuth; Volz et al. ). Furthermore, amphetamine designer drugs have been reported to interact with various monoaminergic receptors, including serotonergic and adrenergic receptors, and trace amine-associated receptor 1 (TAAR1), which negatively modulates monoaminergic neurotransmission (Di Cara et al.; Rickli et al.; Simmler et al., ).

Adverse effects of amphetamines

5Numerous studies have reported the adverse effects of amphetamine, lisdexamfetamine, and methamphetamine. Among amphetamine-derived designer drugs, MDMA is the best studied. For traditional amphetamines, mainly sympathomimetic adverse effects (e.g., anxiety, insomnia, headaches, mydriasis, bruxism, dry mouth, hyperthermia, hypertension, tachycardia, chest pain, palpitations, anorexia, nausea, vomiting, and abdominal pain) can be expected for newly emerged amphetamine-derived designer drugs (Carvalho et al.; Derlet et al.; Dolder et al.; Heal et al.; Vizeli and Liechti; Wijers et al. ). Hyperthermia is a significant contributor to potentially severe adverse effects of amphetamines, including disseminated intravascular coagulation, renal failure, and rhabdomyolysis (Bingham et al.; Carvalho et al.; Cunningham; Fahal et al.; Ginsberg et al.; Greene et al.; Halachanova et al.; Henry et al.; Kendrick et al.; Richards et al.; Screaton et al.; Vanden Eede et al. 2012). The uncoupling of oxidative phosphorylation in skeletal muscle through the activation of uncoupling protein 3 (UCP-3) and agonism at adrenergic receptors by norepinephrine release has previously been identified as an important contributor to MDMA-induced hyperthermia (Mills et al., ). Many adverse effects are similar for most amphetamines, but the prevalence of some events is higher for certain specific amphetamines. A comparison of the structures and pharmacological profiles of newly emerged amphetamine designer drugs with well-studied amphetamine derivatives helps to shed light on the likelihood of these specific adverse events. Hepatotoxicity is a potentially fatal adverse effect that has been associated with the use of amphetamines, and MDMA is the designer drug that has been most frequently linked to liver injury (Andreu et al.; De Carlis et al.; Ellis et al.; Garbino et al.; Jones et al.; Kamijo et al. ). Different mechanisms may contribute to MDMA-induced hepatotoxicity, including monoamine release, hyperthermia, oxidative stress, impairments in the antioxidant response, mitochondrial dysfunction, and the formation of catechol metabolites by demethylenation (Carvalho et al., ). Cardiotoxicity is another potential complication of amphetamine use and largely attributable to sympathomimetic activation and additionally to secondary mechanisms, such as metabolic bioactivation and hyperthermia (Carvalho et al. ). The activation of 5-HT2B receptors in cardiovascular tissues may potentially result in cardiac valvulopathy and is thus a concern for drugs that increase plasma 5-HT levels or directly activate 5-HT2B receptors (Elangbam; Elangbam et al.; Huang et al.; Roth ). Mild-to-moderate valvular heart disease has been observed in a population of heavy recreational MDMA users, and the 5-HT2B receptor-mediated proliferation of cardiac valvular interstitial cells that was induced by MDMA was demonstrated in vitro (Droogmans et al.; Setola et al. ). The MDMA metabolite 4-hydroxy-3-methoxymethamphetamine (HMMA) exhibits higher potency in stimulating vasopressin secretion; together with the excessive intake of hypotonic liquids and hyperthermia, it may cause potentially fatal hyponatremia, especially in female users likely because of effects of estrogen on vasopressin (Campbell and Rosner; Fallon et al.; Farah and Farah; Forsling et al.; Forsling et al.; Ghatol and Kazory; Hartung et al.; Moritz et al.; Rosenson et al.; Simmler et al.; Van Dijken et al. ). Monoamine depletion and reactive species contribute to the neurotoxicity of amphetamines (Carvalho et al. ). However, despite extensive research, the extent to which different amphetamines are neurotoxic remains largely unknown. Compared with amphetamine, an increase in serotonergic toxicity has been reported for the para-chlorinated derivative 4-chloroamphetamine, likely explained by highly potent serotonergic activity coupled with considerably potent dopaminergic activity (Colado et al.; Fuller; Johnson et al.; Luethi et al.; Miller et al. ). However, unlike other halogenated stimulants, such as 4-fluoroamphetamine, 4-chloroamphetamine never achieved popularity as a designer drug, possibly because of its well-documented neurotoxicity. Nevertheless, the widely used 4-fluoroamphetamine has been associated with various mild-to-moderate adverse effects (e.g., agitation, severe headache, anxiety, confusion, tachypnea, hypertension, tachycardia, chest pain, electrocardiographic abnormalities, and nausea) and severe adverse effects (e.g., coma, convulsions, cerebral hemorrhage, inverted takotsubo cardiomyopathy, myocardial infarction, and fatalities following cardiac arrest) (Hondebrink et al. ). A detailed review of amphetamine toxicity, including toxicological pathways that involve the formation of reactive species, the depletion of antioxidants, and microglial activation, was previously published (Carvalho et al. ).

Cathinone and pyrovalerone derivatives

6Cathinone designer drugs are derivatives of the β-keto-amphetamine cathinone, an alkaloid that is found in the leaves of the Catha edulis plant. The large-scale recreational use of synthetic cathinones is a relatively new phenomenon, although several compounds have been known for a long time. For example, the first synthesis of 4-methylmethcathinone (mephedrone) was published in 1929 (Sanchez ). Several other synthetic cathinones have been investigated for their medical potential, mostly as antidepressant or anorectic agents, but only a few were ever marketed because of concerns about abuse (Canning et al.; Cunningham; Dal Cason et al.; Seaton et al.; Soroko et al.; Valente et al. ). Pyrovalerone derivatives represent a subgroup of synthetic cathinones based on the structure of pyrovalerone, which was developed in the 1960s as a treatment option for lethargy, fatigue, and obesity (Gardos and Cole ). As a result of their initial misleading marketing as “bath salts”, synthetic cathinones are still often referred to by that term (Baumann et al. ). Currently, synthetic cathinones (Fig. 3) represent the largest group of designer stimulants that are monitored by the European Monitoring Center for Drugs and Drug Addiction (EMCDDA) (European Monitoring Centre for Drugs and Drug Addiction ).

Mechanism of action of cathinone and pyrovalerone derivatives

7Similar to other monoaminergic stimulants, the psychoactive effects of synthetic cathinones are primarily mediated by interactions with monoamine transporters. Many cathinones are partially or fully effective substrate-type releasers at one or several monoamine transporters, but some compounds, such as pyrovalerone derivatives, are transporter inhibitors (Baumann et al.; Eshleman et al.,; Luethi et al.; Mayer et al.,; Niello et al.; Rickli et al.; Simmler et al. ). Mephedrone has additionally been shown to mediate monoamine release via organic cation transporter 3 (OCT3), indicating that cathinones target both high-affinity and low-affinity/high-capacity transporters (Mayer et al. ). Similar to amphetamines, cathinone designer drugs also interact with several adrenergic and serotonergic receptors (Luethi et al.; Rickli et al.; Simmler et al. ). Compared with amphetamines, however, cathinone designer drugs have been shown to interact less potently with TAAR1 and VMAT2 (Eshleman et al.; Simmler et al. ). These less potent interactions at TAAR1 may result in a higher risk of cathinone dependence compared with amphetamines.

Adverse effects of cathinone and pyrovalerone derivatives

8The use of synthetic cathinones has been associated with mainly sympathomimetic toxicity, which may manifest as agitation, tachycardia, hypertension and less frequently as lower levels of consciousness, hallucinations, hyponatremia, chest pain, palpitations, and nausea (Bäckberg et al.; Beck et al.,; Borek and Holstege; Boulanger-Gobeil et al.; Franzén et al.; James et al.; Ross et al.,; Umebachi et al.; Wood et al. ). Rarely, severe adverse effects (e.g., seizures, significant peripheral organ damage, and rhabdomyolysis) have been reported (Bäckberg et al.; Beck et al.,; Borek and Holstege; Boulanger-Gobeil et al.; Franzén et al.; Fröhlich et al.; Penders et al.; Ross et al., ). In vitro studies in neuronal, skeletal muscle, and hepatic cells indicated various cytotoxic mechanisms of synthetic cathinones, including mitochondrial dysfunction, glutathione depletion, oxidative stress, and apoptosis pathway activation, which are aggravated under hyperthermic conditions (Dias da Silva et al.; Luethi et al.,; Valente et al.,,,; Zhou et al. ). Unclear, however, is the extent to which these mechanisms contribute to clinical adverse effects of cathinones relative to sympathomimetic toxicity. Numerous cathinone-related fatalities have been reported (Adamowicz et al.,; Bäckberg et al.; Barrios et al.; Beck et al.; Busardò et al.; Carbone et al.; DeRoux and Dunn; Eiden et al.; Forrester; Kesha et al.; Kudo et al.; Lee et al.; Liveri et al.; Majchrzak et al.; Marinetti and Antonides; Maskell et al.; Nagai et al.; Pearson et al.; Pieprzyca et al.; Potocka-Banas et al.; Schifano et al.; Sellors et al.; Thirakul et al.; Umebachi et al.; Wood et al.; Wright et al.; Wyman et al.; Zaami et al. ). Analytically confirmed cases of cathinone-related deaths were mainly attributed to hyperthermia, hypertension, cardiac arrest, and serotonin syndrome (Busardò et al.; Zaami et al. ).

Benzofuran and indole derivatives

9Various analogs of MDMA and its metabolite 3,4-methylenedioxyamphetamine (MDA) have become available as designer drugs, in which a dihydrobenzofuran, benzofuran, or indole group replaces the benzodioxole group (Fig. 4). Some benzofuran designer drugs were originally investigated as part of a study that examined the role of ring oxygen atoms in interactions between MDA and monoamine transporters (Monte et al. ). The indole designer drugs 5-(2-aminopropyl)indole (5-IT, 5-API) and 6-(2-aminopropyl)indole (6-IT, 6-API) emerged from industrial research and are positional isomers of the psychedelic tryptamine α-methyltryptamine (αMT) (Hofmann and Troxler ).

Mechanism of action of benzofuran and indole derivatives

10In addition to norepinephrine uptake inhibition, stimulant benzofuran and dihydrobenzofuran designer drugs have moderate-to-high selectivity in inhibiting 5-HT vs. dopamine uptake, often with substrate activity at the transporters (Monte et al.; Rickli et al. ). Furthermore, affinity at adrenergic, serotonergic, and histaminergic receptors, partial agonism at 5-HT2A receptors, and partial to full agonism at 5-HT2B receptors have been reported for these designer drugs (Dawson et al.; Iversen et al.; Rickli et al. ). The indoles 5-IT and 6-IT are potent substrates at the NET, DAT, and SERT in rat synaptosomes (Marusich et al. ). The position of the alkylamine side chain is determining of DAT vs. SERT selectivity, with 5-IT having significantly (eightfold) more potent monoamine-releasing actions at the DAT vs. SERT in rat synaptosomes, whereas 6-IT is eightfold more selective for the SERT (Marusich et al. ). In human transporter-transfected cells, 5-IT has been shown to be a very potent inhibiter of norepinephrine uptake, but it did not significantly induce norepinephrine efflux at a single high concentration. However, it had substrate activity at the DAT and SERT (Luethi et al. ). Additionally, 5-IT has affinity for adrenergic and serotonergic receptors and partially activates 5-HT2A and 5-HT2B receptors, which may result in additional perceptual psychedelic-like effects at high doses (Luethi et al. ). Furthermore, 5-IT is an inhibitor of human monoamine oxidase (MAO)-A (Herraiz and Brandt ).

Adverse effects of benzofuran and indole derivatives

11Benzofuran designer drugs may cause agitation, insomnia, headache, drowsiness, dry mouth, dry eyes, bruxism, hyperthermia, tachycardia, palpitations, nausea, diarrhea, hot flashes, clonus of the hands and feet, and psychological symptoms, including visual and auditory hallucinations, depression, anxiety, panic attacks, paranoia, and psychosis (Jebadurai et al.; Nugteren-van Lonkhuyzen et al. ). A case of drug-induced psychosis with symptoms of self-harm, paranoia, and suicidal thoughts but unremarkable physical examination was reported with the analytically confirmed presence of 6-(2-aminopropyl)benzofuran (6-APB) in combination with metabolites of a synthetic cannabinoid and tetrahydrocannabinol (Chan et al. ). In addition to fatal intoxications that involve benzofurans combined with other designer drugs (Adamowicz et al.; Elliott and Evans ), benzofuran toxicity was implicated as the cause of death in an accidental intoxication, in which 5-APB and presumptively a smaller amount of 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB) were detected as sole compounds in addition to alcohol (McIntyre et al. ). Autopsy revealed white foam in the trachea, marked congestion and edema of the lungs, and congestive splenomegaly (McIntyre et al. ). Benzofurans induce oxidative stress, disrupt mitochondrial function, and activate apoptosis cascades in vitro, but the in vivo relevance of these sequelae remain unclear (Roque Bravo et al. ). 5-IT has been linked to various sympathomimetic adverse effects, including extreme agitation, anxiety, confusion, insomnia, restlessness, hallucinations, seizures, tremors, dilated pupils without light reaction, hyperthermia, sweating, hypertension, tachycardia, arrhythmias, renal failure, myoclonus, muscle rigidity, rhabdomyolysis, and in some cases, serotonergic toxicity (Bäckberg et al.; Coppola and Mondola; Katselou et al. ). Furthermore, 5-IT was involved in several intoxication cases with a fatal outcome within a time span of only a few months (Katselou et al.; Kronstrand et al.; Seetohul and Pounder ). Many of 5-IT-associated deaths have been attributed to cardiac arrest, to which 5-HT2B receptor activation by 5-IT may have contributed (Katselou et al.; Luethi et al.; Seetohul and Pounder ). In most of the fatal and non-fatal intoxication cases, additional substances have been detected. In some cases, the users reported to be unaware that they took 5-IT, because the products were mislabeled as 6-APB (Bäckberg et al.; Kronstrand et al.; Seetohul and Pounder ). Although the reported doses of 5-IT and 6-APB are similar, they differ in their selectivity for the dopaminergic vs. serotonergic system (Luethi et al.; Luethi and Liechti; Rickli et al. ). The extent to which mislabeling played a role in 5-IT intoxication remains unclear.

Aminoindanes

12Aminoindane designer drugs (Fig. 4) have become widely available when first-generation designer stimulants, including mephedrone, were finally placed under legal control (Pinterova et al.; Sainsbury et al. ). Aminoindanes are conformationally restricted analogs of amphetamine that were originally investigated as bronchodilatory, analgesic, and anti-Parkinson agents, and subsequently as drugs with psychotherapeutic value (Pinterova et al.; Solomons and Sam ). Some aminoindane designer drugs have been reported to be entactogens with lower serotonergic neurotoxicity relative to non-aminoindane entactogens (Johnson et al.; Nichols et al. ). The desired psychoactive effects of aminoindane designer drugs include euphoria, the mild distortion of vision, time, and space, a greater intensity of perceptions and colors, empathy, and arousal (Coppola and Mondola; Corkery et al. ).

Mechanism of action of aminoindanes

13Similar to amphetamines, aminoindane designer drugs are monoamine transporter substrates, with relevant affinity for adrenergic, dopaminergic, and serotonergic receptors (Iversen et al.; Luethi et al.; Simmler et al. ). Ring-substituted aminoindanes, such as 5,6-methylenedioxy-2-aminoindane (MDAI), 5-iodoaminoindane (5-IAI), and 5-methoxy-6-methyl-2-aminoindane (MMAI), are selective for the SERT vs. DAT (Luethi et al.; Simmler et al. ). Potent actions of MDAI and 5-IAI on the NET result in an in vitro pharmacological profile that is similar to MDMA, suggesting similar entactogenic effects (Simmler et al. ). MMAI acts as a selective 5-HT releaser with less pronounced effects on the NET, indicating that its effects are different from typical entactogens, such as MDMA (Luethi et al. ). According to in vitro studies, the non-ring-substituted aminoindanes 2-aminoindane (2-AI) and N-methyl-2-AI are selective norepinephrine releasers and devoid of pharmacologically relevant DAT or SERT interactions (Luethi et al.; Simmler et al. ).

Adverse effects of aminoindanes

14Self-reported undesirable effects of aminoindane designer drugs include agitation, anxiety, panic attacks, headache, insomnia, hallucinations, and tachycardia (Coppola and Mondola ). Three fatal cases were reported with confirmed MDAI intake, and serotonin syndrome could have been a factor that contributed to death (Corkery et al. ). The likelihood of the serotonergic toxicity of aminoindanes in humans has not been investigated, but signs of serotonin syndrome were reported for a high dose of MDAI in rats (Palenicek et al. ).

Piperazines

15Piperazine designer drugs (Fig. 4) have been widely sold as legal party pills or powders and appeared as pure substances or adulterants in pills that are sold as “ecstasy” because of their somewhat MDMA-like pharmacological profile, alone or combined (Baumann et al.; Bossong et al.; Lin et al.; Sheridan et al.; Wood et al. ). Various therapeutic drugs have a piperazine moiety, and some piperazine designer drugs have a history of medical use. For example, 1-benzylpiperazine (BZP) has been investigated as an antihelmintic agent and antidepressant, and meta-chlorophenylpiperazine (m-CPP) is an active metabolite of different antidepressants (Arbo et al.; Schep et al. ). Other frequently used piperazine designer drugs include trifluoromethylphenylpiperazine (TFMPP), 1-(3,4-methylenedioxybenzyl)piperazine (MDBZP), and 4-methoxyphenylpiperazine (MeOPP).

Mechanism of action of piperazines

16Piperazine designer drugs exert mixed effects at monoamine transporters. TFMPP and m-CPP are selective 5-HT vs. dopamine reuptake inhibitors (DAT/SERT ratio < 0.05), and m-CPP also inhibits norepinephrine uptake with potency that is similar to the inhibition of 5-HT uptake (Simmler et al. ). Both substances bind to several serotonergic, adrenergic, dopaminergic, and histaminergic receptors with submicromolar or low micromolar affinity (Simmler et al. ). In contrast, BZP is a selective NET inhibitor with relatively weak inhibition of dopamine and 5-HT uptake, without any potent affinity at monoamine receptors (Simmler et al. ). BZP was also shown to be a DAT substrate in rat synaptosomes and human DAT-transfected cells, and m-CPP was reported to elicit 5-HT efflux in human SERT-transfected cells (Baumann et al.; Simmler et al. ). TFMPP mediated 5-HT efflux in rat synaptosomes but not in transfected cells at a single high concentration of 100 μM (Baumann et al.; Simmler et al. ). A combination of TFMPP and BZP was reported to closely mimic the effects of MDMA in rats (Baumann et al. ).

Adverse effects of piperazines

17Adverse effects of piperazine designer drugs are mostly sympathomimetic, including agitation, insomnia, headaches, dizziness, dilated pupils, hyperthermia, tachycardia, nausea, urine retention, and inducible clonus (Arbo et al.; Gee et al.,,; Katz et al.; Kovaleva et al.; Schep et al.; Wilkins et al.; Wood et al. ). In addition to sympathomimetic toxicity, dissociative symptoms, visual and auditory hallucinations, and psychological symptoms (e.g., short temper, confusion, anxiety, depression, and paranoia) have been associated with the use of piperazine designer drugs (Gee et al.; Kovaleva et al.; Schep et al.; Wilkins et al.; Wood et al. ). Furthermore, toxic seizures were frequently observed in patients who were admitted to the emergency department after the use of BZP-containing party pills. Although there seems to be a trend toward higher concentrations being more frequently associated with seizures, they may also occur at low doses (Gee et al., ). Other severe adverse effects of BZP include hyponatremia, severe combined metabolic and respiratory acidosis, hepatic injury, renal failure, disseminated intravascular coagulation, and rhabdomyolysis (Gee et al.; Katz et al. ). A case of severe hyperthermia with resultant multi-organ failure and a case of hyponatremia that led to fatal brain edema were reported for the concomitant use of piperazine designer drugs and MDMA (Balmelli et al.; Gee et al. ). The contribution of these individual compounds to the observed clinical manifestations remains unclear, but piperazines and MDMA may elicit additive or synergistic toxicity. In vitro, piperazine designer drugs have been reported to upregulate key enzymes of cholesterol biosynthesis, induce oxidative stress, disrupt mitochondrial function, and activate apoptosis pathways, all of which may potentially contribute to clinical toxicity (Arbo et al.,; Dias da Silva et al.; Dias-da-Silva et al.; Majrashi et al. ).

Phenidate derivatives

18Derivatives of the piperidine prescription drug methylphenidate have appeared as designer drugs (Fig. 4), with substitutions at the phenyl ring and different lengths of the carbon side chain (Luethi et al. ). Similar to methylphenidate, phenidate derivatives may be used to induce euphoria or as cognitive enhancers (Ho et al.; Lüthi and Liechti ). Various methylphenidate-based designer drugs originated from drug development efforts and later appeared on the recreational drug market as pure compounds or in the form of branded products (Bailey et al.; Deutsch et al.; Ho et al.; Markowitz et al.; Misra et al. ). When insufflated, the pharmacological and subjective-effect profile of methylphenidate is similar to cocaine, and phenidate derivatives may, therefore, be used as substitutes for cocaine (Vogel et al. ).

Mechanism of action of phenidate derivatives

19Similar to methylphenidate, methylphenidate-based designer drugs act as potent NET and DAT inhibitors that are devoid of substrate activity (Luethi et al.; Simmler et al. ). Some less potent interactions with the SERT and adrenergic and serotonergic receptors have been reported but are not likely to play a relevant role in the psychoactive actions of most phenidate derivatives (Luethi et al. ).

Adverse effects of phenidate derivatives

20Adverse effects of phenidate derivatives are similar to amphetamines and include agitation, anxiety, hypertension, tachycardia, and palpitations (Bailey et al. ). Because of their relatively slow onset of action when taken orally, the nasal insufflation or injection of phenidate derivatives is common, especially in heavy users. Nasal pain and septum perforations after insufflation and infections after intravenous injection may occur (Ho et al.; Lafferty et al.; Parks et al. ). The rapid onset of action after nasal or intravenous use, combined with the marked DAT vs. SERT selectivity of phenidate derivatives, has been linked to a higher risk of addiction (Luethi et al. ). In several cases, phenidate derivatives have been analytically confirmed post-mortem, in which ethylphenidate is the most frequently detected compound (Krueger et al.; Maskell et al.; Parks et al.; Shoff et al. ). Many decedents had a history of heroin use, and intravenous injection was a common route of administration. In addition to phenidate derivatives, other drugs, including benzodiazepines and opioids, have been detected in most fatal cases (Krueger et al.; Maskell et al.; Parks et al. ).

Aminorex analogs

21Various analogs of the anorectic agent aminorex have become available as designer drugs (Fig. 4). Aminorex was first marketed as an over-the-counter appetite suppressant in parts of Europe in the 1960s, but it was withdrawn a few years later because of an epidemic of chronic pulmonary hypertension that was associated with many fatalities (Maier et al. ). Aminorex analogs that have found their way onto the designer drug market include 4-methylaminorex (4-MAR) and 4,4′-dimethylaminorex (4,4′-DMAR), the reported effects of which include euphoria, mental and physical stimulation, sociability, empathy, arousal, and changes in visual perception (European Monitoring Centre for Drugs and Drug Addiction; Glanville et al.; Loi et al. ). A comprehensive review of the history of aminorex use and the emergence of its designer drug analogs was recently published (Maier et al. ).

Mechanism of action of aminorex analogs

22In human transporter-transfected cells, 4,4′-DMAR is a potent inhibitor of norepinephrine, dopamine, and 5-HT reuptake. 4-MAR has similarly potent dopamine and norepinephrine reuptake properties as 4,4′-DMAR, but 5-HT uptake inhibition is less pronounced compared with its para-methylated counterpart (Maier et al.; Rickli et al. ). Aminorex and its derivative 4-MAR mediate norepinephrine and dopamine efflux in rat synaptosomes, with weak substrate activity at the SERT (Brandt et al.; Rothman et al. ). 4,4′-DMAR and 3′,4′-methylenedioxy-4-methylaminorex (MDMAR) induce norepinephrine, dopamine, and 5-HT efflux in rat synaptosomes (Brandt et al.; McLaughlin et al. ). Dynamic superfusion experiments revealed the substrate activity of 4,4′-DMAR at human monoamine transporters (Maier et al. ). In human transporter-transfected cells that were preloaded with monoamines and exposed to drugs at a single high concentration (100 μM), only dopamine efflux was observed for 4,4′-DMAR, and dopamine and 5-HT efflux was observed for 4-MAR (Rickli et al. ). In addition to interactions with plasmalemmal transporters, 4,4′-DMAR has been shown to inhibit human VMAT2-mediated dopamine uptake (Maier et al. ). In addition to their primary effects on transporters, minor interactions with serotonergic 5-HT2C and adrenergic α2A receptors have been described for 4-MAR, and low affinity at 5-HT2A and 5-HT2C receptors has been described for 4,4′-DMAR (Maier et al.; Rickli et al. ).

Adverse effects of aminorex analogs

23Adverse effects of aminorex designer drugs that have been reported by users on various Internet discussion platforms include agitation, dysphoria, insomnia, amnesia, panic attacks, psychosis, hallucinations, facial spasms, dilated pupils, foaming at the mouth, dry mouth, jaw clenching, elevations of body temperature, sweating, elevations of heart rate, nausea, and restless legs (Glanville et al.; Loi et al.; Maier et al. ). Pulmonary hypertension (i.e., the adverse effect that led to the removal of aminorex from the market) has been associated with the recreational use of 4-MAR (Gaine et al. ). Designer drug analogs of aminorex have been analytically confirmed in several drug-related deaths (Cosbey et al.; Davis and Brewster; European Monitoring Centre for Drugs and Drug Addiction ). Although other substances were present in most fatal cases, 4,4′-DMAR was mentioned to be the cause of death or to have played a contributory role in several of these fatalities (European Monitoring Centre for Drugs and Drug Addiction ). Brain edema, seizures, hyperthermia, respiratory and cardiac arrest, and internal bleeding were all listed as adverse events or autopsy findings that were associated with the use of 4,4′-DMAR (European Monitoring Centre for Drugs and Drug Addiction ).

Phenmetrazine derivatives

24Phenmetrazine is a reinforcing stimulant, which was previously used as an appetite suppressant before it was eventually withdrawn from the market (Chait et al. ). Phenmetrazine-derived designer drugs (Fig. 4) represent a relatively understudied class of drugs, among which 3-fluorophenmetrazine (3-FPM) use appears to be the most widespread.

Mechanism of action of phenmetrazine derivatives

25Like the parent compound, ring-fluorinated derivatives of phenmetrazine are substrates at the NET and DAT, with minor substrate activity at the SERT (Mayer et al.; Rothman et al. ). Ring-methylated phenmetrazine derivatives were reported to have greater potency at the SERT, in addition to activity at the NET and DAT (McLaughlin et al. ). Para-substituted compounds were shown to have the greatest serotonergic effects among the phenmetrazine derivatives, similar to ring-substituted amphetamine and cathinone designer drugs (Luethi et al.; Rickli et al. ).

Adverse effects of phenmetrazine derivatives

26Based on their mechanism of action, phenmetrazine designer drugs are expected to elicit stimulatory toxicity that is similar to amphetamines. A series of non-fatal intoxications that involved 3-FPM were reported within the Swedish STRIDA project, mostly with sympathomimetic adverse effects (Bäckberg et al. ). However, polydrug intoxication prevented attribution of the observed effects to 3-FPM, underscored by the fact that the clinical features included some oppositional effects (e.g., both miotic and dilated pupils and both hypertension and hypotension) (Bäckberg et al. ). Nevertheless, the authors of this case series suggested that 3-FPM is a harmful compound, as one-third of patients presented severe adverse events (Bäckberg et al. ). In addition to other polydrug intoxications that involve 3-FPM (Benesch and Iqbal; Ellefsen et al. ), a case of severe kidney injury and limb ischemia that were associated with intravenous 3-FPM use was reported (Fawzy et al. ). The authors of the latter case report hypothesized that the intravenous use of 3-FPM resulted in severe vasoconstriction, possibly with concomitant infection, and caused widespread ischemia (Fawzy et al. ).

Thiophene designer drugs

27Various analogs of amphetamines and cathinones with a thiophene group that replaces the phenyl ring have appeared as designer drugs (Fig. 4). Some of the thiophene designer drugs were first described in the 1940s and elicited effects that were reported to be comparable to their phenyl ring analogs (Alles and Feigen; Blicke and Burckhalter ). To date, most pharmacological studies and toxicological reports involve methiopropamine (MPA), the thiophene analog of methamphetamine.

Mechanism of action of thiophene designer drugs

28MPA is a quasi-equipotent inhibitor of norepinephrine and dopamine uptake and was reported to interact with various serotonergic, adrenergic, dopaminergic, N-methyl-d-aspartate (NMDA), and sigma-1 receptors (Iversen et al. ).

Adverse effects of thiophene designer drugs

29MPA use has been associated with significant acute toxicity and psychotic, cardiovascular, and gastrointestinal symptoms, including agitation, anxiety, confusion, a lower level of consciousness, insomnia, visual hallucinations, elevations of creatine kinase, tachycardia, palpitations, chest tightness, nausea, and vomiting (Daveluy et al.; Lee et al.; White et al. ). However, for most intoxication cases, the use of multiple substances was reported, and the extent to which MPA contributed to the reported adverse effects remains unclear. A death from isolated MPA use was described, in which cardiac arrhythmia that induced cardiovascular collapse was named as the probable cause of death (Anne et al. ). Dopaminergic neurodegeneration and myocardial, renal, and gastrointestinal damage were observed in mice that were exposed to MPA (Foti et al.; Nguyen et al. ).

Miscellaneous stimulants

30Several designer drugs have appeared that do not belong to any classes that are discussed in the previous sections. Any substance that interacts with monoamine transporters may potentially be sold as a stimulant designer drug, even if it is not or only remotely chemically related to the widely used stimulant classes. One example of such a substance is the potent NET, DAT, and SERT blocker diclofensine, a tetrahydroisoquinoline derivative that was originally developed as an antidepressant (Luethi et al. ).

Synthetic opioids

31While being essential for pain treatment, the non-medical use of opioids has been a public health threat for centuries and includes the recreational use of illegal substances, the abuse of prescription medications, and drug adulteration with non-pharmaceutical opioids (Armenian et al. ). Opioids induce euphoria, anxiolysis, feelings of relaxation, and drowsiness (Suzuki and El-Haddad ). Repeated use leads to the development of dependence. In recent years, the growing prevalence of non-pharmaceutical fentanyl, highly potent designer fentanyls, and other novel synthetic opioids (Fig. 5) has critically contributed to the opioid crisis, particularly in the United States (Daniulaityte et al.; Denton et al.; Lucyk and Nelson; Peterson et al.; Rudd et al.; Scholl et al.; Seth et al. ). Notably, fentanyl-type substances are often detected in fatalities that are presumably associated with intravenous heroin use (Gladden et al. ). The higher potency of fentanyl and its analogs compared with classic heroin results in a higher risk of overdose, particularly when they are mistaken for heroin. Fentanyl itself was first synthesized in 1960 and has become essential and widely used for intraoperative analgesia and in the form of transdermal patches for the management of chronic pain (Stanley ). Following its medical approval, reports of fentanyl misuse among clinicians and subsequently patients began to emerge, and several fentanyl analogs appeared on the illicit market (Armenian et al.; Suzuki and El-Haddad ). In Europe’s drug market, 49 new synthetic opioids were detected between 2009 and 2018, 34 of which are fentanyl derivatives (European Monitoring Centre for Drugs and Drug Addiction ).

Mechanism of action of synthetic opioids

32Novel fentanyl analogs and other synthetic opioids interact with G protein-coupled opioid receptors in the brain and spinal cord as partial to full agonists at μ-, δ-, and κ-opioid receptor subtypes, with selectivity for the μ-opioid receptor (Armenian et al.; Baumann et al.; Codd et al.; Maguire et al.; Prekupec et al. ). Multiple lines of evidence indicate that agonism at μ-opioid receptors drives the main pharmacological effects of opioids, including euphoria, analgesia, respiratory depression, and the development of dependence (Charbogne et al.; Kieffer ). A detailed overview of signaling mechanisms and behavioral effects of opioid receptor activation is provided elsewhere (Al-Hasani and Bruchas ). In vitro pharmacological profiling appears to be only a limited predictor of the clinical potency of opioids (Baumann et al. ). However, rodent tail flick tests suggest mostly distinctively greater potencies of novel synthetic opioids compared with morphine (Armenian et al. ). For example, the potency of fentanyl is reported to be 50- to 200-fold higher than morphine, and the potency of carfentanil is reported to be approximately 10,000 times higher than morphine (Armenian et al.; Concheiro et al.; Suzuki and El-Haddad ). Several prescription opioids inhibit the NET and SERT and interact with 5-HT2 receptors (Codd et al.; Rickli et al. ). Fentanyl has affinity for 5-HT1A and 5-HT2A receptors but is devoid of relevant monoamine transporter interactions (Barann et al.; Rickli et al. ). No data are currently available on monoamine transporter interactions of designer opioids.

Adverse effects of synthetic opioids

33Adverse effects of novel synthetic opioids include typical symptoms of opioid overdose, such as dizziness, a lower level of consciousness, miosis, central nervous system depression, respiratory depression, pulmonary edema, hypoxia, bradycardia, pruritus, nausea, vomiting, constipation, and also such symptoms as agitation, hypertension, and tachycardia (Armenian et al.,; Bäckberg et al.; Domanski et al.; Helander et al.,,; Jones et al.; Müller et al.; Schneir et al.; Siddiqi et al.; Wilde et al. ). Pulmonary edema, acute lung injury, diffuse alveolar hemorrhage, renal insufficiency, and rhabdomyolysis were also reported in patients who presented with designer opioid intoxication (Cole et al.; Helander et al., ). The synthetic opioid 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45) has been associated with bilateral hearing loss and hearing disturbances, with likely irreversible and pronounced sensorineural hearing impairment in one case (Helander et al. ). Furthermore, acute skin and hair symptoms followed by severe delayed eye complications were reported in patients with confirmed MT-45 use; cataract surgery was required in two of these patients (Helander et al. ). Remaining unclear, however, is whether the aforementioned complications are solely attributable to MT-45 toxicity. Serotonergic toxicity is one adverse effect that needs to be considered for opioid designer drugs when combined with other serotonergic agents (Baldo; Rickli et al. ). Similar to traditional opioids, withdrawal from designer opioids may result in physiological and psychological distress (Siddiqi et al. ). Numerous fatalities have been attributed to either designer opioids alone or designer opioids combined with other psychoactive substances (Coopman et al.,; Cunningham et al.; Dussy et al.; Dwyer et al.; Elliott et al.; Fels et al.,; Fort et al.; Garneau et al.; Gillespie et al.; Guerrieri et al.; Helander et al.; Karinen et al.; Koch et al.; Kriikku et al.; Kronstrand et al.; Krotulski et al.; Martucci et al.; McIntyre et al.,,; Mohr et al.; Nash et al.; Ojanperä et al.; Papsun et al.; Partridge et al.; Poklis et al.; Richeval et al.; Ruan et al.; Sofalvi et al.; Staeheli et al.; Swanson et al.; Takase et al.; Vorce et al.; Yonemitsu et al. ). Frisoni and colleagues recently published an overview of opioid-related fatalities that were attributed to synthetic opioids (Frisoni et al. ). In addition to central nervous system and respiratory depression, chest wall rigidity after intravenous use could be a cause of death in synthetic opioid overdose cases (Burns et al. ). The competitive μ-opioid receptor antagonist naloxone rapidly reverses central and peripheral effects of opioids and is thus an effective antidote for opioid toxicity (Armenian et al. ). The initial care of patients who are intoxicated with designer opioids should focus on airway protection and maintaining breathing and circulation (Armenian et al. ). Naloxone should be administered as soon as possible (Armenian et al.; Kim and Nelson ).

Designer benzodiazepines

34In 1960, chlordiazepoxide became the first of several medically approved benzodiazepines that today represent a widely prescribed class of drugs for the treatment of psychiatric and neurological conditions, particularly insomnia and anxiety disorders (Longo and Johnson; Sternbach ). Benzodiazepine abuse is frequent. The main reasons for such abuse are to facilitate sleep, cope with stress, ease effects of stimulants, self-treat withdrawal symptoms, and get high (Kapil et al.; Vogel et al.; Zawilska and Wojcieszak ). Benzodiazepines have limited potential as euphoriants when administered alone. When taken in combination with opioids, however, benzodiazepines appear to enhance the euphoric effects of opioid use (Jones et al. ). Since 2007, several benzodiazepine designer drugs (Fig. 5) have become available, some of which are precursors or metabolites of prescription benzodiazepines and are approved for medical use in other countries (Bäckberg et al.; Manchester et al. ). Effects of designer benzodiazepines reported on internet forums resemble those of prescription benzodiazepines (El Balkhi et al. ). Chronological overviews of the appearance of benzodiazepine designer drugs on the recreational drug market were recently published (Manchester et al.; Moosmann and Auwärter ).

Mechanism of action of designer benzodiazepines

35The mechanism of action of most benzodiazepine designer drugs currently remains understudied. In silico experiments suggest that they mediate their effects through interactions at γ-aminobutyric acid-A (GABAA) receptors such as prescription benzodiazepines (Waters et al. ). GABAA receptors are ion channels that consist of pentamers of different subunit compositions, responding to the inhibitory neurotransmitter GABA. Benzodiazepines enhance the effects of GABA as positive allosteric modulators by binding to a receptor site that is different from the binding site of GABA (Manchester et al.; Moosmann and Auwärter ).

Adverse effects of designer benzodiazepines

36Despite their depressive actions on central nervous system function and respiration, the isolated use of benzodiazepines is rarely fatal. However, in reported intoxication cases, designer benzodiazepines have mostly been detected in combination with other psychoactive substances, such as stimulants or depressants (Bäckberg et al. ). The concurrent use of benzodiazepines and other depressants, such as opioids and alcohol, may produce prolonged and potentially fatal respiratory depression (Jones et al.; Zawilska and Wojcieszak ). Reported adverse effects of isolated benzodiazepine designer drugs are typical for a sedative-hypnotic toxidrome but may include atypical symptoms in some cases, such as agitation, hyperthermia, and tachycardia (Bäckberg et al.; Carpenter et al.; Zawilska and Wojcieszak ). The recent review by Zawilska and Wojcieszak mentioned the following adverse effects of designer benzodiazepines: fatigue, impairment of thinking, confusion, dizziness, drowsiness, lethargy, amnesia, blurred vision, slurred speech, palpitations, and muscle weakness, as well as auditory and visual hallucinations, delirium, seizures, deep sleep, and coma at high doses (Zawilska and Wojcieszak ). The chronic use of designer benzodiazepines may also lead to the development of tolerance and dependence (Zawilska and Wojcieszak ). Withdrawal symptoms, such as anxiety, panic attacks, restlessness, insomnia, seizures, and life-threatening convulsions, may follow the abrupt cessation of chronic designer benzodiazepines use (Andersson and Kjellgren; Zawilska and Wojcieszak ). Designer benzodiazepines have been reported to contribute to numerous deaths (Bailey et al.; Crichton et al.; Domingo et al.; Karinen et al.; Koch et al.; Liveri et al.; Maskell et al.; Papsun et al.; Partridge et al.; Shearer et al.; Tanaka et al., ). In a few cases, the cause of death was solely attributed to the designer benzodiazepine phenazepam (Crichton et al.; Shearer et al. ) or etizolam (Carpenter et al. ). A more detailed summary of benzodiazepine-related fatalities was recently published (Zawilska and Wojcieszak ).

γ-Aminobutyric acid analogs

37γ-Hydroxybutyrate (GHB) is a short-chain fatty acid analog of the inhibitory neurotransmitter GABA. It has become popular among drug users because of its ability to induce feelings of euphoria and relaxation, reduce social anxiety, and increase sexual drive (Brennan and Van Hout; Brown et al. ). Although it is an endogenous compound and its sodium salt is approved as a prescription drug against narcolepsy, GHB and its metabolic precursors (e.g., γ-butyrolactone [GBL] and 1,4-butanediol [1,4-BD]) are often referred to as designer drugs because of their widespread illicit production in clandestine laboratories (Brennan and Van Hout; Fuller et al. ). Other structural analogs of GABA that have become available as designer drugs (Fig. 5) include the 4-methyl-substituted GHB derivative γ-hydroxyvaleric acid (GHV) and 4-amino-3-phenyl-butyric acid (phenibut) (Carter et al.; Owen et al. ).

Mechanism of action of GABA analogs

38Metabotropic G protein-coupled GABAB receptors are the primary targets of designer drug analogs of GABA (Brennan and Van Hout; Carai et al.; Lapin ). Other postulated mechanisms of action include high-affinity binding to receptor sites that are distinct from the GABAB receptor (i.e., GHB receptors), binding to specific GABAA receptor subtypes, and monoaminergic modulation (Bay et al.; Carter et al.; Crunelli et al.; Lapin; Wood et al. ).

Adverse effects of GABA analogs

39Comprehensive reviews of the potential clinical complications of the use of GHB and its metabolic precursors are provided elsewhere (Busardò and Jones; Schep et al. ). The subjective benefits of GHB and its analogs outweigh adverse events only over a narrow range of doses. Adverse events include a lower level of consciousness, hypothermia, respiratory depression, aspiration, bradycardia, gastrointestinal upset, and nonsedative adverse effects, such as agitation, seizures, and myoclonus (Busardò and Jones; Isoardi et al.; Liakoni et al.; McCabe et al.; Schep et al.; Zvosec and Smith ). These adverse effects typically have a relatively short duration and are usually managed with supportive care (Busardò and Jones; Schep et al.; Wood et al. ). GABAB and monocarboxylate transporter inhibitors have been proposed as potential treatment options for GHB-induced respiratory depression (Morse et al. ). GHB and its analogs are associated with the rapid development of tolerance. Abrupt cessation after regular use may trigger a potentially life-threatening withdrawal syndrome that can manifest as agitation, anxiety, confusion, disorientation, paranoia, aggression, insomnia, auditory and visual hallucinations, tremors, sweating, hypertension, and tachycardia (Busardò and Jones; Owen et al.; Schep et al.; Wood et al. ). Benzodiazepines appear to be the treatment of choice for withdrawal from GHB and its analogs (Busardò and Jones; Schep et al.; Wood et al. ). Zvosec and colleagues reported a series of 226 GHB-associated deaths, 213 of which were attributed to cardiorespiratory arrest and 13 of which were attributed to fatal accidents (Zvosec et al. ). In approximately one-third of these fatal cases, GHB was the sole toxicant detected (Zvosec et al. ). Similar findings were reported by Corkery and colleagues, who reported a series of 159 GHB and GBL-associated fatalities (Corkery et al. ). The co-ingestion of opioids increases the depressant toxicity of GHB, and stimulant intake does not appear to prevent GHB toxicity (Knudsen et al. ).

Arylcyclohexylamine and diarylethylamine designer drugs

40Dissociative agents are appreciated in medicine because of their unique pharmacological effects. These pharmacological effects, however, are also popular among recreational drug users. The dissociative anesthetic ketamine produces analgesia without cardiovascular or respiratory depression at doses that produce anesthesia, a feature that is not shared by other common anesthetics (Li and Vlisides ). Furthermore, ketamine induces rapid and sustained antidepressant actions at a single sub-anesthetic dose and has become a widely abused recreational drug because of its dissociative effects, including sensory and tactile distortions, euphoria, and depersonalization (Li and Vlisides; Zanos and Gould ). Ketamine was first synthesized in 1962 as a short-acting anesthetic with lower potency in producing emergence delirium compared with the structurally similar phencyclidine (PCP). PCP was developed before ketamine as a promising dissociative anesthetic, but its use in humans and animals was discontinued because of its unfavorable side effects (Domino ). Various similar substances have been clinically investigated. Dissociatives began to appear on the illicit drug market in the late 1960s (Morris and Wallach ). Today, several dissociative designer drugs (Fig. 6) are available, mostly arylcyclohexylamines (e.g., ketamine and PCP) and diarylethylamines. Morris, Wallach, and Brandt previously published comprehensive overviews of the history, availability, and use of several arylcyclohexylamine and diarylethylamine designer drugs and other dissociative agents (Morris and Wallach; Wallach and Brandt, ).

Mechanism of action of arylcyclohexylamine and diarylethylamine designer drugs

41Similar to ketamine and PCP, dissociative arylcyclohexylamine and diarylethylamine designer drugs act as relatively selective noncompetitive antagonists at ionotropic glutamatergic NMDA receptors. Their NMDA receptor affinity is strongly correlated with their clinical potency in inducing dissociative effects in vivo (Anis et al.; Morris and Wallach; Wallach et al. ). Some dissociative designer drugs also moderately inhibit the reuptake of norepinephrine and dopamine, whereas others have appreciable affinity for the SERT (Luethi et al.; Roth et al.; Wallach et al. ). Binding affinity at various receptors, including α adrenergic, serotonergic, histaminergic, cholinergic, opioidergic, and sigma receptors, has been reported for arylcyclohexylamines and diarylethylamines (Luethi et al.; Roth et al.; Wallach et al. ). Summarized, NMDA receptor antagonism mainly mediates the dissociative effects of arylcyclohexylamines and diarylethylamines, and interactions with other pharmacological targets may modify the activity of different compounds.

Adverse effects of arylcyclohexylamine and diarylethylamine designer drugs

42Adverse effects of dissociative arylcyclohexylamine and diarylethylamine designer drugs resemble adverse effects of traditional dissociatives, including agitation, confusion, disorientation, dissociation, hallucinations, amnesia, nystagmus, slurred speech, diaphoresis, hypertension, tachycardia, renal deficiency, nausea, ataxia, and muscle rigidity (Bäckberg et al.; Dunlop et al.; Gerace et al.; Helander et al.; Hofer et al.,; Johansson et al.; Shields et al.; Thornton et al.; Ward et al.; Wood et al.; Zawilska; Zidkova et al. ). In severe cases, dissociative designer drugs may potentially cause neurological impairment, manifested as cerebellar toxicity (Shields et al. ) or rhabdomyolysis (Bäckberg et al.; Lam et al. ). Severe adverse effects associated with inhalation of the designer drug methoxetamine include seizures, hyponatremia, and sinus bradycardia (Imbert et al. ). Regular ketamine use has been associated with potentially irreversible bladder dysfunction and subsequent renal impairment (Chu et al.; Tsai et al. ). Animal studies suggest that this may also be a consequence of regular methoxetamine use (Dargan et al.; Wang et al. ). In a survey of methoxetamine users, approximately one-fourth reported urinary symptoms (Lawn et al. ). The prevalence of urinary symptoms was related to the frequency of methoxetamine use during the previous month, but prior ketamine use could have also contributed to these symptoms (Lawn et al. ). Other dissociative designer drugs may also cause such severe urinary tract dysfunction, but detailed research has not been conducted. Additionally, the acute and chronic use of dissociative designer drugs potentially elicits wide-ranging effects on memory systems, similar to ketamine (Morgan and Curran ). Dissociative designer drugs have been involved in numerous fatal intoxications, mostly in combination with other designer drugs, including stimulants, opioids, cannabinoids, and psychedelics (Adamowicz and Zuba; Bakota et al.; Chiappini et al.; De Jong et al.; Elliott et al.; Johansson et al.; Krotulski et al.; Kudo et al.; Kusano et al.; McIntyre et al.; Mitchell-Mata et al.; Wiergowski et al.; Wikström et al. ). Wallach and Brandt previously published a detailed overview of the clinical toxicology of individual PCP analogs (Wallach and Brandt ) and diarylethylamine- and ketamine-based designer drugs (Wallach and Brandt ).

Synthetic cannabinoids

43The endocannabinoid system is involved in various physiological functions, including cognition, behavior, memory, motor control, pain sensation, appetite, cardiovascular parameters, gastrointestinal motility, and immunoregulation (Le Boisselier et al. ). The term “cannabinoid” refers to a class of compounds that are produced by Cannabis sativa and Cannabis indica, and endogenous and exogenous ligands that interact with G protein-coupled cannabinoid type 1 (CB1) and CB2 receptors (Banister and Connor; Le Boisselier et al. ). CB1 receptors are mainly expressed in the brain and modulate neurotransmitter signaling, whereas CB2 receptors are abundant in immune tissues (Banister and Connor; Le Boisselier et al. ). The first synthetic cannabinoids were developed in the second half of the twentieth century to study human endocannabinoid receptor systems (Banister and Connor; Le Boisselier et al.; Trecki et al. ). Today, synthetic cannabinoids (Fig. 7) represent the largest and most structurally diverse class of designer drugs, and some of these compounds are similar to phyto- and endocannabinoids (Banister and Connor; Trecki et al. ). Synthetic cannabinoids are often referred to as “Spice,” based on the first branded synthetic cannabinoid product. They are commonly applied to dried herbs that mimic cannabis (Banister and Connor; Le Boisselier et al.; Trecki et al. ). Desired effects of synthetic cannabinoids include relaxation, euphoria, and disinhibition, thus not significantly differing from desired effects of Δ9-tetrahydrocannabinol (Δ9-THC), the main psychoactive constituent of cannabis (Le Boisselier et al. ). However, compared with cannabis, synthetic cannabinoids have a less desirable effect profile and are associated with more severe adverse events that sometimes can result in death (Trecki et al.; Winstock and Barratt ).

Mechanism of action of synthetic cannabinoids

44Various synthetic cannabinoids have been reported to bind to CB1 and CB2 receptors with higher efficacy at both receptors compared with Δ9-THC (Banister et al.,,,; Gamage et al.; Sachdev et al. ). Biased signaling at cannabinoid receptors or the disruption of mitochondrial homeostasis may play a role in the difference between clinical effects of Δ9-THC and synthetic cannabinoids, but research in this area is still in its infancy (Finlay et al.; Silva et al., ). CB1 receptors are involved in multiple mechanisms that lead to the suppression of synaptic transmission. Compared with CB2 receptor expression, the predominance of CB1 receptors in the central nervous system indicates that they mainly mediate the psychoactive effects of synthetic cannabinoids (Atwood et al.; Castillo et al.; Kano et al.; Le Boisselier et al. ). This assumption is strengthened by studies that reported that CB1 receptor antagonism but not CB2 receptor antagonism inhibits the synthetic cannabinoid-induced lowering of heart rate and body temperature in rodents (Banister et al., ). In vitro studies showed that various metabolites of synthetic cannabinoids retain some cannabimimetic activity, indicating that they could contribute to the pharmacological effects of the drugs (Longworth et al. ). In contrast, some substances that are promoted as cannabinoid designer drugs have only low in vitro affinity for cannabinoid receptors and fail to exert significant cannabinoid activity in vivo, thus calling into question their classification as synthetic cannabinoids (Banister et al. ). Only a few synthetic cannabinoids have been studied to date with regard to their interactions with non-cannabinoid targets, with low or no affinity for most major neurotransmitter receptors (Wiley et al. ). This suggests that different effects of synthetic cannabinoids compared with Δ9-THC are mainly related to greater potency and efficacy at CB1 receptors, but possible effects on non-cannabinoid receptors and different signaling pathways that have not yet been discovered cannot be ruled out (Finlay et al.; Wiley et al. ). Furthermore, pharmacokinetic differences may contribute to these differences.

Adverse effects of synthetic cannabinoids

45The most common adverse effects of synthetic cannabinoids include agitation, drowsiness, dizziness, confusion, hallucinations, hypertension, tachycardia, chest pain, nausea, and vomiting, which typically have a short duration and require only symptomatic or supportive treatment (Forrester; Forrester et al.,; Hoyte et al.; Law et al.; Tait et al. ). Nevertheless, compared with cannabis, complications that are associated with synthetic cannabinoid use are more frequent and in some cases, more severe (Alipour et al.; Bäckberg et al.; Mensen et al.; Tait et al.; Trecki et al. ). Various severe adverse events that are associated with synthetic cannabinoids have been reported. However, many of these cases were attributed to synthetic cannabinoid use based solely on statements by patients or witnesses, without analytical confirmation of the identity and amount of substances in bodily fluids or remaining drug products. Severe clinical complications that have been reported to be associated with synthetic cannabinoid use include convulsions and seizures (Adamowicz et al.; Bäckberg et al.; Bebarta et al.; De Havenon et al.; Gugelmann et al.; Harris and Brown; Hermanns-Clausen et al.,; Hoyte et al.; Lapoint et al.; McQuade et al.; Pant et al.; Schep et al.; Schneir and Baumbacher; Tofighi and Lee ), status epileptics (Babi et al. ), catatonia (Khan et al.; Leibu et al.; Smith and Roberts ), delirium (Armenian et al.; Armstrong et al.; Bäckberg et al.; Schwartz et al.; Tyndall et al. ), ischemic stroke (Bernson-Leung et al.; Faroqui et al.; Freeman et al.; Moeller et al.; Raheemullah and Laurence; Takematsu et al.; Wolff and Jouanjus ), intracranial hemorrhage (Aydin and Bakar; Rose et al. ), pulmonary embolism (Raheemullah and Laurence; Yirgin et al. ), pneumonia and pulmonary infiltrates (Alhadi et al.; Alon and Saint-Fleur; Berkowitz et al.; Chinnadurai et al.; Öcal et al. ), respiratory depression (Alon and Saint-Fleur; Jinwala and Gupta ), supraventricular and ventricular arrhythmias (Davis and Boddington; Ibrahim et al.; Ozturk et al.; Young et al. ), myocardial ischemia and infarction (Clark et al.; Hamilton et al.; Hirapara and Aggarwal; McIlroy et al.; McKeever et al.; Mehta et al.; Mills et al.; Mir et al.; Ozturk et al.; Shah et al.; Sherpa et al.; Tse et al. ), takotsubo cardiomyopathy (Mohammed ), liver injury (Shahbaz et al. ), acute kidney injury (Argamany et al.; Armstrong et al.; Bhanushali et al.; Buser et al.; El Zahran et al.; Gudsoorkar and Perez; Kamel and Thajudeen; Katz et al.; Kazory and Aiyer; Srisung et al.; Thornton et al.; Zarifi and Vyas; Zhao et al. ), hyperemesis syndrome (Argamany et al.; Bick et al.; Hopkins and Gilchrist; Ukaigwe et al. ), and rhabdomyolysis (Adedinsewo et al.; Argamany et al.; Armstrong et al.; Durand et al.; El Zahran et al.; Katz et al.; Sherpa et al.; Sweeney et al.; Zhao et al. ). Furthermore, various psychiatric adverse effects have been reported, including paranoia, psychosis, and ideations of self-harm and suicide (Akram et al.; Altintas et al.; Bassir Nia et al.; Benford and Caplan; Berry-Caban et al.; Bonaccorso et al.; Darke et al.; Deng et al.; Derungs et al.; Durand et al.; Every-Palmer; Glue et al.; Hermanns-Clausen et al.; Hobbs et al.; Hurst et al.; Kraemer et al.; Martinotti et al.; Meijer et al.; Mensen et al.; Müller et al.; Oliveira et al.; Oluwabusi et al.; Papanti et al.; Patton et al.; Peglow et al.; Roberto et al.; Skryabin and Vinnikova; Sweet et al.; Thomas et al.; Van Amsterdam et al.; Van der Veer and Friday; Welter et al.; Yeruva et al. ). The sudden discontinuation of synthetic cannabinoid use in regular

Psychedelics

46Serotonergic psychedelics induce alterations of perception and cognitive states in users (Nichols, ). Traditional psychedelics, such as the phenethylamine 3,4,5-trimethoxyphenethylamine (mescaline), the tryptamines N,N-dimethyltryptamine (DMT) and psilocybin, and the ergot alkaloid lysergic acid diethylamide (LSD), have a history of being used for religious purposes, as therapeutic agents, and as illicit black market drugs. Although psychedelics interact with various pharmacological targets, their psychedelic effects are mainly mediated by 5-HT2A receptor agonism (Geyer and Vollenweider; Kraehenmann et al.; Madsen et al.; Nichols,; Preller et al.; Vollenweider et al. ). Affinity for 5-HT2A and 5-HT2C receptors is correlated with the amount of drug that induces psychedelic effects in humans (Fig. 8) (Luethi and Liechti ). Designer drug analogs of all the traditional psychedelic drugs are available, some of which were originally developed by industry or university laboratories but have eventually found their way onto the illicit drug market.

Phenethylamines

47Derivatives of mescaline comprise a large amount of psychedelic designer drugs (Fig. 9). The most widespread phenethylamine psychedelics are 2,5-dimethoxyphenethylamines, which bear a small lipophilic substituent at the 4-position (referred to as 2C series because they bear two carbon atoms between the benzene ring and amino group), and their slightly more potent α-methyl (amphetamine) analogs (Shulgin and Shulgin ). Psychedelic phenethylamine derivatives are mostly but not exclusively chemically modified at the phenyl ring. The introduction of an N-benzylmethoxy (“NBOMe”) group has been shown to increase the potency of the resulting derivatives (Eshleman et al.; Halberstadt; Heim; Rickli et al. ). The incorporation of 2′- and 5′-methoxy groups into rigid rings resulted in tetrahydrobenzodifuran and benzodifuran analogs that have been sold as designer drugs. These tetrahydrobenzodifuran and benzodifuran designer drugs are referred to as “FLY” and “dragonFLY” analogs, respectively, because of the shape of their chemical structure (Halberstadt et al.; Trachsel et al. ). In one of the few clinical studies of a designer drug, 4-bromo-2,5-dimethoxyphenylethylamine (2C-B) was shown to induce euphoria, well-being, and changes in perception, and to have mild stimulant properties (González et al. ). 2C-B may thus be classified as a psychedelic with entactogenic properties, an effect profile that is similar to various other phenethylamine psychedelics (Shulgin and Shulgin ).

Mechanism of action of phenethylamines

48Similar to other psychedelics, substituted phenethylamines mainly interact with serotonergic receptors, with the highest affinity for 5-HT2A receptors (Eshleman et al.; Kolaczynska et al.; Luethi et al.; Rickli et al. ). NBOMe derivatives have higher affinity for 5-HT2A and 5-HT2C receptors and lower affinity for 5-HT1A receptors compared with their 2C analogs (Rickli et al. ). At 5-HT2A receptors, 2C and NBOMe derivatives were shown to be partial or full agonists, depending on the functional in vitro assay (Eshleman et al.,; Jensen et al.; Kolaczynska et al.; Luethi et al.,; Moya et al.; Rickli et al. ). NBOMe derivatives and most 2C derivatives have been shown to be partial agonists at 5-HT2B receptors (Eshleman et al.; Jensen et al.; Kolaczynska et al.; Luethi et al.; Rickli et al. ). At 5-HT2C receptors, 2C derivatives were shown to be partial or full agonists (Eshleman et al.; Moya et al. ), and NBOMe derivatives were shown to be full agonists (Eshleman et al.; Jensen et al. ). Consistent with the in vitro findings, psychedelic phenethylamines were shown to induce 5-HT2A-dependent behaviors in vivo, such as wet dog shakes, back muscle contractions, and a head twitch response (Elmore et al.; Fantegrossi et al.; Halberstadt et al.; Halberstadt and Geyer ). In addition to interactions with serotonergic receptors, phenethylamine psychedelics have been shown to interact with other monoaminergic targets, including adrenergic, dopaminergic, and histaminergic receptors, monoamine transporters, and MAOs (Eshleman et al.; Kolaczynska et al.; Luethi et al.; Noble et al.; Rickli et al.; Wagmann et al. ). However, most of these interactions are weak compared with the potent interactions with serotonergic receptors. Therefore, they most likely have little or no pharmacological relevance to the actions of phenethylamine psychedelics. Rodent studies have suggested reinforcing effects for NBOMe derivatives that involve the dopaminergic system (Custodio et al.; Seo et al. ). The NBOMe derivative 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe) was shown to increase extracellular dopamine, 5-HT, and glutamate levels in the rat frontal cortex (Herian et al. ), but unknown are the ways in which these findings translate to humans.

Adverse effects of phenethylamines

49Most of the frequently reported adverse effects of phenethylamine psychedelics are shared by psychedelics of other chemical classes, including agitation, hallucinations, drowsiness, confusion, mydriasis, aggression, hyperthermia, hypertension, and tachycardia (Dean et al.; Forrester,; Hermanns-Clausen et al.; Hill et al.; Iwersen-Bergmann et al.; Rose et al.; Srisuma et al.; Stellpflug et al.; Stoller et al.; Tang et al.; Topeff et al.; Wood et al. ). Moreover, severe adverse effects have been linked to the use of psychedelic phenethylamines, including acute psychosis, seizures, coma, cerebral edema, long-lasting severe neurological impairment, serotonin syndrome, prolonged respiratory failure, renal failure, multi-organ failure, metabolic acidosis, and rhabdomyolysis (Bosak et al.; Grautoff and Kähler; Halberstadt; Huang and Bai; Miyajima et al.; Srisuma et al.; Tang et al.; Wood et al. ). Furthermore, 1-(4-bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine (Bromo-dragonFLY) has been associated with potent vasoconstriction, ischemia, and tissue necrosis in patients, which may be caused by the activation of serotonergic and adrenergic receptors combined with metabolic stability and long-lasting effects (Hill and Thomas; Noble et al.; Thorlacius et al.; Wood et al. ). A remarkable case of mass intoxication with 4-ethyl-2,5-dimethoxyphenethylamine (2C-E) and Bromo-dragonFLY among 29 attendees of an esoteric weekend seminar was reported (Iwersen-Bergmann et al. ). Upon the arrival of paramedics, some of the seminar attendees were rolling on the ground and screaming, and others were unconscious or unresponsive. Several attendees exhibited severe delusions and physical symptoms, including generalized seizures, pain, respiratory distress, and tachycardia (Iwersen-Bergmann et al. ). In some severe cases, the use of psychedelic phenethylamines has even resulted in death (Curtis et al.; Kueppers and Cooke; Poklis et al.; Shanks et al.; Topeff et al.; Walterscheid et al. ). Adverse effects of different phenethylamine designer drugs are mostly comparable. However, a higher incidence of hallucinations, delusions, and single-episode seizures has been observed for NBOMe derivatives compared with 2C derivatives (Srisuma et al. ). This may be explained by the higher potency of NBOMe derivatives compared with most other phenethylamine psychedelics (Braden et al.; Elmore et al.; Halberstadt and Geyer; Rickli et al. ). Several reports have linked severe intoxication to substituted phenethylamines, but the lack of analytical confirmation of the drug prevents the direct attribution of adverse effects to phenethylamines. For example, a 43-year-old woman was reported to have developed severe headaches, progressive encephalopathy, and quadraparesis within 48 h after taking a liquid form of 2C-B that was synthesized according to a manual on the Internet (Ambrose et al. ). However, the patient’s urine tested positive for cannabinoids only, and a sample of the ingested drug could not be obtained for analysis (Ambrose et al. ). Similarly, a patient presented to an emergency department with hallucinations and agitation that progressed to status epilepticus after using of 4-chloro-2,5-dimethoxyamphetamine (DOC). In addition to the analytically confirmed presence of DOC, however, the toxicology screen was positive for cannabinoids and opioids, thus hampering the attribution of seizure development to DOC (Burish et al. ). Additionally, several fatalities from 2C derivative use have been reported in the media, but the accuracy of this information cannot be verified (Dean et al. ).

Tryptamines

50The core structure of tryptamine designer drugs contains an indole ring that is connected to an amino group by an ethyl side chain, a structural feature that is shared by 5-HT. DMT as an ingredient in the psychoactive brew ayahuasca and psilocybin that is contained in Psilocybe spp. mushrooms have been used in sociocultural and ritual contexts since ancient times. They have recently regained interest for their therapeutic use (Araújo et al.; Carhart-Harris et al.; Muttoni et al.; Palhano-Fontes et al.; Roseman et al. ). In addition to naturally occurring compounds, psychedelic properties of various synthetic tryptamines (Fig. 9) have been described (Shulgin and Shulgin ).

Mechanism of action of tryptamines

51Similar to other psychedelics, 5-HT2A receptor agonism plays a key role in mediating the psychedelic effects of naturally occurring and synthetic tryptamine psychedelics (Fantegrossi et al.; Halberstadt; Madsen et al.; Vollenweider et al. ). Although mediating opposing functional effects on 5-HT2A receptors, the concurrent activation of 5-HT1A receptors has been suggested to contribute to the qualitative effects of tryptamine psychedelics, distinguishing them from phenethylamine psychedelics (Fantegrossi et al.; Halberstadt and Geyer; Nichols,; Winter et al. ). Most traditional and novel tryptamine psychedelics bind to 5-HT1A and 5-HT2A receptors with similar affinity. Some tryptamines are slightly more selective for one or the other receptor subtype (Rickli et al. ). However, various tryptamine psychedelics have been reported to be inactive at the 5-HT1A receptor in functional assays at relevant concentrations (EC50 > 10 μM) or act as mostly partial agonists with significantly lower potency compared with 5-HT2A receptors, at which tryptamine psychedelics act as moderate to full agonists (Blough et al.; Rickli et al. ). At 5-HT2B receptors, traditional and novel tryptamine psychedelics have very heterogeneous profiles, with different potencies and efficacies. For example, 5-methoxy-α-methyltryptamine (5-MeO-αMT) is a potent 5-HT2B receptor full agonist with an EC50 in the low nanomolar range, whereas psilocin and 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET) are inactive at the 5-HT2B receptor (EC50 > 20 μM) (Rickli et al. ). Tryptamine designer drugs have been shown to bind to 5-HT2C receptors but with slightly lower affinity compared with 5-HT2A receptors (Rickli et al. ). In addition to their primary effects at serotonergic receptors, tryptamines have been shown to bind to various targets in vitro, including adrenergic, dopaminergic, and histaminergic receptors (Klein et al.; Rickli et al. ). Furthermore, unlike phenethylamine or lysergamide psychedelics, many tryptamine psychedelics interact with monoamine transporters at pharmacologically relevant concentrations. In addition to some interactions with the DAT and NET for some compounds, tryptamines have the most potent transporter interactions at the SERT (Blough et al.; Cozzi et al.; Rickli et al. ). DMT and other tryptamine psychedelics have been reported to elicit 5-HT efflux, suggesting that they are transporter substrates (Blough et al.; Cozzi et al.; Rickli et al. ). In contrast, other tryptamine psychedelics, including psilocin, act as transporter inhibitors that are devoid of substrate activity (Rickli et al. ). In addition to interactions with transmembrane monoamine transporters, substrate activity at the VMAT has been described for tryptamine psychedelics (Cozzi et al. ). Tryptamines are prone to metabolism by MAOs, and MAO inhibitors counteract extensive degradation of tryptamines after oral use (Halberstadt et al.; Ott,; Riba et al. ).

Adverse effects of tryptamines

52Similar to other psychedelics, tryptamine psychedelics alter perception and can induce psychological disturbances in users, including acute psychosis (Meatherall and Sharma; Nichols,; Shulgin and Shulgin; Taljemark and Johansson ). Adverse effects of tryptamine designer drugs include restlessness, disorientation, clouding of consciousness, confusion, hallucinations, amnesia, catalepsy, mydriasis, tachypnea, hypertension, and tachycardia (Alatrash et al.; Itokawa et al.; Jovel et al.; Muller; Smolinske et al. ). 5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT) use has been associated with hallucinogen-persisting perception disorder and was proposed to play a role in the development of prolonged delusions (Fuse-Nagase and Nishikawa; Ikeda et al. ). In severe cases, the use of tryptamine designer drugs has resulted in acute renal failure and rhabdomyolysis (Alatrash et al.; Jovel et al. ). Furthermore, several fatalities after the use of tryptamine designer drugs have been reported (Boland et al.; Sklerov et al.; Tanaka et al. ).

Lysergamides

53Several derivatives of LSD have been described in the scientific literature, and such derivatives are increasingly emerging as designer drugs (Fig. 9) (Brandt et al.,,,,; Shulgin and Shulgin; Troxler and Hofmann ). The LSD-derived designer drugs 1-acetyl-LSD (ALD-52), 1-propionyl-LSD (1P-LSD), and 1-butyryl-LSD (1B-LSD) have been shown to be metabolized to LSD in vitro and are thus considered precursors of LSD with very similar effects (Wagmann et al. ). Whereas self-reported effects of some LSD analogs are similar to LSD but with slightly weaker or less pleasurable effects, other LSD analogs have been reported to be distinctively less potent or significantly differ from LSD in terms of effects (Coney et al.; Shulgin and Shulgin ).

Mechanism of action of lysergamides

54Several LSD-derived designer drugs induce a head twitch response in mice, and pretreatment with a selective 5-HT2A receptor antagonist abolished the 1P-LSD-induced head twitch response (Brandt et al. 2017a; Brandt et al. 2016). This indicates that, similar to LSD, 5-HT2A receptor activation mediates the behavioral effects of LSD analogs (Kraehenmann et al.; Liechti; Preller et al., ). Additionally, 5-HT1A receptor activation likely contributes to the qualitative effects of lysergamide designer drugs similarly to LSD and tryptamine psychedelics (Fantegrossi et al.; Halberstadt and Geyer; Nichols,; Rickli et al.; Winter et al. ). In addition to differences in affinity, LSD-derived designer drugs may activate 5-HT2A receptors with lower relative potency compared with LSD, but more research is needed to test this hypothesis (Brandt et al. 2017a). Furthermore, unclear are the ways in which the behavioral effects of lysergamide designer drugs in animals translate to humans.

Adverse effects of lysergamides

55Little is known about the adverse effects of lysergamide designer drugs. One case of a 17-year-old male who developed anxiety, hallucinations, restlessness, elevations of blood pressure, palpitations, and tachycardia after ingesting 1P-LSD was reported (Grumann et al. ). 1P-LSD was confirmed as an ingredient of the ingested blotter paper but could not be detected in urine or serum samples, despite being sufficiently stable in these matrices. However, LSD was detected in both samples, thus strengthening the assumption that 1P-LSD is readily metabolized to LSD in humans (Grumann et al. ). The patient reported that he recently used the stimulant phenmetrazine derivative 3-FPM. The low serum concentrations of 3-FPM that were detected at the time of hospital admission are, however, not expected to result in acute effects (Grumann et al. ). The symptoms of this 1P-LSD intoxication case are consistent with reported adverse effects of LSD, which is known to potentially cause psychological disturbances and moderately increase body temperature, blood pressure, and heart rate (Dolder et al.; Schmid et al. ). Acute physiological adverse effects of LSD include difficulty concentrating, imbalance, feelings of exhaustion, dizziness, headache, dry mouth, lack of appetite, and nausea (Dolder et al.; Schmid et al. ). Nichols and Grob recently reviewed the risk of LSD toxicity in users, which they concluded was very low (Nichols and Grob ). The few cases of fatality that were attributed to LSD toxicity were either associated with massive overdoses or physical restraint, or they were potentially caused by drugs that remained undetected in the toxicological analysis (Nichols and Grob ). Currently, no evidence suggests that any of the currently available lysergamide designer drugs are significantly more toxic than LSD.

Performance-enhancing designer drugs

56Designer doping agents have become increasingly popular outside of the professional athletic community and include anabolic steroids, peptide hormones, growth factor mimetics, and hormone and metabolic modulators (Joseph and Parr; Poplawska and Blazewicz; Rahnema et al.; Weber et al. ). Such substances are mainly used for performance and image enhancement, exerting effects through several different mechanisms within the hormone system (Graham et al.; Kicman ). Adverse effects that are associated with performance-enhancing designer drugs include secondary hypogonadism, gynecomastia, infertility, hypertension, ischemic stroke, cardiotoxicity, hepatotoxicity, and renal failure (Rahnema et al. ). In addition to substances that are taken to enhance athletic performance and appearance, designer drugs that are taken to enhance sexual performance, such as phosphodiesterase-5 inhibitors with no known safety profile, have also appeared. These substances may potentially induce visual disturbances or severe drug–drug interactions (Venhuis et al. ).

Miscellaneous risks associated with designer drug use

57In addition to adverse effects that are associated with specific classes of designer drugs, some general risks are essentially the same as for traditional drugs of abuse. For example, quality assurance is not guaranteed for clandestine designer drugs. A lack of information about purity, mislabeling, pharmaceutical impurities, and hazardous cutting agents can pose a risk for drug users. A series of patients who presented to a hospital with coagulopathy and bleeding diathesis that were related to long-acting anticoagulant rodenticide adulterants of synthetic cannabinoids exemplifies their potentially fatal consequences (Devgun et al.; Kelkar et al. ). Potentially severe drug–drug interactions are a risk when more than one substance is used, including prescription medications (Contrucci et al.; Inan et al. ). Byproducts and impurities can pose such risks as septum perforation when insufflated or necrotic ulcers and infections when injected (Lafferty et al.; Parks et al. ). Hallucinogen-persisting perception disorder has been associated with psychedelics, cannabinoids, and psychostimulants, manifesting in prolonged or reoccurring perceptual symptoms (Ikeda et al.; Orsolini et al.; Skryabin et al. ). The neurological and psychological changes that are associated with designer drugs can impair safe driving, and driving under the influence can severely jeopardize traffic safety (Adamowicz and Lechowicz; Maas et al.; Musshoff et al. ).

Concluding remarks

58Designer drugs are often used in combination with other substances, thus hindering precise evaluations of the degree of involvement of individual substances to clinical toxicity in patients. Furthermore, designer drugs may remain undetected by routine drug screenings. Nevertheless, the pharmacological and toxicological profiles of most designer drug classes are similar to their related traditional drugs of abuse. Stimulants primarily act as substrates or inhibitors of monoamine transporters. Intoxication with stimulants mostly manifests as sympathomimetic adverse effects, the treatment of which is mainly supportive. Benzodiazepines may be given to control agitation, hypertension, and convulsions. Certain stimulants, including MDMA, have a marked serotonergic profile. Their associated adverse effects, such as serotonin syndrome, can be potentially severe clinical complications. Agonism at μ-opioid receptors mediates the main pharmacological effects of opioids, and GABAA and GABAB receptors drive the effects of designer benzodiazepines and GHB analogs, respectively. Sedatives, including synthetic opioids and GHB analogs, pose a risk of cardiorespiratory arrest, especially when they are used in combination with other depressants, such as alcohol and benzodiazepines. Initial patient care should focus on protecting the airways and maintaining breathing and circulation. Naloxone is an effective antidote to opioid toxicity. Dissociative designer drugs act as NMDA receptor antagonists and induce adverse effects that are similar to the dissociative anesthetics ketamine and PCP. Compared with Δ9-THC, synthetic cannabinoids act as more potent and effective agonists of CB1 and CB2 receptors, but the predominance of CB1 receptors in the central nervous system suggests that they mainly mediate the psychoactive effects. Compared with cannabis, effects of synthetic cannabinoids are less desirable, and adverse effects are more severe. Serotonergic psychedelics alter perception and cognition mainly through 5-HT2A receptor agonism. In addition to psychological disturbances, psychedelics may induce physical adverse effects, which are usually short-lived. Rarely, designer drug use can lead to severe psychiatric and physical complications and even death. Single-drug use and more precise knowledge of substance identity, potency, and purity can reduce the risks of designer drug use.

59Below is the link to the electronic supplementary material.

References 658

1.
Aarde SM, Taffe MA. Predicting the abuse liability of entactogen-class, new and emerging psychoactive substances via preclinical models of drug self-administration. Curr Top Behav Neurosci. 2017;32:145-164.
Not in our library10.1007/7854_2016_54
2.
Adamowicz P. Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Sci Int. 2016;261:e5-10.
Not in our library10.1016/j.forsciint.2016.02.024
3.
Adamowicz P, Lechowicz W. The influence of synthetic cannabinoid UR-144 on human psychomotor performance–a case report demonstrating road traffic risks. Traffic Inj Prev. 2015;16(8):754-759.
Not in our library10.1080/15389588.2015.1018990
4.
Adamowicz P, Zuba D. Fatal intoxication with methoxetamine. J Forensic Sci. 2015;60(Suppl 1):S264-S268.
Not in our library10.1111/1556-4029.12594
5.
Adamowicz P, Zuba D, Byrska B. Fatal intoxication with 3-methyl-N-methylcathinone (3-MMC) and 5-(2-aminopropyl)benzofuran (5-APB). Forensic Sci Int. 2014;245:126-132.
Not in our library10.1016/j.forsciint.2014.10.016
6.
Adamowicz P, Gieron J, Gil D, Lechowicz W, Skulska A, Tokarczyk B. 3-Methylmethcathinone-interpretation of blood concentrations based on analysis of 95 cases. J Anal Toxicol. 2016;40(4):272-276.
Not in our library10.1093/jat/bkw018
7.
Adamowicz P, Gieron J, Gil D, Lechowicz W, Skulska A, Tokarczyk B. The effects of synthetic cannabinoid UR-144 on the human body—a review of 39 cases. Forensic Sci Int. 2017;273:e18-e21.
Not in our library10.1016/j.forsciint.2017.02.031
8.
Adamowicz P, Meissner E, Maslanka M. Fatal intoxication with new synthetic cannabinoids AMB-FUBINACA and EMB-FUBINACA. Clin Toxicol (Phila). 2019;57(11):1103-1108.
Not in our library10.1080/15563650.2019.1580371
9.
Adedinsewo DA, Odewole O, Todd T. Acute rhabdomyolysis following synthetic cannabinoid ingestion. N Am J Med Sci. 2016;8(6):256-258.
Not in our library10.4103/1947-2714.185038
10.
Akram H, Mokrysz C, Curran HV. What are the psychological effects of using synthetic cannabinoids? A systematic review. J Psychopharmacol. 2019;33(3):271-283.
Not in our library10.1177/0269881119826592
11.
Alatrash G, Majhail NS, Pile JC. Rhabdomyolysis after ingestion of "foxy", a hallucinogenic tryptamine derivative. Mayo Clin Proc. 2006;81(4):550-551.
Not in our library10.4065/81.4.550
12.
Alhadi S, Tiwari A, Vohra R, Gerona R, Acharya J, Bilello K. High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J Med Toxicol. 2013;9(2):199-206.
Not in our library10.1007/s13181-013-0288-9
13.
Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011;115(6):1363-1381.
Not in our library10.1097/aln.0b013e318238bba6
14.
Alipour A, Patel PB, Shabbir Z, Gabrielson S. Review of the many faces of synthetic cannabinoid toxicities. Ment Health Clin. 2019;9(2):93-99.
Not in our library10.9740/mhc.2019.03.093
15.
Alles GA, Feigen GA. Comparative physiological actions of phenyl-, thienyl- and furylisopropylamines. J Pharmacol Exp Ther. 1941;72(3):265-275.
Not in our library
16.
Al-Matrouk A, Alqallaf M, AlShemmeri A, BoJbarah H. Identification of synthetic cannabinoids that were seized, consumed, or associated with deaths in Kuwait in 2018 using GC–MS and LC–MS–MS analysis. Forensic Sci Int. 2019;303:109960.
Not in our library10.1016/j.forsciint.2019.109960
17.
Alon MH, Saint-Fleur MO. Synthetic cannabinoid induced acute respiratory depression: case series and literature review. Respir Med Case Rep. 2017;22:137-141.
Not in our library10.1016/j.rmcr.2017.07.011
18.
Altintas M, Inanc L, Oruc GA, Arpacioglu S, Gulec H. Clinical characteristics of synthetic cannabinoid-induced psychosis in relation to schizophrenia: a single-center cross-sectional analysis of concurrently hospitalized patients. Neuropsychiatr Dis Treat. 2016;12:1893-1900.
Not in our library10.2147/ndt.s107622
19.
Ambrose JB, Bennett HD, Lee HS, Josephson SA. Cerebral vasculopathy after 4-bromo-2,5-dimethoxyphenethylamine ingestion. Neurologist. 2010;16(3):199-202.
Not in our library10.1097/nrl.0b013e3181a3cb53
20.
Amoroso T, Workman M. Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: a preliminary meta-analysis and comparison to prolonged exposure therapy. J Psychopharmacol. 2016;30(7):595-600.
Not in our library10.1177/0269881116642542
21.
Andersson M, Kjellgren A. The slippery slope of flubromazolam: experiences of a novel psychoactive benzodiazepine as discussed on a Swedish online forum. Nord Stud Alcohol Drugs. 2017;34(3):217-229.
Not in our library10.1177/1455072517706304
22.
Andreu V, Mas A, Bruguera M, Salmerón JM, Moreno V, Nogué S, Rodés J. Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol. 1998;29(3):394-397.
Not in our library10.1016/s0168-8278(98)80056-1
23.
Angerer V, Jacobi S, Franz F, Auwärter V, Pietsch J. Three fatalities associated with the synthetic cannabinoids 5F-ADB, 5F-PB-22, and AB-CHMINACA. Forensic Sci Int. 2017;281:e9-e15.
Not in our library10.1016/j.forsciint.2017.10.042
24.
Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol. 1983;79(2):565-575.
Not in our library10.1111/j.1476-5381.1983.tb11031.x
25.
Anne S, Tse R, Cala AD. A fatal case of isolated methiopropamine (1-(thiophen-2-yl)-2-methylaminopropane) toxicity: a case report. Am J Forensic Med Pathol. 2015;36(3):205-206.
Not in our library10.1097/paf.0000000000000170
26.
Araújo AM, Carvalho F, Bastos MDL, Guedes De Pinho P, Carvalho M. The hallucinogenic world of tryptamines: an updated review. Arch Toxicol. 2015;89(8):1151-1173.
Not in our library10.1007/s00204-015-1513-x
27.
Arbo MD, Bastos ML, Carmo HF. Piperazine compounds as drugs of abuse. Drug Alcohol Depend. 2012;122(3):174-185.
Not in our library10.1016/j.drugalcdep.2011.10.007
28.
Arbo MD, Melega S, Stöber R, Schug M, Rempel E, Rahnenführer J, Godoy P, Reif R, Cadenas C, De Lourdes BM, Carmo H, Hengstler JG. Hepatotoxicity of piperazine designer drugs: up-regulation of key enzymes of cholesterol and lipid biosynthesis. Arch Toxicol. 2016;90(12):3045-3060.
Not in our library10.1007/s00204-016-1665-3
29.
Arbo MD, Silva R, Barbosa DJ, Dias da Silva D, Silva SP, Teixeira JP, Bastos ML, Carmo H. In vitro neurotoxicity evaluation of piperazine designer drugs in differentiated human neuroblastoma SH-SY5Y cells. J Appl Toxicol. 2016;36(1):121-130.
Not in our library10.1002/jat.3153
30.
Argamany JR, Reveles KR, Duhon B. Synthetic cannabinoid hyperemesis resulting in rhabdomyolysis and acute renal failure. Am J Emerg Med. 2016;34(4):765.e1-2.
Not in our library10.1016/j.ajem.2015.08.051
31.
Armenian P, Olson A, Anaya A, Kurtz A, Ruegner R, Gerona RR. Fentanyl and a novel synthetic opioid U-47700 masquerading as street "Norco" in Central California: a case report. Ann Emerg Med. 2017;69(1):87-90.
Not in our library10.1016/j.annemergmed.2016.06.014
32.
Armenian P, Darracq M, Gevorkyan J, Clark S, Kaye B, Brandehoff NP. Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: a case series and review of the literature. Neuropharmacology. 2018;134(Pt A):82-91.
Not in our library10.1016/j.neuropharm.2017.10.017
33.
Armenian P, Vo KT, Barr-Walker J, Lynch KL. Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology. 2018;134(Pt A):121-132.
Not in our library10.1016/j.neuropharm.2017.10.016
34.
Armstrong F, McCurdy MT, Heavner MS. Synthetic cannabinoid-associated multiple organ failure: case series and literature review. Pharmacotherapy. 2019;39(4):508-513.
Not in our library10.1002/phar.2241
35.
Atwood BK, Huffman J, Straiker A, Mackie K. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol. 2010;160(3):585-593.
Not in our library10.1111/j.1476-5381.2009.00582.x
36.
Aydin G, Bakar B. Delayed intracerebral hemorrhage after synthetic cannabis (Bonsai) abuse; case report and literature review. Bull Emerg Trauma. 2019;7(3):330-334.
Not in our library10.29252/beat-0703019
37.
A spicy status: Synthetic cannabinoid (spice) use and new-onset refractory status epilepticus—A case report and review of the literature · 2017
Not checked
38.
Bäckberg M, Beck O, Hulten P, Rosengren-Holmberg J, Helander A. Intoxications of the new psychoactive substance 5-(2-aminopropyl)indole (5-IT): a case series from the Swedish STRIDA project. Clin Toxicol (Phila). 2014;52(6):618-624.
Not in our library10.3109/15563650.2014.920088
39.
Bäckberg M, Beck O, Helander A. Phencyclidine analog use in Sweden–intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. Clin Toxicol (Phila). 2015;53(9):856-864.
Not in our library10.3109/15563650.2015.1079325
40.
Bäckberg M, Beck O, Jonsson KH, Helander A. Opioid intoxications involving butyrfentanyl, 4-fluorobutyrfentanyl, and fentanyl from the Swedish STRIDA project. Clin Toxicol (Phila). 2015;53(7):609-617.
Not in our library10.3109/15563650.2015.1054505
41.
Bäckberg M, Lindeman E, Beck O, Helander A. Characteristics of analytically confirmed 3-MMC-related intoxications from the Swedish STRIDA project. Clin Toxicol (Phila). 2015;53(1):46-53.
Not in our library10.3109/15563650.2014.981823
42.
Bäckberg M, Westerbergh J, Beck O, Helander A. Adverse events related to the new psychoactive substance 3-fluorophenmetrazine—results from the Swedish STRIDA project. Clin Toxicol (Phila). 2016;54(9):819-825.
Not in our library10.1080/15563650.2016.1211288
43.
Bäckberg M, Tworek L, Beck O, Helander A. Analytically confirmed intoxications involving MDMB-CHMICA from the STRIDA project. J Med Toxicol. 2017;13(1):52-60.
Not in our library10.1007/s13181-016-0584-2
44.
Bäckberg M, Pettersson Bergstrand M, Beck O, Helander A. Occurrence and time course of NPS benzodiazepines in Sweden–results from intoxication cases in the STRIDA project. Clin Toxicol (Phila). 2019;57(3):203-212.
Not in our library10.1080/15563650.2018.1506130
45.
Bailey K, Richards-Waugh L, Clay D, Gebhardt M, Mahmoud H, Kraner JC. Fatality involving the ingestion of phenazepam and poppy seed tea. J Anal Toxicol. 2010;34(8):527-532.
Not in our library10.1093/jat/34.8.527
46.
Bailey GP, Ho JH, Hudson S, Dines A, Archer JR, Dargan PI, Wood DM. Nopaine no gain: recreational ethylphenidate toxicity. Clin Toxicol. 2015;53(5):498-499.
Not in our library10.3109/15563650.2015.1033062
47.
Bakota E, Arndt C, Romoser AA, Wilson SK. Fatal intoxication involving 3-MeO–PCP: a case report and validated method. J Anal Toxicol. 2016;40(7):504-510.
Not in our library10.1093/jat/bkw056
48.
Baldo BA. Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch Toxicol. 2018;92(8):2457-2473.
Not in our library10.1007/s00204-018-2244-6
49.
Balmelli C, Kupferschmidt H, Rentsch K, Schneemann M. Tödliches Hirnödem nach Einnahme von Ecstasy und Benzylpiperazin. Dtsch Med Wochenschr. 2001;126(28–29):809-811.
Not in our library10.1055/s-2001-15702
50.
Banister SD, Connor M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: origins. Handb Exp Pharmacol. 2018;252:165-190.
Not in our library10.1007/164_2018_143
51.
Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Glass M, Connor M, McGregor IS, Kassiou M. Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chem Neurosci. 2015;6(9):1546-1559.
Not in our library10.1021/acschemneuro.5b00112
52.
Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M. Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chem Neurosci. 2015;6(8):1445-1458.
Not in our library10.1021/acschemneuro.5b00107
53.
Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, Mack JB, Glass M, McGregor IS, Connor M, Kassiou M. Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues. ACS Chem Neurosci. 2016;7(9):1241-1254.
Not in our library10.1021/acschemneuro.6b00137
54.
Banister SD, Adams A, Kevin RC, Macdonald C, Glass M, Boyd R, Connor M, McGregor IS, Havel CM, Bright SJ, Vilamala MV, Lladanosa CG, Barratt MJ, Gerona RR. Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold-hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. Drug Test Anal. 2019;11(2):279-291.
Not in our library10.1002/dta.2491
55.
Banister SD, Kevin RC, Martin L, Adams A, Macdonald C, Manning JJ, Boyd R, Cunningham M, Stevens MY, McGregor IS, Glass M, Connor M, Gerona RR. The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs. Drug Test Anal. 2019;11(7):976-989.
Not in our library10.1002/dta.2583
56.
Barann M, Stamer UM, Lyutenska M, Stuber F, Bonisch H, Urban B. Effects of opioids on human serotonin transporters. Naunyn Schmiedeberg’s Arch Pharmacol. 2015;388(1):43-49.
Not in our library10.1007/s00210-014-1056-3
57.
Barrios L, Grison-Hernando H, Boels D, Bouquie R, Monteil-Ganiere C, Clement R. Death following ingestion of methylone. Int J Legal Med. 2016;130(2):381-385.
Not in our library10.1007/s00414-015-1212-4
58.
Bassir Nia A, Mann CL, Spriggs S, DeFrancisco DR, Carbonaro S, Parvez L, Galynker II, Perkel CA, Hurd YL. The relevance of sex in the association of synthetic cannabinoid use with psychosis and agitation in an inpatient population. J Clin Psychiatry. 2019;80(4):1.
Not in our library10.4088/jcp.18m12539
59.
Baumann MH, Ayestas MA, Dersch CM, Brockington A, Rice KC, Rothman RB. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications. Synapse. 2000;36(2):102-113.
Not in our library10.1002/(sici)1098-2396(200005)36:2<102::aid-syn3>3.0.co;2-#
60.
Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology. 2005;30(3):550-560.
Not in our library10.1038/sj.npp.1300585
61.
Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology. 2012;37(5):1192-1203.
Not in our library10.1038/npp.2011.304
62.
Baumann MH, Partilla JS, Lehner KR. Psychoactive "bath salts": not so soothing. Eur J Pharmacol. 2013;698(1–3):1-5.
Not in our library10.1016/j.ejphar.2012.11.020
63.
Baumann MH, Majumdar S, Le Rouzic V, Hunkele A, Uprety R, Huang XP, Xu J, Roth BL, Pan YX, Pasternak GW. Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace. Neuropharmacology. 2018;134(Pt A):101-107.
Not in our library10.1016/j.neuropharm.2017.08.016
64.
Bay T, Eghorn LF, Klein AB, Wellendorph P. GHB receptor targets in the CNS: focus on high-affinity binding sites. Biochem Pharmacol. 2014;87(2):220-228.
Not in our library10.1016/j.bcp.2013.10.028
65.
Bebarta VS, Ramirez S, Varney SM. Complication of spice use in a deployed combat setting-seizure while on duty. Am J Addict. 2012;21(5):496-497.
Not in our library10.1111/j.1521-0391.2012.00264.x
66.
Beck O, Franzén L, Bäckberg M, Signell P, Helander A. Intoxications involving MDPV in Sweden during 2010–2014: results from the STRIDA project. Clin Toxicol (Phila). 2015;53(9):865-873.
Not in our library10.3109/15563650.2015.1089576
67.
Beck O, Franzén L, Bäckberg M, Signell P, Helander A. Toxicity evaluation of α-pyrrolidinovalerophenone (α-PVP): results from intoxication cases within the STRIDA project. Clin Toxicol (Phila). 2016;54(7):568-575.
Not in our library10.1080/15563650.2016.1190979
68.
Behonick G, Shanks KG, Firchau DJ, Mathur G, Lynch CF, Nashelsky M, Jaskierny DJ, Meroueh C. Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J Anal Toxicol. 2014;38(8):559-562.
Not in our library10.1093/jat/bku048
69.
Benesch MGK, Iqbal SJ. Novel psychoactive substances: overdose of 3-fluorophenmetrazine (3-FPM) and etizolam in a 33-year-old man. BMJ Case Rep. 2018.
Not in our library10.1136/bcr-2018-224995
70.
Benford DM, Caplan JP. Psychiatric sequelae of Spice, K2, and synthetic cannabinoid receptor agonists. Psychosomatics. 2011;52(3):295.
Not in our library10.1016/j.psym.2011.01.004
71.
Berkowitz EA, Henry TS, Veeraraghavan S, Staton GW, Gal AA. Pulmonary effects of synthetic marijuana: chest radiography and CT findings. AJR Am J Roentgenol. 2015;204(4):750-757.
Not in our library10.2214/ajr.14.13138
72.
Bernson-Leung ME, Leung LY, Kumar S. Synthetic cannabis and acute ischemic stroke. J Stroke Cerebrovasc Dis. 2014;23(5):1239-1241.
Not in our library10.1016/j.jstrokecerebrovasdis.2013.07.030
73.
Berry-Caban CS, Ee J, Ingram V, Berry CE, Kim EH. Synthetic cannabinoid overdose in a 20-year-old male US soldier. Subst Abus. 2013;34(1):70-72.
Not in our library10.1080/08897077.2012.677754
74.
Bhanushali GK, Jain G, Fatima H, Leisch LJ, Thornley-Brown D. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol. 2013;8(4):523-526.
Not in our library10.2215/cjn.05690612
75.
Bick BL, Szostek JH, Mangan TF. Synthetic cannabinoid leading to cannabinoid hyperemesis syndrome. Mayo Clin Proc. 2014;89(8):1168-1169.
Not in our library10.1016/j.mayocp.2014.06.013
76.
Bingham C, Beaman M, Nicholls AJ, Anthony PP. Necrotizing renal vasculopathy resulting in chronic renal failure after ingestion of methamphetamine and 3,4-methylenedioxymethamphetamine ('ecstasy'). Nephrol Dial Transplant. 1998;13(10):2654-2655.
Not in our library10.1093/ndt/13.10.2654
77.
Blicke FF, Burckhalter JH. α-Thienylaminoalkanes. J Am Chem Soc. 1942;64(3):477-480.
Not in our library10.1021/ja01255a001
78.
Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB. Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes. Psychopharmacology. 2014;231(21):4135-4144.
Not in our library10.1007/s00213-014-3557-7
79.
Boland DM, Andollo W, Hime GW, Hearn WL. Fatality due to acute α-methyltryptamine intoxication. J Anal Toxicol. 2005;29(5):394-397.
Not in our library10.1093/jat/29.5.394
80.
Boland DM, Reidy LJ, Seither JM, Radtke JM, Lew EO. Forty-three fatalities involving the synthetic cannabinoid, 5-fluoro-ADB: forensic pathology and toxicology implications. J Forensic Sci. 2019.
Not in our library10.1111/1556-4029.14098
81.
Bonaccorso S, Metastasio A, Ricciardi A, Stewart N, Jamal L, Rujully NU, Theleritis C, Ferracuti S, Ducci G, Schifano F. Synthetic cannabinoid use in a case series of patients with psychosis presenting to acute psychiatric settings: clinical presentation and management issues. Brain Sci. 2018;8(7):1.
Not in our library10.3390/brainsci8070133
82.
Borek HA, Holstege CP. Hyperthermia and multiorgan failure after abuse of “bath salts” containing 3,4-methylenedioxypyrovalerone. Ann Emerg Med. 2012;60(1):103-105.
Not in our library10.1016/j.annemergmed.2012.01.005
83.
Bosak A, LoVecchio F, Levine M. Recurrent seizures and serotonin syndrome following "2C-I" ingestion. J Med Toxicol. 2013;9(2):196-198.
Not in our library10.1007/s13181-013-0287-x
84.
Bossong MG, Brunt TM, Van Dijk JP, Rigter SM, Hoek J, Goldschmidt HM, Niesink RJ. mCPP: an undesired addition to the ecstasy market. J Psychopharmacol. 2010;24(9):1395-1401.
Not in our library10.1177/0269881109102541
85.
Boulanger-Gobeil C, St-Onge M, Laliberte M, Auger PL. Seizures and hyponatremia related to ethcathinone and methylone poisoning. J Med Toxicol. 2012;8(1):59-61.
Not in our library10.1007/s13181-011-0159-1
86.
Braden MR, Parrish JC, Naylor JC, Nichols DE. Molecular interaction of serotonin 5-HT2A receptor residues Phe 339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol. 2006;70(6):1956-1964.
Not in our library10.1124/mol.106.028720
87.
Brandt SD, Baumann MH, Partilla JS, Kavanagh PV, Power JD, Talbot B, Twamley B, Mahony O, O'Brien J, Elliott SP, Archer RP, Patrick J, Singh K, Dempster NM, Cosbey SH. Characterization of a novel and potentially lethal designer drug (±)-cis-para-methyl-4-methylaminorex (4,4'-DMAR, or 'Serotoni'). Drug Test Anal. 2014;6(7–8):684-695.
Not in our library10.1002/dta.1668
88.
Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Hoang K, Wallach J, Halberstadt AL. Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD). Drug Test Anal. 2016;8(9):891-902.
Not in our library10.1002/dta.1884
89.
Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T, Burrow TE, Chapman SJ, Stratford A, Nichols DE, Halberstadt AL. Return of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2ʹS,4ʹS)-lysergic acid 2,4-dimethylazetidide (LSZ). Drug Test Anal. 2017;9(1):38-50.
Not in our library10.1002/dta.1985
90.
Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Stratford A, Nichols DE, Halberstadt AL. Return of the lysergamides. Part III: Analytical characterization of N6-ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). Drug Test Anal. 2017;9(10):1641-1649.
Not in our library10.1002/dta.2196
91.
Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J, Stratford A, Klein LM, McCorvy JD, Nichols DE, Halberstadt AL. Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). Drug Test Anal. 2018;10(2):310-322.
Not in our library10.1002/dta.2222
92.
Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Dowling G, Wallach J, Halberstadt AL. Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD). Drug Test Anal. 2019;11(8):1122-1133.
Not in our library10.1002/dta.2613
93.
Brennan R, Van Hout MC. Gamma-hydroxybutyrate (GHB): a scoping review of pharmacology, toxicology, motives for use, and user groups. J Psychoactive Drugs. 2014;46(3):243-251.
Not in our library10.1080/02791072.2014.921746
94.
Brown PC, Alfonso J, Dunn ME. Gamma hydroxybutyrate use: exploring the influence of outcome expectancies through memory modeling. Am J Addict. 2011;20(2):127-136.
Not in our library10.1111/j.1521-0391.2010.00113.x
95.
Burish MJ, Thoren KL, Madou M, Toossi S, Shah M. Hallucinogens causing seizures? A case report of the synthetic amphetamine 2,5-dimethoxy-4-chloroamphetamine. Neurohospitalist. 2015;5(1):32-34.
Not in our library10.1177/1941874414528939
96.
Burns G, DeRienz RT, Baker DD, Casavant M, Spiller HA. Could chest wall rigidity be a factor in rapid death from illicit fentanyl abuse? Clin Toxicol (Phila). 2016;54(5):420-423.
Not in our library10.3109/15563650.2016.1157722
97.
Busardò FP, Jones AW. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol. 2015;13(1):47-70.
Not in our library10.2174/1570159x13666141210215423
98.
Busardò FP, Kyriakou C, Napoletano S, Marinelli E, Zaami S. Mephedrone related fatalities: a review. Eur Rev Med Pharmacol Sci. 2015;19(19):3777-3790.
Not in our library
99.
Buser GL, Gerona RR, Horowitz BZ, Vian KP, Troxell ML, Hendrickson RG, Houghton DC, Rozansky D, Su SW, Leman RF. Acute kidney injury associated with smoking synthetic cannabinoid. Clin Toxicol (Phila). 2014;52(7):664-673.
Not in our library10.3109/15563650.2014.932365
100.
Campbell GA, Rosner MH. The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney. Clin J Am Soc Nephrol. 2008;3(6):1852-1860.
Not in our library10.2215/cjn.02080508
101.
Canning H, Goff D, Leach MJ, Miller AA, Tateson JE, Wheatley PL. The involvement of dopamine in the central actions of bupropion, a new antidepressant [proceedings]. Br J Pharmacol. 1979;66(1):104p-105p.
Not in our library
102.
Carai MA, Colombo G, Brunetti G, Melis S, Serra S, Vacca G, Mastinu S, Pistuddi AM, Solinas C, Cignarella G, Minardi G, Gessa GL. Role of GABAB receptors in the sedative/hypnotic effect of γ-hydroxybutyric acid. Eur J Pharmacol. 2001;428(3):315-321.
Not in our library10.1016/s0014-2999(01)01334-6
103.
Carbone PN, Carbone DL, Carstairs SD, Luzi SA. Sudden cardiac death associated with methylone use. Am J Forensic Med Pathol. 2013;34(1):26-28.
Not in our library10.1097/paf.0b013e31827ab5da
104.
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up · 2017
No notice
105.
Carpenter JE, Murray BP, Dunkley C, Kazzi ZN, Gittinger MH. Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014–2017. Clin Toxicol (Phila). 2019;57(4):282-286.
Not in our library10.1080/15563650.2018.1510502
106.
Carter LP, Chen W, Wu H, Mehta AK, Hernandez RJ, Ticku MK, Coop A, Koek W, France CP. Comparison of the behavioral effects of gamma-hydroxybutyric acid (GHB) and its 4-methyl-substituted analog, gamma-hydroxyvaleric acid (GHV). Drug Alcohol Depend. 2005;78(1):91-99.
Not in our library10.1016/j.drugalcdep.2004.10.002
107.
Carter LP, Koek W, France CP. Behavioral analyses of GHB: receptor mechanisms. Pharmacol Ther. 2009;121(1):100-114.
Not in our library10.1016/j.pharmthera.2008.10.003
108.
Carvalho M, Pontes H, Remiao F, Bastos ML, Carvalho F. Mechanisms underlying the hepatotoxic effects of ecstasy. Curr Pharm Biotechnol. 2010;11(5):476-495.
Not in our library10.2174/138920110791591535
109.
Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, Carvalho F, MeL B. Toxicity of amphetamines: an update. Arch Toxicol. 2012;86(8):1167-1231.
Not in our library10.1007/s00204-012-0815-5
110.
Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron. 2012;76(1):70-81.
Not in our library10.1016/j.neuron.2012.09.020
111.
Chait LD, Uhlenhuth EH, Johanson CE. Reinforcing and subjective effects of several anorectics in normal human volunteers. J Pharmacol Exp Ther. 1987;242(3):777-783.
Not in our library
112.
Chan WL, Wood DM, Hudson S, Dargan PI. Acute psychosis associated with recreational use of benzofuran 6-(2-aminopropyl)benzofuran (6-APB) and cannabis. J Med Toxicol. 2013;9(3):278-281.
Not in our library10.1007/s13181-013-0306-y
113.
Charbogne P, Kieffer BL, Befort K. 15 years of genetic approaches in vivo for addiction research: opioid receptor and peptide gene knockout in mouse models of drug abuse. Neuropharmacology. 2014;76(Pt B):204-217.
Not in our library10.1016/j.neuropharm.2013.08.028
114.
Chiappini S, Claridge H, Corkery JM, Goodair C, Loi B, Schifano F. Methoxetamine-related deaths in the UK: an overview. Hum Psychopharmacol. 2015;30(4):244-248.
Not in our library10.1002/hup.2422
115.
Chinnadurai T, Shrestha S, Ayinla R. A curious case of inhalation fever caused by synthetic cannabinoid. Am J Case Rep. 2016;17:379-383.
Not in our library10.12659/ajcr.898500
116.
Chu PS, Kwok SC, Lam KM, Chu TY, Chan SW, Man CW, Ma WK, Chui KL, Yiu MK, Chan YC, Tse ML, Lau FL. 'Street ketamine'-associated bladder dysfunction: a report of ten cases. Hong Kong Med J. 2007;13(4):311-313.
Not in our library
117.
Clark BC, Georgekutty J, Berul CI. Myocardial ischemia secondary to synthetic cannabinoid (K2) use in pediatric patients. J Pediatr. 2015;167(3):757-61.e1.
Not in our library10.1016/j.jpeds.2015.06.001
118.
Codd EE, Shank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995;274(3):1263-1270.
Not in our library
119.
Colado MI, Murray TK, Green AR. 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br J Pharmacol. 1993;108(3):583-589.
Not in our library10.1111/j.1476-5381.1993.tb12846.x
120.
Cole JB, Dunbar JF, McIntire SA, Regelmann WE, Slusher TM. Butyrfentanyl overdose resulting in diffuse alveolar hemorrhage. Pediatrics. 2015;135(3):e740-e743.
Not in our library10.1542/peds.2014-2878
121.
Postmortem Toxicology of New Synthetic Opioids · 2018
Not checked
122.
Coney LD, Maier LJ, Ferris JA, Winstock AR, Barratt MJ. Genie in a blotter: a comparative study of LSD and LSD analogues' effects and user profile. Hum Psychopharmacol. 2017;32(3):1.
Not in our library10.1002/hup.2599
123.
Contrucci RR, Brunt TM, Inan F, Franssen EJF, Hondebrink L. Synthetic cathinones and their potential interactions with prescription drugs. Ther Drug Monit. 2020;42(1):75-82.
Not in our library10.1097/ftd.0000000000000682
124.
Coopman V, Blanckaert P, Van Parys G, Van Calenbergh S, Cordonnier J. A case of acute intoxication due to combined use of fentanyl and 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700). Forensic Sci Int. 2016;266:68-72.
Not in our library10.1016/j.forsciint.2016.05.001
125.
Coopman V, Cordonnier J, De Leeuw M, Cirimele V. Ocfentanil overdose fatality in the recreational drug scene. Forensic Sci Int. 2016;266:469-473.
Not in our library10.1016/j.forsciint.2016.07.005
126.
Coppola M, Mondola R. 5-Iodo-2-aminoindan (5-IAI): chemistry, pharmacology, and toxicology of a research chemical producing MDMA-like effects. Toxicol Lett. 2013;218(1):24-29.
Not in our library10.1016/j.toxlet.2013.01.008
127.
Coppola M, Mondola R. A new stimulant of abuse: 5-(2-aminopropyl)indole. Am J Psychiatry. 2013;170(2):226.
Not in our library10.1176/appi.ajp.2012.12091168
128.
Corkery JM, Elliott S, Schifano F, Corazza O, Ghodse AH. MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; 'sparkle'; 'mindy') toxicity: a brief overview and update. Hum Psychopharmacol. 2013;28(4):345-355.
Not in our library10.1002/hup.2298
129.
Corkery JM, Loi B, Claridge H, Goodair C, Corazza O, Elliott S, Schifano F. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): a literature review with a focus on UK fatalities related to non-medical use. Neurosci Biobehav Rev. 2015;53:52-78.
Not in our library10.1016/j.neubiorev.2015.03.012
130.
Cosbey S, Kirk S, McNaul M, Peters L, Prentice B, Quinn A, Elliott SP, Brandt SD, Archer RP. Multiple fatalities involving a new designer drug: para-methyl-4-methylaminorex. J Anal Toxicol. 2014;38(6):383-384.
Not in our library10.1093/jat/bku031
131.
Cozzi NV, Gopalakrishnan A, Anderson LL, Feih JT, Shulgin AT, Daley PF, Ruoho AE. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J Neural Transm (Vienna). 2009;116(12):1591-1599.
Not in our library10.1007/s00702-009-0308-8
132.
Crichton ML, Shenton CF, Drummond G, Beer LJ, Seetohul LN, Maskell PD. Analysis of phenazepam and 3-hydroxyphenazepam in post-mortem fluids and tissues. Drug Test Anal. 2015;7(10):926-936.
Not in our library10.1002/dta.1790
133.
Crunelli V, Emri Z, Leresche N. Unravelling the brain targets of γ-hydroxybutyric acid. Curr Opin Pharmacol. 2006;6(1):44-52.
Not in our library10.1016/j.coph.2005.10.001
134.
Cunningham G. Diethylpropion in the treatment of obesity. Br J Gen Pract. 1963;6(2):347.
Not in our library
135.
Cunningham M. Ecstasy-induced rhabdomyolysis and its role in the development of acute renal failure. Intensive Crit Care Nurs. 1997;13(4):216-223.
Not in our library10.1016/s0964-3397(97)80056-0
136.
Cunningham SM, Haikal NA, Kraner JC. Fatal intoxication with acetyl fentanyl. J Forensic Sci. 2016;61(Suppl 1):S276-S280.
Not in our library10.1111/1556-4029.12953
137.
Curtis B, Kemp P, Harty L, Choi C, Christensen D. Postmortem identification and quantitation of 2,5-dimethoxy-4-n-propylthiophenethylamine using GC-MSD and GC-NPD. J Anal Toxicol. 2003;27(7):493-498.
Not in our library10.1093/jat/27.7.493
138.
Custodio RJP, Sayson LV, Botanas CJ, Abiero A, You KY, Kim M, Lee HJ, Yoo SY, Lee KW, Lee YS, Seo JW, Ryu IS, Kim HJ, Cheong JH. 25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: evidence of abuse potential. Addict Biol. 2019.
Not in our library10.1111/adb.12850
139.
Dal Cason TA, Young R, Glennon RA. Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs. Pharmacol Biochem Behav. 1997;58(4):1109-1116.
Not in our library10.1016/s0091-3057(97)00323-7
140.
Daniulaityte R, Juhascik MP, Strayer KE, Sizemore IE, Harshbarger KE, Antonides HM, Carlson RR. Overdose deaths related to fentanyl and its analogs—Ohio, January–February 2017. MMWR Morb Mortal Wkly Rep. 2017;66(34):904-908.
Not in our library10.15585/mmwr.mm6634a3
141.
Dargan PI, Tang HC, Liang W, Wood DM, Yew DT. Three months of methoxetamine administration is associated with significant bladder and renal toxicity in mice. Clin Toxicol (Phila). 2014;52(3):176-180.
Not in our library10.3109/15563650.2014.892605
142.
Darke S, Duflou J, Farrell M, Peacock A, Lappin J. Characteristics and circumstances of synthetic cannabinoid-related death. Clin Toxicol (Phila). 2019;1:1-7.
Not in our library10.1080/15563650.2019.1647344
143.
Daveluy A, Castaing N, Cherifi H, Richeval C, Humbert L, Faure I, Labadie M, Allorge D, Haramburu F, Molimard M, Titier K. Acute methiopropamine intoxication after “synthacaine" consumption. J Anal Toxicol. 2016;40(9):758-760.
Not in our library10.1093/jat/bkw073
144.
Davis C, Boddington D. Teenage cardiac arrest following abuse of synthetic cannabis. Heart Lung Circ. 2015;24(10):e162-e163.
Not in our library10.1016/j.hlc.2015.04.176
145.
Davis FT, Brewster ME. A fatality involving U4Euh, a cyclic derivative of phenylpropanolamine. J Forensic Sci. 1988;33(2):549-553.
Not in our library10.1520/jfs11971j
146.
Dawson P, Opacka-Juffry J, Moffatt JD, Daniju Y, Dutta N, Ramsey J, Davidson C. The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:57-63.
Not in our library10.1016/j.pnpbp.2013.08.013
147.
De Carlis L, De Gasperi A, Slim AO, Giacomoni A, Corti A, Mazza E, Di Benedetto F, Lauterio A, Arcieri K, Maione G, Rondinara GF, Forti D. Liver transplantation for ecstasy-induced fulminant hepatic failure. Transplant Proc. 2001;33(5):2743-2744.
Not in our library10.1016/s0041-1345(01)02176-5
148.
De Havenon A, Chin B, Thomas KC, Afra P. The secret "spice": an undetectable toxic cause of seizure. Neurohospitalist. 2011;1(4):182-186.
Not in our library10.1177/1941874411417977
149.
De Jong LAA, Olyslager EJH, Duijst W. The risk of emerging new psychoactive substances: the first fatal 3-MeO-PCP intoxication in The Netherlands. J Forensic Leg Med. 2019;65:101-104.
Not in our library10.1016/j.jflm.2019.05.011
150.
Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM. 2C or not 2C: phenethylamine designer drug review. J Med Toxicol. 2013;9(2):172-178.
Not in our library10.1007/s13181-013-0295-x
151.
Deng H, Verrico CD, Kosten TR, Nielsen DA. Psychosis and synthetic cannabinoids. Psychiatry Res. 2018;268:400-412.
Not in our library10.1016/j.psychres.2018.08.012
152.
Denton JS, Donoghue ER, McReynolds J, Kalelkar MB. An epidemic of illicit fentanyl deaths in Cook County, Illinois: September 2005 through April 2007. J Forensic Sci. 2008;53(2):452-454.
Not in our library10.1111/j.1556-4029.2008.00669.x
153.
Derlet RW, Rice P, Horowitz BZ, Lord RV. Amphetamine toxicity: experience with 127 cases. J Emerg Med. 1989;7(2):157-161.
Not in our library10.1016/0736-4679(89)90263-1
154.
DeRoux SJ, Dunn WA. "Bath Salts" the New York City medical examiner experience: a 3-year retrospective review. J Forensic Sci. 2017;62(3):695-699.
Not in our library10.1111/1556-4029.13316
155.
Derungs A, Schwaninger AE, Mansella G, Bingisser R, Kraemer T, Liechti ME. Symptoms, toxicities, and analytical results for a patient after smoking herbs containing the novel synthetic cannabinoid MAM-2201. Forensic Toxicol. 2013;31(1):164-171.
Not in our library10.1007/s11419-012-0166-1
156.
Deutsch HM, Shi Q, Gruszecka-Kowalik E, Schweri MM. Synthesis and pharmacology of potential cocaine antagonists. 2. Structure-activity relationship studies of aromatic ring-substituted methylphenidate analogs. J Med Chem. 1996;39(6):1201-1209.
Not in our library10.1021/jm950697c
157.
Devgun JM, Rasin A, Kim T, Mycyk MB, Bryant SM, Wahl MS, DesLauriers C, Navon L, Moritz ED, Thompson TM, Swoboda HD, Lu J, Aks SE. An outbreak of severe coagulopathy from synthetic cannabinoids tainted with long-acting anticoagulant rodenticides. Clin Toxicol (Phila). 2019;1:1-8.
Not in our library10.1080/15563650.2019.1690149
158.
Di Cara B, Maggio R, Aloisi G, Rivet JM, Lundius EG, Yoshitake T, Svenningsson P, Brocco M, Gobert A, De Groote L, Cistarelli L, Veiga S, De Montrion C, Rodriguez M, Galizzi JP, Lockhart BP, Coge F, Boutin JA, Vayer P, Verdouw PM, Groenink L, Millan MJ. Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA). J Neurosci. 2011;31(47):16928-16940.
Not in our library10.1523/jneurosci.2502-11.2011
159.
Dias da Silva D, Silva MJ, Moreira P, Martins MJ, Valente MJ, Carvalho F, Bastos ML, Carmo H. In vitro hepatotoxicity of 'Legal X': the combination of 1-benzylpiperazine (BZP) and 1-(m-trifluoromethylphenyl)piperazine (TFMPP) triggers oxidative stress, mitochondrial impairment and apoptosis. Arch Toxicol. 2017;91(3):1413-1430.
Not in our library10.1007/s00204-016-1777-9
160.
Dias da Silva D, Ferreira B, Roque Bravo R, Rebelo R, Duarte de Almeida T, Valente MJ, Silva JP, Carvalho F, Bastos ML, Carmo H. The new psychoactive substance 3-methylmethcathinone (3-MMC or metaphedrone) induces oxidative stress, apoptosis, and autophagy in primary rat hepatocytes at human-relevant concentrations. Arch Toxicol. 2019;93(9):2617-2634.
Not in our library10.1007/s00204-019-02539-x
161.
Dias-da-Silva D, Arbo MD, Valente MJ, Bastos ML, Carmo H. Hepatotoxicity of piperazine designer drugs: comparison of different in vitro models. Toxicol In Vitro. 2015;29(5):987-996.
Not in our library10.1016/j.tiv.2015.04.001
162.
Dolder PC, Schmid Y, Müller F, Borgwardt S, Liechti ME. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology. 2016;41(11):2638-2646.
Not in our library10.1038/npp.2016.82
163.
Dolder PC, Strajhar P, Vizeli P, Hammann F, Odermatt A, Liechti ME. Pharmacokinetics and pharmacodynamics of lisdexamfetamine compared with D-amphetamine in healthy subjects. Front Pharmacol. 2017;8:617.
Not in our library10.3389/fphar.2017.00617
164.
Domanski K, Kleinschmidt KC, Schulte JM, Fleming S, Frazee C, Menendez A, Tavakoli K. Two cases of intoxication with new synthetic opioid, U-47700. Clin Toxicol (Phila). 2017;55(1):46-50.
Not in our library10.1080/15563650.2016.1209763
165.
Domingo O, Roider G, Stover A, Graw M, Musshoff F, Sachs H, Bicker W. Mitragynine concentrations in two fatalities. Forensic Sci Int. 2017;271:e1-e7.
Not in our library10.1016/j.forsciint.2016.12.020
166.
Domino EF. History and pharmacology of PCP and PCP-related analogs. J Psychedelic Drugs. 1980;12(3–4):223-227.
Not in our library10.1080/02791072.1980.10471430
167.
Droogmans S, Cosyns B, D'Haenen H, Creeten E, Weytjens C, Franken PR, Scott B, Schoors D, Kemdem A, Close L, Vandenbossche JL, Bechet S, Van Camp G. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol. 2007;100(9):1442-1445.
Not in our library10.1016/j.amjcard.2007.06.045
168.
Dunlop LC, Wood D, Archer J, Hudson S, Dargan P. Severe toxicity to the new psychoactive substances 3-hydroxyphencyclidine and N-ethylhexedrone: an analytically confirmed case report. J Med Toxicol. 2019.
Not in our library10.1007/s13181-019-00734-x
169.
Durand D, Delgado LL, De la Parra-Pellot DM, Nichols-Vinueza D. Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: a case report. Clin Schizophr Relat Psychoses. 2015;8(4):205-208.
Not in our library10.3371/csrp.dude.031513
170.
Dussy FE, Hangartner S, Hamberg C, Berchtold C, Scherer U, Schlotterbeck G, Wyler D, Briellmann TA. An acute ocfentanil fatality: a case report with postmortem concentrations. J Anal Toxicol. 2016;40(9):761-766.
Not in our library10.1093/jat/bkw096
171.
Dwyer JB, Janssen J, Luckasevic TM, Williams KE. Report of increasing overdose deaths that include acetyl fentanyl in multiple counties of the southwestern region of the Commonwealth of Pennsylvania in 2015–2016. J Forensic Sci. 2018;63(1):195-200.
Not in our library10.1111/1556-4029.13517
172.
Eiden C, Mathieu O, Cathala P, Debruyne D, Baccino E, Petit P, Peyriere H. Toxicity and death following recreational use of 2-pyrrolidino valerophenone. Clin Toxicol (Phila). 2013;51(9):899-903.
Not in our library10.3109/15563650.2013.847187
173.
El Balkhi S, Monchaud C, Herault F, Geniaux H, Saint-Marcoux F. Designer benzodiazepines' pharmacological effects and potencies: how to find the information. J Psychopharmacol. 2020;1:2.
Not in our library10.1177/0269881119901096
174.
El Zahran T, Gerona R, Morgan BW, Pomerleau AC. A novel synthetic cannabinoid (cumyl-4-cyano-BINACA) resulting in hyperthermia, rhabdomyolysis, and renal failure in a 29-year-old patient: it's not meningitis. Clin Toxicol (Phila). 2019;57(6):421-422.
Not in our library10.1080/15563650.2018.1534241
175.
Elangbam CS. Drug-induced valvulopathy: an update. Toxicol Pathol. 2010;38(6):837-848.
Not in our library10.1177/0192623310378027
176.
Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, Gates LD, Slocum N. 5-Hydroxytryptamine (5-HT)-induced valvulopathy: compositional valvular alterations are associated with 5-HT2B receptor and 5-HT transporter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol. 2008;60(4–5):253-262.
Not in our library10.1016/j.etp.2008.03.005
177.
Ellefsen KN, Taylor EA, Simmons P, Willoughby V, Hall BJ. Multiple drug-toxicity involving novel psychoactive substances, 3-fluorophenmetrazine and U-47700. J Anal Toxicol. 2017;41(9):765-770.
Not in our library10.1093/jat/bkx060
178.
Elliott S, Evans J. A 3-year review of new psychoactive substances in casework. Forensic Sci Int. 2014;243:55-60.
Not in our library10.1016/j.forsciint.2014.04.017
179.
Elliott SP, Brandt SD, Wallach J, Morris H, Kavanagh PV. First reported fatalities associated with the 'research chemical' 2-methoxydiphenidine. J Anal Toxicol. 2015;39(4):287-293.
Not in our library10.1093/jat/bkv006
180.
Elliott SP, Brandt SD, Smith C. The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700) and implications for forensic analysis. Drug Test Anal. 2016;8(8):875-879.
Not in our library10.1002/dta.1984
181.
Ellis AJ, Wendon JA, Portmann B, Williams R. Acute liver damage and ecstasy ingestion. Gut. 1996;38(3):454-458.
Not in our library10.1136/gut.38.3.454
182.
Elmore JS, Decker AM, Sulima A, Rice KC, Partilla JS, Blough BE, Baumann MH. Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats. Neuropharmacology. 2018;142:240-250.
Not in our library10.1016/j.neuropharm.2018.02.033
183.
Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A. Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol. 2013;85(12):1803-1815.
Not in our library10.1016/j.bcp.2013.04.004
184.
Eshleman AJ, Forster MJ, Wolfrum KM, Johnson RA, Janowsky A, Gatch MB. Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. Psychopharmacology. 2014;231(5):875-888.
Not in our library10.1007/s00213-013-3303-6
185.
Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Swanson T, Johnson RA, Janowsky A. Structure-activity relationships of substituted cathinones, with transporter binding, uptake, and release. J Pharmacol Exp Ther. 2017;360(1):33-47.
Not in our library10.1124/jpet.116.236349
186.
Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A. Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: high potency agonists at 5-HT2A receptors. Biochem Pharmacol. 2018;158:27-34.
Not in our library10.1016/j.bcp.2018.09.024
187.
European Monitoring Centre for Drugs and Drug Addiction (2015) Report on the risk assessment of 4,4ʹ-DMAR. https://www.emcdda.europa.eu/system/files/publications/1864/TDAK14005ENN.pdf, Accessed 7 Jan 2020
Not in our library
188.
European Monitoring Centre for Drugs and Drug Addiction (2019) European drug report 2019. https://www.emcdda.europa.eu/system/files/publications/11364/20191724_TDAT19001ENN_PDF.pdf. Accessed 7 Jan 2020
Not in our library
189.
Every-Palmer S. Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction. 2010;105(10):1859-1860.
Not in our library10.1111/j.1360-0443.2010.03119.x
190.
Fahal IH, Sallomi DF, Yaqoob M, Bell GM. Acute renal failure after ecstasy. BMJ. 1992;305(6844):29.
Not in our library10.1136/bmj.305.6844.29
191.
Fallon JK, Shah D, Kicman AT, Hutt AJ, Henry JA, Cowan DA, Forsling M. Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release. Ann N Y Acad Sci. 2002;965:399-409.
Not in our library10.1111/j.1749-6632.2002.tb04181.x
192.
Fantegrossi WE, Harrington AW, Eckler JR, Arshad S, Rabin RA, Winter JC, Coop A, Rice KC, Woods JH. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology. 2005;181(3):496-503.
Not in our library10.1007/s00213-005-0009-4
193.
Fantegrossi WE, Reissig CJ, Katz EB, Yarosh HL, Rice KC, Winter JC. Hallucinogen-like effects of N, N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents. Pharmacol Biochem Behav. 2008;88(3):358-365.
Not in our library10.1016/j.pbb.2007.09.007
194.
Farah R, Farah R. Ecstasy (3,4-methylenedioxymethamphetamine)-induced inappropriate antidiuretic hormone secretion. Pediatr Emerg Care. 2008;24(9):615-617.
Not in our library10.1097/pec.0b013e3181850c91
195.
Faroqui R, Mena P, Wolfe AR, Bibawy J, Visvikis GA, Mantello MT. Acute carotid thrombosis and ischemic stroke following overdose of the synthetic cannabinoid K2 in a previously healthy young adult male. Radiol Case Rep. 2018;13(3):747-752.
Not in our library10.1016/j.radcr.2018.02.023
196.
Fawzy M, Wong-Morrow WS, Beaumont A, Farmer CKT. Acute kidney injury and critical limb ischaemia associated with the use of the so called "legal high" 3-fluorophenmetrazine. CEN Case Rep. 2017;6(2):152-155.
Not in our library10.1007/s13730-017-0263-4
197.
Fels H, Krueger J, Sachs H, Musshoff F, Graw M, Roider G, Stoever A. Two fatalities associated with synthetic opioids: AH-7921 and MT-45. Forensic Sci Int. 2017;277:e30-e35.
Not in our library10.1016/j.forsciint.2017.04.003
198.
Fels H, Lottner-Nau S, Sax T, Roider G, Graw M, Auwärter V, Musshoff F. Postmortem concentrations of the synthetic opioid U-47700 in 26 fatalities associated with the drug. Forensic Sci Int. 2019;301:e20-e28.
Not in our library10.1016/j.forsciint.2019.04.010
199.
Finlay DB, Manning JJ, Ibsen MS, Macdonald CE, Patel M, Javitch JA, Banister SD, Glass M. Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA. ACS Chem Neurosci. 2019;10(10):4350-4360.
Not in our library10.1021/acschemneuro.9b00429
200.
Fleckenstein AE, Gibb JW, Hanson GR. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol. 2000;406(1):1-13.
Not in our library10.1016/s0014-2999(00)00639-7
201.
Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681-698.
Not in our library10.1146/annurev.pharmtox.47.120505.105140
202.
Forrester MB. Adolescent synthetic cannabinoid exposures reported to Texas poison centers. Pediatr Emerg Care. 2012;28(10):985-989.
Not in our library10.1097/pec.0b013e31826c9a97
203.
Forrester MB. Synthetic cathinone exposures reported to Texas poison centers. Am J Drug Alcohol Abuse. 2012;38(6):609-615.
Not in our library10.3109/00952990.2012.677890
204.
Forrester MB. 2C series phenethylamine derivative exposures in Texas. Subst Abus. 2013;34(1):81-82.
Not in our library10.1080/08897077.2012.715623
205.
Forrester MB. NBOMe designer drug exposures reported to Texas poison centers. J Addict Dis. 2014;33(3):196-201.
Not in our library10.1080/10550887.2014.950027
206.
Forrester MB, Kleinschmidt K, Schwarz E, Young A. Synthetic cannabinoid exposures reported to Texas poison centers. J Addict Dis. 2011;30(4):351-358.
Not in our library10.1080/10550887.2011.609807
207.
Forrester MB, Kleinschmidt K, Schwarz E, Young A. Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol. 2012;31(10):1006-1011.
Not in our library10.1177/0960327111421945
208.
Forsling M, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Henry JA. Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine ("ecstasy"): is metabolism a contributory factor? J Pharm Pharmacol. 2001;53(10):1357-1363.
Not in our library10.1211/0022357011777855
209.
Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT, Hutt AJ. The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol. 2002;135(3):649-656.
Not in our library10.1038/sj.bjp.0704502
210.
Fort C, Curtis B, Nichols C, Niblo C. Acetyl fentanyl toxicity: two case reports. J Anal Toxicol. 2016;40(9):754-757.
Not in our library10.1093/jat/bkw068
211.
Foti F, Marti M, Ossato A, Bilel S, Sangiorgi E, Botre F, Cerbelli B, Baldi A, De-Giorgio F. Phenotypic effects of chronic and acute use of methiopropamine in a mouse model. Int J Legal Med. 2019;133(3):811-820.
Not in our library10.1007/s00414-018-1891-8
212.
Franzén L, Bäckberg M, Beck O, Helander A. Acute intoxications involving α-pyrrolidinobutiophenone (α-PBP): results from the Swedish STRIDA project. J Med Toxicol. 2018;14(4):265-271.
Not in our library10.1007/s13181-018-0668-2
213.
Freeman MJ, Rose DZ, Myers MA, Gooch CL, Bozeman AC, Burgin WS. Ischemic stroke after use of the synthetic marijuana "spice". Neurology. 2013;81(24):2090-2093.
Not in our library10.1212/01.wnl.0000437297.05570.a2
214.
Freudenmann RW, Oxler F, Bernschneider-Reif S. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006;101(9):1241-1245.
Not in our library10.1111/j.1360-0443.2006.01511.x
215.
Frisoni P, Bacchio E, Bilel S, Talarico A, Gaudio RM, Barbieri M, Neri M, Marti M. Novel synthetic opioids: the pathologist's point of view. Brain Sci. 2018;8(9):1.
Not in our library10.3390/brainsci8090170
216.
Fröhlich S, Lambe E, O'Dea J. Acute liver failure following recreational use of psychotropic "head shop" compounds. Ir J Med Sci. 2011;180(1):263-264.
Not in our library10.1007/s11845-010-0636-6
217.
Fuller RW. Effects of p-chloroamphetamine on brain serotonin neurons. Neurochem Res. 1992;17(5):449-456.
Not in our library10.1007/bf00969891
218.
Fuller DE, Hornfeldt CS, Kelloway JS, Stahl PJ, Anderson TF. The Xyrem risk management program. Drug Saf. 2004;27(5):293-306.
Not in our library10.2165/00002018-200427050-00002
219.
Fuse-Nagase Y, Nishikawa T. Prolonged delusional state triggered by repeated ingestion of aromatic liquid in a past 5-methoxy-NN-diisopropyltryptamine abuser. Addict Sci Clin Pract. 2013;8(1):9.
Not in our library10.1186/1940-0640-8-9
220.
Gaine SP, Rubin LJ, Kmetzo JJ, Palevsky HI, Traill TA. Recreational use of aminorex and pulmonary hypertension. Chest. 2000;118(5):1496-1497.
Not in our library10.1378/chest.118.5.1496
221.
Gamage TF, Farquhar CE, Lefever TW, Marusich JA, Kevin RC, McGregor IS, Wiley JL, Thomas BF. Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-fluoro-CUMYL-PICA. J Pharmacol Exp Ther. 2018;365(2):437-446.
Not in our library10.1124/jpet.117.246983
222.
Gannon BM, Galindo KI, Mesmin MP, Sulima A, Rice KC, Collins GT. Relative reinforcing effects of second-generation synthetic cathinones: acquisition of self-administration and fixed ratio dose-response curves in rats. Neuropharmacology. 2018;134(Pt A):28-35.
Not in our library10.1016/j.neuropharm.2017.08.018
223.
Garbino J, Henry JA, Mentha G, Romand JA. Ecstasy ingestion and fulminant hepatic failure: liver transplantation to be considered as a last therapeutic option. Vet Hum Toxicol. 2001;43(2):99-102.
Not in our library
224.
Gardos G, Cole JO. Evaluation of pyrovalerone in chronically fatigued volunteers. Curr Ther Res Clin Exp. 1971;13(10):631-635.
Not in our library
225.
Garneau B, Desharnais B, Beauchamp-Dore A, Lavallee C, Mireault P, Lajeunesse A. Challenges related to three cases of fatal intoxication to multiple novel synthetic opioids. J Anal Toxicol. 2019.
Not in our library10.1093/jat/bkz018
226.
Gaunitz F, Lehmann S, Thomas A, Thevis M, Rothschild MA, Mercer-Chalmers-Bender K. Post-mortem distribution of the synthetic cannabinoid MDMB-CHMICA and its metabolites in a case of combined drug intoxication. Int J Legal Med. 2018;132(6):1645-1657.
Not in our library10.1007/s00414-018-1911-8
227.
Gee P, Richardson S, Woltersdorf W, Moore G. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch. New Zealand N Z Med J. 2005;118(1227):U1784.
Not in our library
228.
Gee P, Gilbert M, Richardson S, Moore G, Paterson S, Graham P. Toxicity from the recreational use of 1-benzylpiperazine. Clin Toxicol (Phila). 2008;46(9):802-807.
Not in our library10.1080/15563650802307602
229.
Gee P, Jerram T, Bowie D. Multiorgan failure from 1-benzylpiperazine ingestion—legal high or lethal high? Clin Toxicol (Phila). 2010;48(3):230-233.
Not in our library10.3109/15563651003592948
230.
Gerace E, Bovetto E, Corcia DD, Vincenti M, Salomone A. A case of nonfatal intoxication associated with the recreational use of diphenidine. J Forensic Sci. 2017;62(4):1107-1111.
Not in our library10.1111/1556-4029.13355
231.
Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci. 2008;29(9):445-453.
Not in our library10.1016/j.tips.2008.06.006
232.
Ghatol A, Kazory A. Ecstasy-associated acute severe hyponatremia and cerebral edema: a role for osmotic diuresis? J Emerg Med. 2012;42(6):e137-e140.
Not in our library10.1016/j.jemermed.2009.05.001
233.
Gillespie TJ, Gandolfi AJ, Davis TP, Morano RA. Identification and quantification of alpha-methylfentanyl in post mortem specimens. J Anal Toxicol. 1982;6(3):139-142.
Not in our library10.1093/jat/6.3.139
234.
Ginsberg MD, Hertzman M, Schmidt-Nowara WW. Amphetamine intoxication with coagulopathy, hyperthermia, and reversible renal failure: a syndrome resembling heatstroke. Ann Intern Med. 1970;73(1):81-85.
Not in our library10.7326/0003-4819-73-1-81
235.
Changes in Opioid-Involved Overdose Deaths by Opioid Type and Presence of Benzodiazepines, Cocaine, and Methamphetamine — 25 States, July–December 2017 to January–June 2018 · 2019
No notice
236.
Glanville J, Dargan PI, Wood DM. 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4ʹ-DMAR, 4,4ʹ-dimethylaminorex): availability, prevalence of use, desired effects and acute toxicity. Hum Psychopharmacol. 2015;30(3):193-198.
Not in our library10.1002/hup.2472
237.
Glue P, Al-Shaqsi S, Hancock D, Gale C, Strong B, Schep L. Hospitalisation associated with use of the synthetic cannabinoid K2. N Z Med J. 2013;126(1377):18-23.
Not in our library
238.
González D, Torrens M, Farré M. Acute effects of the novel psychoactive drug 2C-B on emotions. Biomed Res Int. 2015;2015:643878.
Not in our library10.1155/2015/643878
239.
Graham MR, Ryan P, Baker JS, Davies B, Thomas NE, Cooper SM, Evans P, Easmon S, Walker CJ, Cowan D, Kicman AT. Counterfeiting in performance- and image-enhancing drugs. Drug Test Anal. 2009;1(3):135-142.
Not in our library10.1002/dta.30
240.
Grautoff S, Kähler J. Lebensgefährliche Intoxikation mit der neuen psychoaktiven Substanz 25C-NBOMe. Medizinische Klinik Intensivmedizin und Notfallmedizin. 2014;109(4):271-275.
Not in our library10.1007/s00063-014-0360-5
241.
Green AR, Mechan AO, Elliott JM, Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev. 2003;55(3):463.
Not in our library10.1124/pr.55.3.3
242.
Greene SL, Dargan PI, O'Connor N, Jones AL, Kerins M. Multiple toxicity from 3,4-methylenedioxymethamphetamine ("ecstasy"). Am J Emerg Med. 2003;21(2):121-124.
Not in our library10.1053/ajem.2003.50028
243.
Grumann C, Henkel K, Stratford A, Hermanns-Clausen M, Passie T, Brandt SD, Auwärter V. Validation of an LC–MS/MS method for the quantitative analysis of 1P-LSD and its tentative metabolite LSD in fortified urine and serum samples including stability tests for 1P-LSD under different storage conditions. J Pharm Biomed Anal. 2019;174:270-276.
Not in our library10.1016/j.jpba.2019.05.062
244.
Gudsoorkar VS, Perez JA. A new differential diagnosis: synthetic cannabinoids-associated acute renal failure. Methodist Debakey Cardiovasc J. 2015;11(3):189-191.
Not in our library10.14797/mdcj-11-3-189
245.
Guerrieri D, Rapp E, Roman M, Druid H, Kronstrand R. Postmortem and toxicological findings in a series of furanylfentanyl-related deaths. J Anal Toxicol. 2017;41(3):242-249.
Not in our library10.1093/jat/bkw129
246.
Gugelmann H, Gerona R, Li C, Tsutaoka B, Olson KR, Lung D. 'Crazy Monkey' poisons man and dog: human and canine seizures due to PB-22, a novel synthetic cannabinoid. Clin Toxicol (Phila). 2014;52(6):635-638.
Not in our library10.3109/15563650.2014.925562
247.
Halachanova V, Sansone RA, McDonald S. Delayed rhabdomyolysis after ecstasy use. Mayo Clin Proc. 2001;76(1):112-113.
Not in our library10.4065/76.1.112
248.
Halberstadt AL. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N, N-dimethyltryptamine. Pharmacol Biochem Behav. 2016;143:1-10.
Not in our library10.1016/j.pbb.2016.01.005
249.
Halberstadt AL. Pharmacology and toxicology of N-benzylphenethylamine ("NBOMe") hallucinogens. Curr Top Behav Neurosci. 2017;32:283-311.
Not in our library10.1007/7854_2016_64
250.
Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 2011;61(3):364-381.
Not in our library10.1016/j.neuropharm.2011.01.017
251.
Halberstadt AL, Geyer MA. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology. 2014;77:200-207.
Not in our library10.1016/j.neuropharm.2013.08.025
252.
Halberstadt AL, Nichols DE, Geyer MA. Behavioral effects of α, α, β, β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. Psychopharmacology. 2012;221(4):709-718.
Not in our library10.1007/s00213-011-2616-6
253.
Halberstadt AL, Chatha M, Stratford A, Grill M, Brandt SD. Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran ("FLY") and benzodifuran ("DragonFLY") analogs. Neuropharmacology. 2019;144:368-376.
Not in our library10.1016/j.neuropharm.2018.10.037
254.
Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology. 2020;1:107933.
Not in our library10.1016/j.neuropharm.2019.107933
255.
Hamilton RJ, Keyfes V, Banka SS. Synthetic cannabinoid abuse resulting in ST-segment elevation myocardial infarction requiring percutaneous coronary intervention. J Emerg Med. 2017;52(4):496-498.
Not in our library10.1016/j.jemermed.2016.09.023
256.
Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med. 2013;44(2):360-366.
Not in our library10.1016/j.jemermed.2012.07.061
257.
Hartung TK, Schofield E, Short AI, Parr MJ, Henry JA. Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion. QJM. 2002;95(7):431-437.
Not in our library10.1093/qjmed/95.7.431
258.
Hasegawa K, Wurita A, Minakata K, Gonmori K, Yamagishi I, Nozawa H, Watanabe K, Suzuki O. Identification and quantitation of 5-fluoro-ADB, one of the most dangerous synthetic cannabinoids, in the stomach contents and solid tissues of a human cadaver and in some herbal products. Forensic Toxicol. 2015;33(1):112-121.
Not in our library10.1007/s11419-014-0259-0
259.
Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present—a pharmacological and clinical perspective. J Psychopharmacol. 2013;27(6):479-496.
Not in our library10.1177/0269881113482532
260.
Heim R (2004) Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur: Entwicklung eines neuen Struktur-Wirkungskonzepts. Dissertation, Freie Universität Berlin. https://refubium.fu-berlin.de/bitstream/handle/fub188/11995/0_RalfHeimTitelblatt.pdf?sequence=1&isAllowed=y. Accessed 7 Jan 2020
Not in our library
261.
Helander A, Bäckberg M, Beck O. MT-45, a new psychoactive substance associated with hearing loss and unconsciousness. Clin Toxicol (Phila). 2014;52(8):901-904.
Not in our library10.3109/15563650.2014.943908
262.
Helander A, Beck O, Bäckberg M. Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine. Clin Toxicol (Phila). 2015;53(5):446-453.
Not in our library10.3109/15563650.2015.1033630
263.
Helander A, Bäckberg M, Beck O. Intoxications involving the fentanyl analogs acetylfentanyl, 4-methoxybutyrfentanyl and furanylfentanyl: results from the Swedish STRIDA project. Clin Toxicol (Phila). 2016;54(4):324-332.
Not in our library10.3109/15563650.2016.1139715
264.
Helander A, Bäckberg M, Signell P, Beck O. Intoxications involving acrylfentanyl and other novel designer fentanyls – results from the Swedish STRIDA project. Clin Toxicol (Phila). 2017;55(6):589-599.
Not in our library10.1080/15563650.2017.1303141
265.
Helander A, Bradley M, Hasselblad A, Norlen L, Vassilaki I, Bäckberg M, Lapins J. Acute skin and hair symptoms followed by severe, delayed eye complications in subjects using the synthetic opioid MT-45. Br J Dermatol. 2017;176(4):1021-1027.
Not in our library10.1111/bjd.15174
266.
Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet. 1992;340(8816):384-387.
Not in our library10.1016/0140-6736(92)91469-o
267.
Herian M, Wojtas A, Kaminska K, Swit P, Wach A, Golembiowska K. Hallucinogen-like action of the novel designer drug 25I-NBOMe and its effect on cortical neurotransmitters in rats. Neurotox Res. 2019;36(1):91-100.
Not in our library10.1007/s12640-019-00033-x
268.
Hermanns-Clausen M, Kneisel S, Hutter M, Szabo B, Auwärter V. Acute intoxication by synthetic cannabinoids—four case reports. Drug Test Anal. 2013;5(9–10):790-794.
Not in our library10.1002/dta.1483
269.
Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013;108(3):534-544.
Not in our library10.1111/j.1360-0443.2012.04078.x
270.
Hermanns-Clausen M, Angerer V, Kithinji J, Grumann C, Auwärter V. Bad trip due to 25I-NBOMe: a case report from the EU project SPICE II plus. Clin Toxicol (Phila). 2017;55(8):922-924.
Not in our library10.1080/15563650.2017.1319572
271.
Herraiz T, Brandt SD. 5-(2-Aminopropyl)indole (5-IT): a psychoactive substance used for recreational purposes is an inhibitor of human monoamine oxidase (MAO). Drug Test Anal. 2014;6(7–8):607-613.
Not in our library10.1002/dta.1530
272.
Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila). 2011;49(8):705-719.
Not in our library10.3109/15563650.2011.615318
273.
Hill SL, Doris T, Gurung S, Katebe S, Lomas A, Dunn M, Blain P, Thomas SH. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin Toxicol (Phila). 2013;51(6):487-492.
Not in our library10.3109/15563650.2013.802795
274.
Hirapara K, Aggarwal R. Synthetic cannabis and myocardial infarction: a complication less known! Psychosomatics. 2015;56(6):712-713.
Not in our library10.1016/j.psym.2015.07.009
275.
Ho JH, Bailey GP, Archer JR, Dargan PI, Wood DM. Ethylphenidate: availability, patterns of use, and acute effects of this novel psychoactive substance. Eur J Clin Pharmacol. 2015;71(10):1185-1196.
Not in our library10.1007/s00228-015-1906-z
276.
Hobbs M, Kalk NJ, Morrison PD, Stone JM. Spicing it up—synthetic cannabinoid receptor agonists and psychosis—a systematic review. Eur Neuropsychopharmacol. 2018;28(12):1289-1304.
Not in our library10.1016/j.euroneuro.2018.10.004
277.
Hofer KE, Grager B, Müller DM, Rauber-Lüthy C, Kupferschmidt H, Rentsch KM, Ceschi A. Ketamine-like effects after recreational use of methoxetamine. Ann Emerg Med. 2012;60(1):97-99.
Not in our library10.1016/j.annemergmed.2011.11.018
278.
Hofer KE, Degrandi C, Müller DM, Zürrer-Härdi U, Wahl S, Rauber-Lüthy C, Ceschi A. Acute toxicity associated with the recreational use of the novel dissociative psychoactive substance methoxphenidine. Clin Toxicol (Phila). 2014;52(10):1288-1291.
Not in our library10.3109/15563650.2014.974264
279.
Hofmann A, Troxler F (1962) Nouveaux dérivés de l'indole, procédé de préparation et médicaments les contenant. FR1344579
Not in our library
280.
Hondebrink L, Nugteren-van Lonkhuyzen JJ, Rietjens SJ, Brunt TM, Venhuis B, Soerdjbalie-Maikoe V, Smink BE, Van Riel A, De Vries I. Fatalities, cerebral hemorrhage, and severe cardiovascular toxicity after exposure to the new psychoactive substance 4-fluoroamphetamine: a prospective cohort study. Ann Emerg Med. 2018;71(3):294-305.
Not in our library10.1016/j.annemergmed.2017.07.482
281.
Hopkins CY, Gilchrist BL. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med. 2013;45(4):544-546.
Not in our library10.1016/j.jemermed.2012.11.034
282.
Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med. 2012;60(4):435-438.
Not in our library10.1016/j.annemergmed.2012.03.007
283.
Huang HH, Bai YM. Persistent psychosis after ingestion of a single tablet of '2C-B'. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):293-294.
Not in our library10.1016/j.pnpbp.2010.10.018
284.
Huang XP, Setola V, Yadav PN, Allen JA, Rogan SC, Hanson BJ, Revankar C, Robers M, Doucette C, Roth BL. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: implications for drug safety assessment. Mol Pharmacol. 2009;76(4):710-722.
Not in our library10.1124/mol.109.058057
285.
Hurst D, Loeffler G, McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry. 2011;168(10):1119.
Not in our library10.1176/appi.ajp.2011.11010176
286.
Ibrahim S, Al-Saffar F, Wannenburg T. A unique case of cardiac arrest following K2 abuse. Case Rep Cardiol. 2014;2014:120607.
Not in our library10.1155/2014/120607
287.
Ikeda A, Sekiguchi K, Fujita K, Yamadera H, Koga Y. 5-methoxy-N, N-diisopropyltryptamine-induced flashbacks. Am J Psychiatry. 2005;162(4):815.
Not in our library10.1176/appi.ajp.162.4.815
288.
Imbert L, Boucher A, Delhome G, Cueto T, Boudinaud M, Maublanc J, Dulaurent S, Descotes J, Lachatre G, Gaulier JM. Analytical findings of an acute intoxication after inhalation of methoxetamine. J Anal Toxicol. 2014;38(7):410-415.
Not in our library10.1093/jat/bku052
289.
Inan F, Brunt TM, Contrucci RR, Hondebrink L, Franssen EJF. Novel phenethylamines and their potential interactions with prescription drugs: a systematic critical review. Ther Drug Monit. 2020.
Not in our library10.1097/ftd.0000000000000725
290.
Isoardi KZ, Kulawickrama S, Isbister GK. Severe phenibut poisoning: an adolescent case cluster. J Paediatr Child Health. 2020;56(2):330-331.
Not in our library10.1111/jpc.14605
291.
Itokawa M, Iwata K, Takahashi M, Sugihara G, Sasaki T, Abe Y, Uno M, Hobo M, Jitoku D, Inoue K, Arai M, Yasuda I, Shintani M. Acute confusional state after designer tryptamine abuse. Psychiatry Clin Neurosci. 2007;61(2):196-199.
Not in our library10.1111/j.1440-1819.2007.01638.x
292.
Ivanov ID, Stoykova S, Ivanova E, Vlahova A, Burdzhiev N, Pantcheva I, Atanasov VN. A case of 5F-ADB/FUB-AMB abuse: drug-induced or drug-related death? Forensic Sci Int. 2019;297:372-377.
Not in our library10.1016/j.forsciint.2019.02.005
293.
Iversen L, Gibbons S, Treble R, Setola V, Huang XP, Roth BL. Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol. 2013;700(1–3):147-151.
Not in our library10.1016/j.ejphar.2012.12.006
294.
Iwersen-Bergmann S, Lehmann S, Heinemann A, Schröder C, Müller A, Jungen H, Andresen-Streichert H, Pueschel K, Vidal C, Mercer-Chalmers-Bender K. Mass poisoning with NPS: 2C-E and Bromo-DragonFly. Int J Legal Med. 2019;133(1):123-129.
Not in our library10.1007/s00414-018-1882-9
295.
James D, Adams RD, Spears R, Cooper G, Lupton DJ, Thompson JP, Thomas SH. Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg Med J. 2011;28(8):686-689.
Not in our library10.1136/emj.2010.096636
296.
Javadi-Paydar M, Nguyen JD, Vandewater SA, Dickerson TJ, Taffe MA. Locomotor and reinforcing effects of pentedrone, pentylone and methylone in rats. Neuropharmacology. 2018;134(Pt A):57-64.
Not in our library10.1016/j.neuropharm.2017.09.002
297.
Jebadurai J, Schifano F, Deluca P. Recreational use of 1-(2-naphthyl)-2-(1-pyrrolidinyl)-1-pentanone hydrochloride (NRG-1), 6-(2-aminopropyl)benzofuran (benzofury/6-APB) and NRG-2 with review of available evidence-based literature. Hum Psychopharmacol. 2013;28(4):356-364.
Not in our library10.1002/hup.2302
298.
Jensen AA, McCorvy JD, Leth-Petersen S, Bundgaard C, Liebscher G, Kenakin TP, Brauner-Osborne H, Kehler J, Kristensen JL. Detailed characterization of the in vitro pharmacological and pharmacokinetic properties of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine (25CN-NBOH), a highly selective and brain-penetrant 5-HT2A receptor agonist. J Pharmacol Exp Ther. 2017;361(3):441-453.
Not in our library10.1124/jpet.117.239905
299.
Jerrard DA. "Designer drugs”—a current perspective. J Emerg Med. 1990;8(6):733-741.
Not in our library10.1016/0736-4679(90)90288-7
300.
Jinwala FN, Gupta M. Synthetic cannabis and respiratory depression. J Child Adolesc Psychopharmacol. 2012;22(6):459-462.
Not in our library10.1089/cap.2011.0122
301.
Johansson A, Lindstedt D, Roman M, Thelander G, Nielsen EI, Lennborn U, Sandler H, Rubertsson S, Ahlner J, Kronstrand R, Kugelberg FC. A non-fatal intoxication and seven deaths involving the dissociative drug 3-MeO-PCP. Forensic Sci Int. 2017;275:76-82.
Not in our library10.1016/j.forsciint.2017.02.034
302.
Johnson MP, Huang XM, Oberlender R, Nash JF, Nichols DE. Behavioral, biochemical and neurotoxicological actions of the α-ethyl homologue of p-chloroamphetamine. Eur J Pharmacol. 1990;191(1):1-10.
Not in our library10.1016/0014-2999(90)94090-k
303.
Johnson LA, Johnson RL, Alfonzo C. Spice: a legal marijuana equivalent. Mil Med. 2011;176(6):718-720.
Not in our library10.7205/milmed-d-10-00356
304.
Jones AL, Jarvie DR, McDermid G, Proudfoot AT. Hepatocellular damage following amphetamine intoxication. J Toxicol Clin Toxicol. 1994;32(4):435-444.
Not in our library10.3109/15563659409011046
305.
Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125(1–2):8-18.
Not in our library10.1016/j.drugalcdep.2012.07.004
306.
Jones MJ, Hernandez BS, Janis GC, Stellpflug SJ. A case of U-47700 overdose with laboratory confirmation and metabolite identification. Clin Toxicol (Phila). 2017;55(1):55-59.
Not in our library10.1080/15563650.2016.1209767
307.
Joseph JF, Parr MK. Synthetic androgens as designer supplements. Curr Neuropharmacol. 2015;13(1):89-100.
Not in our library10.2174/1570159x13666141210224756
308.
Jovel A, Felthous A, Bhattacharyya A. Delirium due to intoxication from the novel synthetic tryptamine 5-MeO-DALT. J Forensic Sci. 2014;59(3):844-846.
Not in our library10.1111/1556-4029.12367
309.
Kamel M, Thajudeen B. A case of acute kidney injury and calcium oxalate deposition associated with synthetic cannabinoids. Saudi J Kidney Dis Transpl. 2015;26(4):802-803.
Not in our library10.4103/1319-2442.160222
310.
Kamijo Y, Soma K, Nishida M, Namera A, Ohwada T. Acute liver failure following intravenous methamphetamine. Vet Hum Toxicol. 2002;44(4):216-217.
Not in our library
311.
Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009;89(1):309-380.
Not in our library10.1152/physrev.00019.2008
312.
Kapil V, Green JL, Le Lait C, Wood DM, Dargan PI. Misuse of benzodiazepines and Z-drugs in the UK. Br J Psychiatry. 2014;205(5):407-408.
Not in our library10.1192/bjp.bp.114.149252
313.
Karinen R, Tuv SS, Rogde S, Peres MD, Johansen U, Frost J, Vindenes V, Oiestad AM. Lethal poisonings with AH-7921 in combination with other substances. Forensic Sci Int. 2014;244:e21-e24.
Not in our library10.1016/j.forsciint.2014.08.013
314.
Katselou M, Papoutsis I, Nikolaou P, Spiliopoulou C, Athanaselis S. 5-(2-aminopropyl)indole: a new player in the drama of 'legal highs' alerts the community. Drug Alcohol Rev. 2015;34(1):51-57.
Not in our library10.1111/dar.12136
315.
Katz DP, Deruiter J, Bhattacharya D, Ahuja M, Bhattacharya S, Clark CR, Suppiramaniam V, Dhanasekaran M. Benzylpiperazine: “a messy drug". Drug Alcohol Depend. 2016;164:1-7.
Not in our library10.1016/j.drugalcdep.2016.04.010
316.
Katz KD, Leonetti AL, Bailey BC, Surmaitis RM, Eustice ER, Kacinko S, Wheatley SM. Case series of synthetic cannabinoid intoxication from one toxicology center. West J Emerg Med. 2016;17(3):290-294.
Not in our library10.5811/westjem.2016.2.29519
317.
Kazory A, Aiyer R. Synthetic marijuana and acute kidney injury: an unforeseen association. Clin Kidney J. 2013;6(3):330-333.
Not in our library10.1093/ckj/sft047
318.
Kelkar AH, Smith NA, Martial A, Moole H, Tarantino MD, Roberts JC. An outbreak of synthetic cannabinoid-associated coagulopathy in Illinois. N Engl J Med. 2018;379(13):1216-1223.
Not in our library10.1056/nejmoa1807652
319.
Kendrick WC, Hull AR, Knochel JP. Rhabdomyolysis and shock after intravenous amphetamine administration. Ann Intern Med. 1977;86(4):381-387.
Not in our library10.7326/0003-4819-86-4-381
320.
Kesha K, Boggs CL, Ripple MG, Allan CH, Levine B, Jufer-Phipps R, Doyon S, Chi P, Fowler DR. Methylenedioxypyrovalerone ("bath salts"), related death: case report and review of the literature. J Forensic Sci. 2013;58(6):1654-1659.
Not in our library10.1111/1556-4029.12202
321.
Khan M, Pace L, Truong A, Gordon M, Moukaddam N. Catatonia secondary to synthetic cannabinoid use in two patients with no previous psychosis. Am J Addict. 2016;25(1):25-27.
Not in our library10.1111/ajad.12318
322.
Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502-521.
Not in our library10.1038/bjp.2008.165
323.
Kieffer BL. Opioids: first lessons from knockout mice. Trends Pharmacol Sci. 1999;20(1):19-26.
Not in our library10.1016/s0165-6147(98)01279-6
324.
Kim HK, Nelson LS. Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert Opin Drug Saf. 2015;14(7):1137-1146.
Not in our library10.1517/14740338.2015.1037274
325.
Klein LM, Cozzi NV, Daley PF, Brandt SD, Halberstadt AL. Receptor binding profiles and behavioral pharmacology of ring-substituted N, N-diallyltryptamine analogs. Neuropharmacology. 2018;142:231-239.
Not in our library10.1016/j.neuropharm.2018.02.028
326.
Knudsen K, Jonsson U, Abrahamsson J. Twenty-three deaths with γ-hydroxybutyrate overdose in western Sweden between 2000 and 2007. Acta Anaesthesiol Scand. 2010;54(8):987-992.
Not in our library10.1111/j.1399-6576.2010.02278.x
327.
Koch K, Auwärter V, Hermanns-Clausen M, Wilde M, Neukamm MA. Mixed intoxication by the synthetic opioid U-47700 and the benzodiazepine flubromazepam with lethal outcome: pharmacokinetic data. Drug Test Anal. 2018.
Not in our library10.1002/dta.2391
328.
Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME. Receptor interaction profiles of 4-alkoxy-substituted 2,5-dimethoxyphenethylamines and related amphetamines. Front Pharmacol. 2019;10:1423.
Not in our library10.3389/fphar.2019.01423
329.
Kovacs K, Kereszty E, Berkecz R, Tiszlavicz L, Sija E, Kormoczi T, Jenei N, Revesz-Schmehl H, Institoris L. Fatal intoxication of a regular drug user following N-ethyl-hexedrone and ADB-FUBINACA consumption. J Forensic Leg Med. 2019;65:92-100.
Not in our library10.1016/j.jflm.2019.04.012
330.
Kovaleva J, Devuyst E, De Paepe P, Verstraete A. Acute chlorophenylpiperazine overdose: a case report and review of the literature. Ther Drug Monit. 2008;30(3):394-398.
Not in our library10.1097/ftd.0b013e318170a879
331.
Kraehenmann R, Pokorny D, Vollenweider L, Preller KH, Pokorny T, Seifritz E, Vollenweider FX. Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology. 2017.
Not in our library10.1007/s00213-017-4610-0
332.
Kraemer M, Fels H, Dame T, Musshoff F, Halter S, Mogler L, Hess C, Madea B, Maas A. Mono-/polyintoxication with 5F-ADB: a case series. Forensic Sci Int. 2019;301:e29-e37.
Not in our library10.1016/j.forsciint.2019.05.017
333.
Kriikku P, Pelander A, Rasanen I, Ojanpera I. Toxic lifespan of the synthetic opioid U-47,700 in Finland verified by re-analysis of UPLC–TOF–MS data. Forensic Sci Int. 2019;300:85-88.
Not in our library10.1016/j.forsciint.2019.04.030
334.
Kronstrand R, Roman M, Dahlgren M, Thelander G, Wikström M, Druid H. A cluster of deaths involving 5-(2-aminopropyl)indole (5-IT). J Anal Toxicol. 2013;37(8):542-546.
Not in our library10.1093/jat/bkt058
335.
Kronstrand R, Thelander G, Lindstedt D, Roman M, Kugelberg FC. Fatal intoxications associated with the designer opioid AH-7921. J Anal Toxicol. 2014;38(8):599-604.
Not in our library10.1093/jat/bku057
336.
Krotulski AJ, Papsun DM, Friscia M, Swartz JL, Holsey BD, Logan BK. Fatality following ingestion of tetrahydrofuranylfentanyl, U-49900 and methoxy-phencyclidine. J Anal Toxicol. 2018;42(3):e27-e32.
Not in our library10.1093/jat/bkx092
337.
Krueger J, Sachs H, Musshoff F, Dame T, Schaeper J, Schwerer M, Graw M, Roider G. First detection of ethylphenidate in human fatalities after ethylphenidate intake. Forensic Sci Int. 2014;243:126-129.
Not in our library10.1016/j.forsciint.2014.07.017
338.
Kudo K, Usumoto Y, Kikura-Hanajiri R, Sameshima N, Tsuji A, Ikeda N. A fatal case of poisoning related to new cathinone designer drugs, 4-methoxy PV8, PV9, and 4-methoxy PV9, and a dissociative agent, diphenidine. Leg Med (Tokyo). 2015;17(5):421-426.
Not in our library10.1016/j.legalmed.2015.06.005
339.
Kueppers VB, Cooke CT. 25I-NBOMe related death in Australia: a case report. Forensic Sci Int. 2015;249:e15-e18.
Not in our library10.1016/j.forsciint.2015.02.010
340.
Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. 1991;14(7):299-302.
Not in our library10.1016/0166-2236(91)90141-g
341.
Kusano M, Zaitsu K, Taki K, Hisatsune K, Nakajima J, Moriyasu T, Asano T, Hayashi Y, Tsuchihashi H, Ishii A. Fatal intoxication by 5F-ADB and diphenidine: detection, quantification, and investigation of their main metabolic pathways in humans by LC/MS/MS and LC/Q–TOFMS. Drug Test Anal. 2018;10(2):284-293.
Not in our library10.1002/dta.2215
342.
Labay LM, Caruso JL, Gilson TP, Phipps RJ, Knight LD, Lemos NP, McIntyre IM, Stoppacher R, Tormos LM, Wiens AL, Williams E, Logan BK. Synthetic cannabinoid drug use as a cause or contributory cause of death. Forensic Sci Int. 2016;260:31-39.
Not in our library10.1016/j.forsciint.2015.12.046
343.
Lafferty C, Smith L, Coull A, Shanley J. The experience of an increase in the injection of ethylphenidate in Lothian April 2014–March 2015. Scott Med J. 2016;61(2):74-83.
Not in our library10.1177/0036933016649871
344.
Lam RP, Yip WL, Tsui MS, Ng SW, Ching CK, Mak TW. Severe rhabdomyolysis and acute kidney injury associated with methoxphenidine. Clin Toxicol (Phila). 2016;54(5):464-465.
Not in our library10.3109/15563650.2016.1157724
345.
Lapin I. Phenibut (β-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Rev. 2001;7(4):471-481.
Not in our library10.1111/j.1527-3458.2001.tb00211.x
346.
Lapoint J, James LP, Moran CL, Nelson LS, Hoffman RS, Moran JH. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila). 2011;49(8):760-764.
Not in our library10.3109/15563650.2011.609822
347.
Law R, Schier J, Martin C, Chang A, Wolkin A. Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use—United States, January–May 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):618-619.
Not in our library
348.
Le Boisselier R, Alexandre J, Lelong-Boulouard V, Debruyne D. Focus on cannabinoids and synthetic cannabinoids. Clin Pharmacol Ther. 2017;101(2):220-229.
Not in our library10.1002/cpt.563
349.
Lawn W, Borschmann R, Cottrell A, Winstock A. Methoxetamine: prevalence of use in the USA and UK and associated urinary problems. J Subst Use. 2016;21(2):115-120.
Not in our library10.3109/14659891.2014.966345
350.
Lee HM, Wood DM, Hudson S, Archer JR, Dargan PI. Acute toxicity associated with analytically confirmed recreational use of methiopropamine (1-(thiophen-2-yl)-2-methylaminopropane). J Med Toxicol. 2014;10(3):299-302.
Not in our library10.1007/s13181-014-0399-y
351.
Lee D, Chronister CW, Hoyer J, Goldberger BA. Ethylone-related deaths: toxicological findings. J Anal Toxicol. 2015;39(7):567-571.
Not in our library10.1093/jat/bkv053
352.
Leibu E, Garakani A, McGonigle DP, Liebman LS, Loh D, Bryson EO, Kellner CH. Electroconvulsive therapy (ECT) for catatonia in a patient with schizophrenia and synthetic cannabinoid abuse: a case report. J ECT. 2013;29(4):e61-e62.
Not in our library10.1097/yct.0b013e318290fa36
353.
Ketamine: 50 Years of Modulating the Mind · 2016
No notice
354.
Liakoni E, Walther F, Nickel CH, Liechti ME. Presentations to an urban emergency department in Switzerland due to acute γ-hydroxybutyrate toxicity. Scand J Trauma Resusc Emerg Med. 2016;24(1):107.
Not in our library10.1186/s13049-016-0299-z
355.
Liechti ME. Modern clinical research on LSD. Neuropsychopharmacology. 2017;42(11):2114-2127.
Not in our library10.1038/npp.2017.86
356.
Lin JC, Jan RK, Lee H, Jensen MA, Kydd RR, Russell BR. Determining the subjective and physiological effects of BZP combined with TFMPP in human males. Psychopharmacology. 2011;214(3):761-768.
Not in our library10.1007/s00213-010-2081-7
357.
Liveri K, Constantinou MA, Afxentiou M, Kanari P. A fatal intoxication related to MDPV and pentedrone combined with antipsychotic and antidepressant substances in Cyprus. Forensic Sci Int. 2016;265:160-165.
Not in our library10.1016/j.forsciint.2016.02.017
358.
Loi B, Zloh M, De Luca MA, Pintori N, Corkery J, Schifano F. 4,4ʹ-Dimethylaminorex (“4,4ʹ-DMAR”; “Serotoni”) misuse: a Web-based study. Hum Psychopharmacol. 2017;32(3):1.
Not in our library10.1002/hup.2575
359.
Longo LP, Johnson B. Addiction. Part I Benzodiazepines–side effects, abuse risk and alternatives. Am Fam Physician. 2000;61(7):2121-2128.
Not in our library
360.
Longworth M, Connor M, Banister SD, Kassiou M. Synthesis and pharmacological profiling of the metabolites of synthetic cannabinoid drugs APICA, STS-135, ADB-PINACA, and 5F-ADB-PINACA. ACS Chem Neurosci. 2017;8(8):1673-1680.
Not in our library10.1021/acschemneuro.7b00116
361.
Lucyk SN, Nelson LS. Novel synthetic opioids: an opioid epidemic within an opioid epidemic. Ann Emerg Med. 2017;69(1):91-93.
Not in our library10.1016/j.annemergmed.2016.08.445
362.
Luethi D, Liechti ME. Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int J Neuropsychopharmacol. 2018;21(10):926-931.
Not in our library10.1093/ijnp/pyy047
363.
Luethi D, Liechti ME, Krähenbühl S. Mechanisms of hepatocellular toxicity associated with new psychoactive synthetic cathinones. Toxicology. 2017;387:57-66.
Not in our library10.1016/j.tox.2017.06.004
364.
Luethi D, Hoener MC, Liechti ME. Effects of the new psychoactive substances diclofensine, diphenidine, and methoxphenidine on monoaminergic systems. Eur J Pharmacol. 2018;819:242-247.
Not in our library10.1016/j.ejphar.2017.12.012
365.
Luethi D, Kaeser PJ, Brandt SD, Krähenbühl S, Hoener MC, Liechti ME. Pharmacological profile of methylphenidate-based designer drugs. Neuropharmacology. 2018;134(Pt A):133-140.
Not in our library10.1016/j.neuropharm.2017.08.020
366.
Luethi D, Kolaczynska KE, Docci L, Krähenbühl S, Hoener MC, Liechti ME. Pharmacological profile of mephedrone analogs and related new psychoactive substances. Neuropharmacology. 2018;134(Pt A):4-12.
Not in our library10.1016/j.neuropharm.2017.07.026
367.
Luethi D, Trachsel D, Hoener MC, Liechti ME. Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs). Neuropharmacology. 2018;134(Pt A):141-148.
Not in our library10.1016/j.neuropharm.2017.07.012
368.
Luethi D, Kolaczynska KE, Walter M, Suzuki M, Rice KC, Blough BE, Hoener MC, Baumann MH, Liechti ME. Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems. J Psychopharmacol. 2019;33(7):831-841.
Not in our library10.1177/0269881119844185
369.
Para-Halogenation Affects Monoamine Transporter Inhibition Properties and Hepatocellular Toxicity of Amphetamines and Methcathinones · 2019
Not checked
370.
Luethi D, Widmer R, Trachsel D, Hoener MC, Liechti ME. Monoamine receptor interaction profiles of 4-aryl-substituted 2,5-dimethoxyphenethylamines (2C-BI derivatives). Eur J Pharmacol. 2019;855:103-111.
Not in our library10.1016/j.ejphar.2019.05.014
371.
Lüthi D, Liechti ME, Corazza O, Roman-Urrestarazu A. Clinical aspects related to methylphenidate-based NPS. Handbook of novel psychoactive substances: what clinicians should know about NPS. 2019;227-244.
Not in our library
372.
Maas A, Wippich C, Madea B, Hess C. Driving under the influence of synthetic phenethylamines: a case series. Int J Legal Med. 2015;129(5):997-1003.
Not in our library10.1007/s00414-015-1150-1
373.
Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbaek DS, Kristiansen S, Johansen SS, Lehel S, Linnet K, Svarer C, Erritzoe D, Ozenne B, Knudsen GM. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019;44(7):1328-1334.
Not in our library10.1038/s41386-019-0324-9
374.
Maeda H, Kikura-Hanajiri R, Kawamura M, Nagashima E, Yoshida KI. AB-CHMINACA-induced sudden death from non-cardiogenic pulmonary edema. Clin Toxicol (Phila). 2018;56(2):143-145.
Not in our library10.1080/15563650.2017.1340648
375.
Maguire P, Tsai N, Kamal J, Cometta-Morini C, Upton C, Loew G. Pharmacological profiles of fentanyl analogs at μ, δ and κ opiate receptors. Eur J Pharmacol. 1992;213(2):219-225.
Not in our library10.1016/0014-2999(92)90685-w
376.
Maier J, Mayer FP, Brandt SD, Sitte HH. DARK classics in chemical neuroscience: aminorex analogues. ACS Chem Neurosci. 2018;9(10):2484-2502.
Not in our library10.1021/acschemneuro.8b00415
377.
Maier J, Mayer FP, Luethi D, Holy M, Jäntsch K, Reither H, Hirtler L, Hoener MC, Liechti ME, Pifl C, Brandt SD, Sitte HH. The psychostimulant (±)-cis-4,4ʹ-dimethylaminorex (4,4ʹ-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters. Neuropharmacology. 2018;138:282-291.
Not in our library10.1016/j.neuropharm.2018.06.018
378.
Majchrzak M, Celinski R, Kowalska T, Sajewicz M. Fatal case of poisoning with a new cathinone derivative: α-propylaminopentiophenone (N-PP). Forensic Toxicol. 2018;36(2):525-533.
Not in our library10.1007/s11419-018-0417-x
379.
Majrashi M, Almaghrabi M, Fadan M, Fujihashi A, Lee W, Deruiter J, Randall Clark C, Dhanasekaran M. Dopaminergic neurotoxic effects of 3-TFMPP derivatives. Life Sci. 2018;209:357-369.
Not in our library10.1016/j.lfs.2018.07.052
380.
Manchester KR, Lomas EC, Waters L, Dempsey FC, Maskell PD. The emergence of new psychoactive substance (NPS) benzodiazepines: a review. Drug Test Anal. 2018;10(1):37-53.
Not in our library10.1002/dta.2211
381.
Marinetti LJ, Antonides HM. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J Anal Toxicol. 2013;37(3):135-146.
Not in our library10.1093/jat/bks136
382.
Markowitz JS, Zhu HJ, Patrick KS. Isopropylphenidate: an ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability. J Child Adolesc Psychopharmacol. 2013;23(10):648-654.
Not in our library10.1089/cap.2013.0074
383.
Martinotti G, Santacroce R, Papanti D, Elgharably Y, Prilutskaya M, Corazza O. Synthetic cannabinoids: psychopharmacology, clinical aspects, psychotic onset. CNS Neurol Disord Drug Targets. 2017;16(5):567-575.
Not in our library10.2174/1871527316666170413101839
384.
Martucci HFH, Ingle EA, Hunter MD, Rodda LN. Distribution of furanyl fentanyl and 4-ANPP in an accidental acute death: a case report. Forensic Sci Int. 2018;283:e13-e17.
Not in our library10.1016/j.forsciint.2017.12.005
385.
Marusich JA, Antonazzo KR, Blough BE, Brandt SD, Kavanagh PV, Partilla JS, Baumann MH. The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue. Neuropharmacology. 2016;101:68-75.
Not in our library10.1016/j.neuropharm.2015.09.004
386.
Maskell PD, De Paoli G, Seneviratne C, Pounder DJ. Mephedrone (4-methylmethcathinone)-related deaths. J Anal Toxicol. 2011;35(3):188-191.
Not in our library10.1093/anatox/35.3.188
387.
Maskell PD, Paoli GD, Seetohul LN, Pounder DJ. Phenazepam is currently being misused in the UK. BMJ. 2011;343:d4207.
Not in our library10.1136/bmj.d4207
388.
Maskell PD, Smith PR, Cole R, Hikin L, Morley SR. Seven fatalities associated with ethylphenidate. Forensic Sci Int. 2016;265:70-74.
Not in our library10.1016/j.forsciint.2015.12.045
389.
Mayer FP, Wimmer L, Dillon-Carter O, Partilla JS, Burchardt NV, Mihovilovic MD, Baumann MH, Sitte HH. Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters. Br J Pharmacol. 2016;173(17):2657-2668.
Not in our library10.1111/bph.13547
390.
Mayer FP, Burchardt NV, Decker AM, Partilla JS, Li Y, McLaughlin G, Kavanagh PV, Sandtner W, Blough BE, Brandt SD, Baumann MH, Sitte HH. Fluorinated phenmetrazine "legal highs" act as substrates for high-affinity monoamine transporters of the SLC6 family. Neuropharmacology. 2018;134(Pt A):149-157.
Not in our library10.1016/j.neuropharm.2017.10.006
391.
Mayer FP, Cintulova D, Pittrich DA, Wimmer L, Luethi D, Holy M, Jaentsch K, Tischberger S, Gmeiner G, Hoener MC, Liechti ME, Mihovilovic MD, Sitte HH. Stereochemistry of phase-1 metabolites of mephedrone determines their effectiveness as releasers at the serotonin transporter. Neuropharmacology. 2019;148:199-209.
Not in our library10.1016/j.neuropharm.2018.12.032
392.
Mayer FP, Schmid D, Holy M, Daws LC, Sitte HH. "Polytox" synthetic cathinone abuse: a potential role for organic cation transporter 3 in combined cathinone-induced efflux. Neurochem Int. 2019;123:7-12.
Not in our library10.1016/j.neuint.2018.09.008
393.
McCabe DJ, Bangh SA, Arens AM, Cole JB. Phenibut exposures and clinical effects reported to a regional poison center. Am J Emerg Med. 2019;37(11):2066-2071.
Not in our library10.1016/j.ajem.2019.02.044
394.
McIlroy G, Ford L, Khan JM. Acute myocardial infarction, associated with the use of a synthetic adamantyl-cannabinoid: a case report. BMC Pharmacol Toxicol. 2016;17:2.
Not in our library10.1186/s40360-016-0045-1
395.
McIntyre IM, Gary RD, Trochta A, Stolberg S, Stabley R. Acute 5-(2-aminopropyl)benzofuran (5-APB) intoxication and fatality: a case report with postmortem concentrations. J Anal Toxicol. 2015;39(2):156-159.
Not in our library10.1093/jat/bku131
396.
McIntyre IM, Trochta A, Gary RD, Malamatos M, Lucas JR. An acute acetyl fentanyl fatality: a case report with postmortem concentrations. J Anal Toxicol. 2015;39(6):490-494.
Not in our library10.1093/jat/bkv043
397.
McIntyre IM, Trochta A, Gary RD, Storey A, Corneal J, Schaber B. A fatality related to two novel hallucinogenic compounds: 4-methoxyphencyclidine and 4-hydroxy-N-methyl-N-ethyltryptamine. J Anal Toxicol. 2015;39(9):751-755.
Not in our library10.1093/jat/bkv089
398.
McIntyre IM, Trochta A, Gary RD, Wright J, Mena O. An acute butyr-fentanyl fatality: a case report with postmortem concentrations. J Anal Toxicol. 2016;40(2):162-166.
Not in our library10.1093/jat/bkv138
399.
McIntyre IM, Gary RD, Joseph S, Stabley R. A fatality related to the synthetic opioid U-47700: postmortem concentration distribution. J Anal Toxicol. 2017;41(2):158-160.
Not in our library10.1093/jat/bkw124
400.
McKeever RG, Vearrier D, Jacobs D, LaSala G, Okaneku J, Greenberg MI. K2–not the spice of life; synthetic cannabinoids and ST elevation myocardial infarction: a case report. J Med Toxicol. 2015;11(1):129-131.
Not in our library10.1007/s13181-014-0424-1
401.
McLaughlin G, Morris N, Kavanagh PV, Power JD, Twamley B, O'Brien J, Talbot B, Dowling G, Mahony O, Brandt SD, Patrick J, Archer RP, Partilla JS, Baumann MH. Synthesis, characterization, and monoamine transporter activity of the new psychoactive substance 3ʹ,4ʹ-methylenedioxy-4-methylaminorex (MDMAR). Drug Test Anal. 2015;7(7):555-564.
Not in our library10.1002/dta.1732
402.
McLaughlin G, Baumann MH, Kavanagh PV, Morris N, Power JD, Dowling G, Twamley B, O'Brien J, Hessman G, Westphal F, Walther D, Brandt SD. Synthesis, analytical characterization, and monoamine transporter activity of the new psychoactive substance 4-methylphenmetrazine (4-MPM), with differentiation from its ortho- and meta- positional isomers. Drug Test Anal. 2018;10(9):1404-1416.
Not in our library10.1002/dta.2396
403.
McQuade D, Hudson S, Dargan PI, Wood DM. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol. 2013;69(3):373-376.
Not in our library10.1007/s00228-012-1379-2
404.
Meatherall R, Sharma P. Foxy, a designer tryptamine hallucinogen. J Anal Toxicol. 2003;27(5):313-317.
Not in our library10.1093/jat/27.5.313
405.
Mehta JJ, Mahendran AK, Bajaj RK, Doshi AR. Myocardial ischemia with cannabinoid use in an adolescent. Cureus. 2017;9(11):e1899.
Not in our library10.7759/cureus.1899
406.
Meijer KA, Russo RR, Adhvaryu DV. Smoking synthetic marijuana leads to self-mutilation requiring bilateral amputations. Orthopedics. 2014;37(4):e391-e394.
Not in our library10.3928/01477447-20140401-62
407.
Mensen VT, Vreeker A, Nordgren J, Atkinson A, De la Torre R, Farre M, Ramaekers JG, Brunt TM. Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis. Psychopharmacology. 2019;236(9):2677-2685.
Not in our library10.1007/s00213-019-05238-8
408.
Miliano C, Margiani G, Fattore L, De Luca MA. Sales and advertising channels of new psychoactive substances (NPS): Internet, social networks, and smartphone apps. Brain Sci. 2018;8(7):1.
Not in our library10.3390/brainsci8070123
409.
Miller KJ, Anderholm DC, Ames MM. Metabolic activation of the serotonergic neurotoxin para-chloroamphetamine to chemically reactive intermediates by hepatic and brain microsomal preparations. Biochem Pharmacol. 1986;35(10):1737-1742.
Not in our library10.1016/0006-2952(86)90332-1
410.
Mills EM, Banks ML, Sprague JE, Finkel T. Pharmacology: uncoupling the agony from ecstasy. Nature. 2003;426(6965):403-404.
Not in our library10.1038/426403a
411.
Mills EM, Rusyniak DE, Sprague JE. The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine. J Mol Med (Berl). 2004;82(12):787-799.
Not in our library10.1007/s00109-004-0591-7
412.
Mills B, Dishner E, Velasco CE. Acute myocardial infarction triggered by use of synthetic cannabis. Proc (Bayl Univ Med Cent). 2018;31(2):200-202.
Not in our library10.1080/08998280.2017.1416243
413.
Mir A, Obafemi A, Young A, Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics. 2011;128(6):e1622-e1627.
Not in our library10.1542/peds.2010-3823
414.
Misra M, Shi Q, Ye X, Gruszecka-Kowalik E, Bu W, Liu Z, Schweri MM, Deutsch HM, Venanzi CA. Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010;18(20):7221-7238.
Not in our library10.1016/j.bmc.2010.08.034
415.
Mitchell-Mata C, Thomas B, Peterson B, Couper F. Two fatal intoxications involving 3-methoxyphencyclidine. J Anal Toxicol. 2017;41(6):503-507.
Not in our library10.1093/jat/bkx048
416.
Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2011;25(4):439-452.
Not in our library10.1177/0269881110378371
417.
Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry. 2016;3(5):481-488.
Not in our library10.1016/s2215-0366(15)00576-3
418.
Miyajima M, Matsumoto T, Ito S. 2C-T-4 intoxication: acute psychosis caused by a designer drug. Psychiatry Clin Neurosci. 2008;62(2):243.
Not in our library10.1111/j.1440-1819.2008.01764.x
419.
Moeller S, Lücke C, Struffert T, Schwarze B, Gerner ST, Schwab S, Köhrmann M, Machold K, Philipsen A, Müller HH. Ischemic stroke associated with the use of a synthetic cannabinoid (spice). Asian J Psychiatr. 2017;25:127-130.
Not in our library10.1016/j.ajp.2016.10.019
420.
Mohammed D. Occurrence of takotsubo cardiomyopathy after synthetic cannabinoid consumption. Addict Health. 2019;11(3):202-206.
Not in our library10.22122/ahj.v11i3.239
421.
Mohr AL, Friscia M, Papsun D, Kacinko SL, Buzby D, Logan BK. Analysis of novel synthetic opioids U-47700, U-50488 and furanyl fentanyl by LC–MS/MS in postmortem casework. J Anal Toxicol. 2016;40(9):709-717.
Not in our library10.1093/jat/bkw086
422.
Monte AP, Marona-Lewicka D, Cozzi NV, Nichols DE. Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine. J Med Chem. 1993;36(23):3700-3706.
Not in our library10.1021/jm00075a027
423.
Moosmann B, Auwärter V. Designer benzodiazepines: another class of new psychoactive substances. Handb Exp Pharmacol. 2018;252:383-410.
Not in our library10.1007/164_2018_154
424.
Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology. 2006;188(4):408-424.
Not in our library10.1007/s00213-006-0572-3
425.
Moritz ML, Kalantar-Zadeh K, Ayus JC. Ecstacy-associated hyponatremia: why are women at risk? Nephrol Dial Transplant. 2013;28(9):2206-2209.
Not in our library10.1093/ndt/gft192
426.
Morris H, Wallach J. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal. 2014;6(7–8):614-632.
Not in our library10.1002/dta.1620
427.
Morse BL, Vijay N, Morris ME. γ-Hydroxybutyrate (GHB)-induced respiratory depression: combined receptor-transporter inhibition therapy for treatment in GHB overdose. Mol Pharmacol. 2012;82(2):226-235.
Not in our library10.1124/mol.112.078154
428.
Moya PR, Berg KA, Gutierrez-Hernandez MA, Saez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Pharmacol Exp Ther. 2007;321(3):1054-1061.
Not in our library10.1124/jpet.106.117507
429.
Muller AA. New drugs of abuse update: Foxy Methoxy. J Emerg Nurs. 2004;30(5):507-508.
Not in our library10.1016/j.jen.2004.07.037
430.
Müller H, Sperling W, Köhrmann M, Huttner HB, Kornhuber J, Maler JM. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res. 2010;118(1–3):309-310.
Not in our library10.1016/j.schres.2009.12.001
431.
Müller D, Neurath H, Neukamm MA, Wilde M, Despicht C, Blaschke S, Grapp M. New synthetic opioid cyclopropylfentanyl together with other novel synthetic opioids in respiratory insufficient comatose patients detected by toxicological analysis. Clin Toxicol (Phila). 2019;57(9):806-812.
Not in our library10.1080/15563650.2018.1554187
432.
Musshoff F, Madea B, Kernbach-Wighton G, Bicker W, Kneisel S, Hutter M, Auwärter V. Driving under the influence of synthetic cannabinoids ("Spice"): a case series. Int J Legal Med. 2014;128(1):59-64.
Not in our library10.1007/s00414-013-0864-1
433.
Muttoni S, Ardissino M, John C. Classical psychedelics for the treatment of depression and anxiety: a systematic review. J Affect Disord. 2019;258:11-24.
Not in our library10.1016/j.jad.2019.07.076
434.
Nacca N, Vatti D, Sullivan R, Sud P, Su M, Marraffa J. The synthetic cannabinoid withdrawal syndrome. J Addict Med. 2013;7(4):296-298.
Not in our library10.1097/adm.0b013e31828e1881
435.
Nagai H, Saka K, Nakajima M, Maeda H, Kuroda R, Igarashi A, Tsujimura-Ito T, Nara A, Komori M, Yoshida K. Sudden death after sustained restraint following self-administration of the designer drug α-pyrrolidinovalerophenone. Int J Cardiol. 2014;172(1):263-265.
Not in our library10.1016/j.ijcard.2013.12.262
436.
Nash C, Butzbach D, Stockham P, Scott T, Abroe G, Painter B, Gilbert J, Kostakis C. A fatality involving furanylfentanyl and MMMP, with presumptive identification of three MMMP metabolites in urine. J Anal Toxicol. 2019;43(4):291-298.
Not in our library10.1093/jat/bky099
437.
Nguyen PT, Dang DK, Tran HQ, Shin EJ, Jeong JH, Nah SY, Cho MC, Lee YS, Jang CG, Kim HC. Methiopropamine, a methamphetamine analogue, produces neurotoxicity via dopamine receptors. Chem Biol Interact. 2019;305:134-147.
Not in our library10.1016/j.cbi.2019.03.017
438.
Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101(2):131-181.
Not in our library10.1016/j.pharmthera.2003.11.002
439.
Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264-355.
Not in our library10.1124/pr.115.011478
440.
Nichols DE, Grob CS. Is LSD toxic? Forensic Sci Int. 2018;284:141-145.
Not in our library10.1016/j.forsciint.2018.01.006
441.
Nichols DE, Johnson MP, Oberlender R. 5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine. Pharmacol Biochem Behav. 1991;38(1):135-139.
Not in our library10.1016/0091-3057(91)90601-w
442.
Niello M, Cintulova D, Hellsberg E, Jäntsch K, Holy M, Ayatollahi LH, Cozzi NV, Freissmuth M, Sandtner W, Ecker GF, Mihovilovic MD, Sitte HH. para-Trifluoromethyl-methcathinone is an allosteric modulator of the serotonin transporter. Neuropharmacology. 2019;161:107615.
Not in our library10.1016/j.neuropharm.2019.04.021
443.
Noble C, Holm NB, Mardal M, Linnet K. Bromo-dragonfly, a psychoactive benzodifuran, is resistant to hepatic metabolism and potently inhibits monoamine oxidase A. Toxicol Lett. 2018;295:397-407.
Not in our library10.1016/j.toxlet.2018.07.018
444.
Nugteren-van Lonkhuyzen JJ, Van Riel AJ, Brunt TM, Hondebrink L. Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans. Drug Alcohol Depend. 2015;157:18-27.
Not in our library10.1016/j.drugalcdep.2015.10.011
445.
Öcal N, Dogan D, Cicek AF, Yücel O, Tozkoparan E. Acute eosinophilic pneumonia with respiratory failure induced by synthetic cannabinoid inhalation. Balkan Med J. 2016;33(6):688-690.
Not in our library10.5152/balkanmedj.2016.151145
446.
Ojanperä I, Gergov M, Rasanen I, Lunetta P, Toivonen S, Tiainen E, Vuori E. Blood levels of 3-methylfentanyl in 3 fatal poisoning cases. Am J Forensic Med Pathol. 2006;27(4):328-331.
Not in our library10.1097/01.paf.0000188097.78132.e5
447.
Oliveira P, Morais ASF, Madeira N. Synthetic cannabis analogues and suicidal behavior: case report. J Addict Med. 2017;11(5):408-410.
Not in our library10.1097/adm.0000000000000335
448.
Oluwabusi OO, Lobach L, Akhtar U, Youngman B, Ambrosini PJ. Synthetic cannabinoid-induced psychosis: two adolescent cases. J Child Adolesc Psychopharmacol. 2012;22(5):393-395.
Not in our library10.1089/cap.2012.0004
449.
Orsolini L, Papanti GD, De Berardis D, Guirguis A, Corkery JM, Schifano F. The "endless trip" among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review. Front Psychiatry. 2017;8:240.
Not in our library10.3389/fpsyt.2017.00240
450.
Ott J. Pharmahuasca: human pharmacology of oral DMT plus harmine. J Psychoact Drugs. 1999;31(2):171-177.
Not in our library10.1080/02791072.1999.10471741
451.
Ott J. Pharmepena-psychonautics: human intranasal, sublingual and oral pharmacology of 5-methoxy-NN-dimethyl-tryptamine. J Psychoact Drugs. 2001;33(4):403-407.
Not in our library10.1080/02791072.2001.10399925
452.
Owen DR, Wood DM, Archer JR, Dargan PI. Phenibut (4-amino-3-phenyl-butyric acid): availability, prevalence of use, desired effects and acute toxicity. Drug Alcohol Rev. 2016;35(5):591-596.
Not in our library10.1111/dar.12356
453.
Ozturk HM, Yetkin E, Ozturk S. Synthetic cannabinoids and cardiac arrhythmia risk: review of the literature. Cardiovasc Toxicol. 2019;19(3):191-197.
Not in our library10.1007/s12012-019-09522-z
454.
Palenicek T, Lhotkova E, Zidkova M, Balikova M, Kuchar M, Himl M, Miksatkova P, Cegan M, Vales K, Tyls F, Horsley RR. Emerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): pharmacokinetics, behaviour, thermoregulation and LD50 in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2016;69:49-59.
Not in our library10.1016/j.pnpbp.2016.04.004
455.
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial · 2018
No notice
456.
Pant S, Deshmukh A, Dholaria B, Kaur V, Ramavaram S, Ukor M, Teran GA. Spicy seizure. Am J Med Sci. 2012;344(1):67-68.
Not in our library10.1097/maj.0b013e31824cf5c2
457.
Papanti D, Schifano F, Botteon G, Bertossi F, Mannix J, Vidoni D, Impagnatiello M, Pascolo-Fabrici E, Bonavigo T. "Spiceophrenia": a systematic overview of "spice"-related psychopathological issues and a case report. Hum Psychopharmacol. 2013;28(4):379-389.
Not in our library10.1002/hup.2312
458.
Papsun D, Krywanczyk A, Vose JC, Bundock EA, Logan BK. Analysis of MT-45, a novel synthetic opioid, in human whole blood by LC–MS–MS and its identification in a drug-related death. J Anal Toxicol. 2016;40(4):313-317.
Not in our library10.1093/jat/bkw012
459.
Parks C, McKeown D, Torrance HJ. A review of ethylphenidate in deaths in east and west Scotland. Forensic Sci Int. 2015;257:203-208.
Not in our library10.1016/j.forsciint.2015.08.008
460.
Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB. Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther. 2006;319(1):237-246.
Not in our library10.1124/jpet.106.103622
461.
Partridge E, Trobbiani S, Stockham P, Charlwood C, Kostakis C. A case study involving U-47700, diclazepam and flubromazepam-application of retrospective analysis of HRMS data. J Anal Toxicol. 2018;42(9):655-660.
Not in our library10.1093/jat/bky039
462.
Patton AL, Chimalakonda KC, Moran CL, McCain KR, Radominska-Pandya A, James LP, Kokes C, Moran JH. K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci. 2013;58(6):1676-1680.
Not in our library10.1111/1556-4029.12216
463.
Paul ABM, Simms L, Amini S, Paul AE. Teens and spice: a review of adolescent fatalities associated with synthetic cannabinoid use. J Forensic Sci. 2018;63(4):1321-1324.
Not in our library10.1111/1556-4029.13704
464.
Pearson JM, Hargraves TL, Hair LS, Massucci CJ, Frazee CC, Garg U, Pietak BR. Three fatal intoxications due to methylone. J Anal Toxicol. 2012;36(6):444-451.
Not in our library10.1093/jat/bks043
465.
Peglow S, Buchner J, Briscoe G. Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient. Am J Addict. 2012;21(3):287-288.
Not in our library10.1111/j.1521-0391.2012.00222.x
466.
Penders TM, Gestring RE, Vilensky DA. Excited delirium following use of synthetic cathinones (bath salts). Gen Hosp Psychiatry. 2012;34(6):647-650.
Not in our library10.1016/j.genhosppsych.2012.06.005
467.
Peterson AB, Gladden RM, Delcher C, Spies E, Garcia-Williams A, Wang Y, Halpin J, Zibbell J, McCarty CL, DeFiore-Hyrmer J, DiOrio M, Goldberger BA. Increasses in fentanyl-related overdose deaths—Florida and Ohio, 2013–2015. MMWR Morb Mortal Wkly Rep. 2016;65(33):844-849.
Not in our library10.15585/mmwr.mm6533a3
468.
Pieprzyca E, Skowronek R, Korczynska M, Kulikowska J, Chowaniec M. A two fatal cases of poisoning involving new cathinone derivative PV8. Leg Med (Tokyo). 2018;33:42-47.
Not in our library10.1016/j.legalmed.2018.05.002
469.
Pinterova N, Horsley RR, Palenicek T. Synthetic aminoindanes: a summary of existing knowledge. Front Psychiatry. 2017;8:236.
Not in our library10.3389/fpsyt.2017.00236
470.
Poklis JL, Nanco CR, Troendle MM, Wolf CE, Poklis A. Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal. 2014;6(7–8):764-769.
Not in our library10.1002/dta.1522
471.
Poklis J, Poklis A, Wolf C, Hathaway C, Arbefeville E, Chrostowski L, Devers K, Hair L, Mainland M, Merves M, Pearson J. Two fatal intoxications involving butyryl fentanyl. J Anal Toxicol. 2016;40(8):703-708.
Not in our library10.1093/jat/bkw048
472.
Poplawska M, Blazewicz A. Identification of a novel growth hormone releasing peptide (a glycine analogue of GHRP-2) in a seized injection vial. Drug Test Anal. 2019;11(1):162-167.
Not in our library10.1002/dta.2467
473.
Potocka-Banas B, Janus T, Majdanik S, Banas T, Dembinska T, Borowiak K. Fatal intoxication with α-PVP, a synthetic cathinone derivative. J Forensic Sci. 2017;62(2):553-556.
Not in our library10.1111/1556-4029.13326
474.
Prekupec MP, Mansky PA, Baumann MH. Misuse of novel synthetic opioids: a deadly new trend. J Addict Med. 2017;11(4):256-265.
Not in our library10.1097/adm.0000000000000324
475.
Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, Liechti ME, Seifritz E, Vollenweider FX. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol. 2017;27(3):451-457.
Not in our library10.1016/j.cub.2016.12.030
476.
Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor · 2018
No notice
477.
Raheemullah A, Laurence TN. Repeated thrombosis after synthetic cannabinoid use. J Emerg Med. 2016;51(5):540-543.
Not in our library10.1016/j.jemermed.2016.06.015
478.
Rahnema CD, Crosnoe LE, Kim ED. Designer steroids—over-the-counter supplements and their androgenic component: review of an increasing problem. Andrology. 2015;3(2):150-155.
Not in our library10.1111/andr.307
479.
Riba J, McIlhenny EH, Bouso JC, Barker SA. Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study. Drug Test Anal. 2015;7(5):401-406.
Not in our library10.1002/dta.1685
480.
Richards JR, Johnson EB, Stark RW, Derlet RW. Methamphetamine abuse and rhabdomyolysis in the ED: a 5-year study. Am J Emerg Med. 1999;17(7):681-685.
Not in our library10.1016/s0735-6757(99)90159-6
481.
Richeval C, Gaulier JM, Romeuf L, Allorge D, Gaillard Y. Case report: relevance of metabolite identification to detect new synthetic opioid intoxications illustrated by U-47700. Int J Legal Med. 2019;133(1):133-142.
Not in our library10.1007/s00414-018-1969-3
482.
Rickli A, Hoener MC, Liechti ME. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol. 2015;25(3):365-376.
Not in our library10.1016/j.euroneuro.2014.12.012
483.
Rickli A, Kopf S, Hoener MC, Liechti ME. Pharmacological profile of novel psychoactive benzofurans. Br J Pharmacol. 2015;172(13):3412-3425.
Not in our library10.1111/bph.13128
484.
Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology. 2015;99:546-553.
Not in our library10.1016/j.neuropharm.2015.08.034
485.
Rickli A, Moning OD, Hoener MC, Liechti ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 2016;26(8):1327-1337.
Not in our library10.1016/j.euroneuro.2016.05.001
486.
Rickli A, Liakoni E, Hoener MC, Liechti ME. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. Br J Pharmacol. 2018;175(3):532-543.
Not in our library10.1111/bph.14105
487.
Rickli A, Kolaczynska K, Hoener MC, Liechti ME. Pharmacological characterization of the aminorex analogs 4-MAR, 4,4ʹ-DMAR, and 3,4-DMAR. Neurotoxicology. 2019;72:95-100.
Not in our library10.1016/j.neuro.2019.02.011
488.
Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987;237(4819):1219-1223.
Not in our library10.1126/science.2820058
489.
Roberto AJ, Lorenzo A, Li KJ, Young J, Mohan A, Pinnaka S, Lapidus KA. First-episode of synthetic cannabinoid-induced psychosis in a young adult, successfully managed with hospitalization and risperidone. Case Rep Psychiatry. 2016;2016:7257489.
Not in our library10.1155/2016/7257489
490.
Roque Bravo R, Carmo H, Silva JP, Valente MJ, Carvalho F, Bastos ML, Dias da Silva D. Emerging club drugs: 5-(2-aminopropyl)benzofuran (5-APB) is more toxic than its isomer 6-(2-aminopropyl)benzofuran (6-APB) in hepatocyte cellular models. Arch Toxicol. 2019.
Not in our library10.1007/s00204-019-02638-9
491.
Rose SR, Poklis JL, Poklis A. A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin Toxicol (Phila). 2013;51(3):174-177.
Not in our library10.3109/15563650.2013.772191
492.
Rose DZ, Guerrero WR, Mokin MV, Gooch CL, Bozeman AC, Pearson JM, Burgin WS. Hemorrhagic stroke following use of the synthetic marijuana "spice". Neurology. 2015;85(13):1177-1179.
Not in our library10.1212/wnl.0000000000001973
493.
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression · 2018
No notice
494.
Rosenson J, Smollin C, Sporer KA, Blanc P, Olson KR. Patterns of ecstasy-associated hyponatremia in California. Ann Emerg Med. 2007;49(2):164-171.
Not in our library10.1016/j.annemergmed.2006.09.018
495.
Ross EA, Watson M, Goldberger B. "Bath salts" intoxication. N Engl J Med. 2011;365(10):967-968.
Not in our library10.1056/nejmc1107097
496.
Ross EA, Reisfield GM, Watson MC, Chronister CW, Goldberger BA. Psychoactive "bath salts" intoxication with methylenedioxypyrovalerone. Am J Med. 2012;125(9):854-858.
Not in our library10.1016/j.amjmed.2012.02.019
497.
Roth BL. Drugs and valvular heart disease. N Engl J Med. 2007;356(1):6-9.
Not in our library10.1056/nejmp068265
498.
The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor · 2013
Corrected
499.
Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol. 2003;479(1–3):23-40.
Not in our library10.1016/j.ejphar.2003.08.054
500.
Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001;39(1):32-41.
Not in our library10.1002/1098-2396(20010101)39:1<32::aid-syn5>3.0.co;2-3
501.
Rothman RB, Katsnelson M, Vu N, Partilla JS, Dersch CM, Blough BE, Baumann MH. Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002;447(1):51-57.
Not in our library10.1016/s0014-2999(02)01830-7
502.
Ruan X, Chiravuri S, Kaye AD. Comparing fatal cases involving U-47700. Forensic Sci Med Pathol. 2016;12(3):369-371.
Not in our library10.1007/s12024-016-9795-8
503.
Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65(50–51):1445-1452.
Not in our library10.15585/mmwr.mm655051e1
504.
Sachdev S, Vemuri K, Banister SD, Longworth M, Kassiou M, Santiago M, Makriyannis A, Connor M. In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids. Br J Pharmacol. 2019.
Not in our library10.1111/bph.14829
505.
Sainsbury PD, Kicman AT, Archer RP, King LA, Braithwaite RA. Aminoindanes—the next wave of 'legal highs'? Drug Test Anal. 2011;3(7–8):479-482.
Not in our library10.1002/dta.318
506.
Saito T, Namera A, Miura N, Ohta S, Miyazaki S, Osawa M, Inokuchi S. A fatal case of MAM-2201 poisoning. Forensic Toxicol. 2013;31(2):333-337.
Not in our library10.1007/s11419-013-0190-9
507.
Sampson CS, Bedy SM, Carlisle T. Withdrawal seizures seen in the setting of synthetic cannabinoid abuse. Am J Emerg Med. 2015;33(11):1712.e3.
Not in our library10.1016/j.ajem.2015.03.025
508.
Sanchez S. Sur un homologue de l’éphédrine. Bull Soc Chim Fr. 1929;45:284-286.
Not in our library
509.
Schep LJ, Slaughter RJ, Vale JA, Beasley DM, Gee P. The clinical toxicology of the designer "party pills" benzylpiperazine and trifluoromethylphenylpiperazine. Clin Toxicol (Phila). 2011;49(3):131-141.
Not in our library10.3109/15563650.2011.572076
510.
Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Mégarbane B. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila). 2012;50(6):458-470.
Not in our library10.3109/15563650.2012.702218
511.
Schep LJ, Slaughter RJ, Hudson S, Place R, Watts M. Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues. Hum Exp Toxicol. 2015;34(5):557-560.
Not in our library10.1177/0960327114550886
512.
Schifano F, Corkery J, Ghodse AH. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, "meow meow") in the United Kingdom. J Clin Psychopharmacol. 2012;32(5):710-714.
Not in our library10.1097/jcp.0b013e318266c70c
513.
Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Müller F, Borgwardt S, Liechti ME. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 2015;78(8):544-553.
Not in our library10.1016/j.biopsych.2014.11.015
514.
Schneir AB, Baumbacher T. Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol. 2012;8(1):62-64.
Not in our library10.1007/s13181-011-0182-2
515.
Schneir A, Metushi IG, Sloane C, Benaron DJ, Fitzgerald RL. Near death from a novel synthetic opioid labeled U-47700: emergence of a new opioid class. Clin Toxicol (Phila). 2017;55(1):51-54.
Not in our library10.1080/15563650.2016.1209764
516.
Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017 · 2018
No notice
517.
Schwartz MD, Trecki J, Edison LA, Steck AR, Arnold JK, Gerona RR. A common source outbreak of severe delirium associated with exposure to the novel synthetic cannabinoid ADB-PINACA. J Emerg Med. 2015;48(5):573-580.
Not in our library10.1016/j.jemermed.2014.12.038
518.
Screaton GR, Singer M, Cairns HS, Thrasher A, Sarner M, Cohen SL. Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse. Lancet. 1992;339(8794):677-678.
Not in our library10.1016/0140-6736(92)90834-p
519.
Seaton DA, Duncan LJ, Rose K, Scott AM. Diethyl-propion in the treatment of “refractory” obesity. Br Med J. 1961;1(5231):1009-1011.
Not in our library10.1136/bmj.1.5231.1009
520.
Seetohul LN, Pounder DJ. Four fatalities involving 5-IT. J Anal Toxicol. 2013;37(7):447-451.
Not in our library10.1093/jat/bkt053
521.
Seither JZ, Reidy LJ, Boland DM. Identification and quantification of 5-fluoro ADB and the 5-fluoro ADB ester hydrolysis metabolite in postmortem blood samples by LC–MS/MS. J Anal Toxicol. 2019.
Not in our library10.1093/jat/bkz043
522.
Sellors K, Jones A, Chan B. Death due to intravenous use of α-pyrrolidinopentiophenone. Med J Aust. 2014;201(10):601-603.
Not in our library10.5694/mja13.00203
523.
Seo JY, Hur KH, Ko YH, Kim K, Lee BR, Kim YJ, Kim SK, Kim SE, Lee YS, Kim HC, Lee SY, Jang CG. A novel designer drug, 25N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents. Brain Res Bull. 2019;152:19-26.
Not in our library10.1016/j.brainresbull.2019.07.002
524.
Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants — United States, 2015–2016 · 2018
No notice
525.
Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol. 2003;63(6):1223-1229.
Not in our library10.1124/mol.63.6.1223
526.
Shah M, Garg J, Patel B, Guthier J, Freudenberger RS. Can your heart handle the spice: a case of acute myocardial infarction and left ventricular apical thrombus. Int J Cardiol. 2016;215:129-131.
Not in our library10.1016/j.ijcard.2016.04.055
527.
Shahbaz A, Gaviria REE, Shahid MF, Yasin MA, Ashraf A, Zaman MA. Acute liver injury induced by synthetic cannabinoid abuse. Cureus. 2018;10(9):e3257-e3257.
Not in our library10.7759/cureus.3257
528.
Shanks KG, Behonick GS. Death after use of the synthetic cannabinoid 5F-AMB. Forensic Sci Int. 2016;262:e21-e24.
Not in our library10.1016/j.forsciint.2016.03.004
529.
Shanks KG, Dahn T, Terrell AR. Detection of JWH-018 and JWH-073 by UPLC–MS–MS in postmortem whole blood casework. J Anal Toxicol. 2012;36(3):145-152.
Not in our library10.1093/jat/bks013
530.
Shanks KG, Sozio T, Behonick GS. Fatal intoxications with 25B-NBOMe and 25I-NBOMe in Indiana during 2014. J Anal Toxicol. 2015;39(8):602-606.
Not in our library10.1093/jat/bkv058
531.
Shanks KG, Winston D, Heidingsfelder J, Behonick G. Case reports of synthetic cannabinoid XLR-11 associated fatalities. Forensic Sci Int. 2015;252:e6-9.
Not in our library10.1016/j.forsciint.2015.04.021
532.
Shanks KG, Clark W, Behonick G. Death associated with the use of the synthetic cannabinoid ADB-FUBINACA. J Anal Toxicol. 2016;40(3):236-239.
Not in our library10.1093/jat/bkv142
533.
Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014;48(2):209-225.
Not in our library10.1177/1060028013510699
534.
Shearer K, Bryce C, Parsons M, Torrance H. Phenazepam: a review of medico-legal deaths in South Scotland between 2010 and 2014. Forensic Sci Int. 2015;254:197-204.
Not in our library10.1016/j.forsciint.2015.07.033
535.
Sheridan J, Butler R, Wilkins C, Russell B. Legal piperazine-containing party pills—a new trend in substance misuse. Drug Alcohol Rev. 2007;26(3):335-343.
Not in our library10.1080/09595230701255791
536.
Sherpa D, Paudel BM, Subedi BH, Chow RD. Synthetic cannabinoids: the multi-organ failure and metabolic derangements associated with getting high. J Community Hosp Intern Med Perspect. 2015;5(4):27540.
Not in our library10.3402/jchimp.v5.27540
537.
Shields JE, Dargan PI, Wood DM, Puchnarewicz M, Davies S, Waring WS. Methoxetamine associated reversible cerebellar toxicity: three cases with analytical confirmation. Clin Toxicol (Phila). 2012;50(5):438-440.
Not in our library10.3109/15563650.2012.683437
538.
Shoff EN, Kahl JH, Hime GW, Coburn M, Boland DM. 4-Fluoromethylphenidate: fatal intoxication involving a previously unreported novel psychoactive substance in the USA. J Anal Toxicol. 2019;43(8):666-672.
Not in our library10.1093/jat/bkz061
539.
Shulgin A, Shulgin A. PIHKAL: a chemical love story. 1995.
Not in our library
540.
Shulgin A, Shulgin A. TIHKAL: the continuation. 1997.
Not in our library
541.
Siddiqi S, Verney C, Dargan P, Wood DM. Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45. Clin Toxicol (Phila). 2015;53(1):54-59.
Not in our library10.3109/15563650.2014.983239
542.
Silva JP, Carmo H, Carvalho F. The synthetic cannabinoid XLR-11 induces in vitro nephrotoxicity by impairment of endocannabinoid-mediated regulation of mitochondrial function homeostasis and triggering of apoptosis. Toxicol Lett. 2018;287:59-69.
Not in our library10.1016/j.toxlet.2018.01.023
543.
Silva JP, Araújo AM, De Pinho PG, Carmo H, Carvalho F. Synthetic cannabinoids JWH-122 and THJ-2201 disrupt endocannabinoid-regulated mitochondrial function and activate apoptotic pathways as a primary mechanism of in vitro nephrotoxicity at in vivo relevant concentrations. Toxicol Sci. 2019;169(2):422-435.
Not in our library10.1093/toxsci/kfz050
544.
Simmler LD, Hysek CM, Liechti ME. Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects. J Clin Endocrinol Metab. 2011;96(9):2844-2850.
Not in our library10.1210/jc.2011-1143
545.
Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2013;168(2):458-470.
Not in our library10.1111/j.1476-5381.2012.02145.x
546.
Simmler LD, Rickli A, Hoener MC, Liechti ME. Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology. 2014;79:152-160.
Not in our library10.1016/j.neuropharm.2013.11.008
547.
Simmler LD, Rickli A, Schramm Y, Hoener MC, Liechti ME. Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochem Pharmacol. 2014;88(2):237-244.
Not in our library10.1016/j.bcp.2014.01.024
548.
Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME. In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1. J Pharmacol Exp Ther. 2016;357(1):134-144.
Not in our library10.1124/jpet.115.229765
549.
Sitte HH, Freissmuth M. Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015;36(1):41-50.
Not in our library10.1016/j.tips.2014.11.006
550.
Sklerov J, Levine B, Moore KA, King T, Fowler D. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J Anal Toxicol. 2005;29(8):838-841.
Not in our library10.1093/jat/29.8.838
551.
Skryabin VY, Vinnikova MA. Clinical characteristics of synthetic cannabinoid-induced psychotic disorders: a single-center analysis of hospitalized patients. J Addict Dis. 2019;1:1-7.
Not in our library10.1080/10550887.2019.1627635
552.
Skryabin VY, Vinnikova M, Nenastieva A, Alekseyuk V. Hallucinogen persisting perception disorder: a literature review and three case reports. J Addict Dis. 2019;1:1-11.
Not in our library10.1080/10550887.2019.1673655
553.
Smith DL, Roberts C. Synthetic marijuana use and development of catatonia in a 17-year-old male. Minn Med. 2014;97(5):38.
Not in our library
554.
Smolinske SC, Rastogi R, Schenkel S. Foxy methoxy: a new drug of abuse. J Med Toxicol. 2005;1(1):22-25.
Not in our library10.1007/bf03160901
555.
Sofalvi S, Schueler HE, Lavins ES, Kaspar CK, Brooker IT, Mazzola CD, Dolinak D, Gilson TP, Perch S. An LC–MS-MS method for the analysis of carfentanil, 3-methylfentanyl, 2-furanyl fentanyl, acetyl fentanyl, fentanyl and norfentanyl in postmortem and impaired-driving cases. J Anal Toxicol. 2017;41(6):473-483.
Not in our library10.1093/jat/bkx052
556.
Solomons E, Sam J. 2-Aminoindans of pharmacological interest. J Med Chem. 1973;16(12):1330-1333.
Not in our library10.1021/jm00270a004
557.
Soroko FE, Mehta NB, Maxwell RA, Ferris RM, Schroeder DH. Bupropion hydrochloride ((±) α-t-butylamino-3-chloropropiophenone HCl): a novel antidepressant agent. J Pharm Pharmacol. 1977;29(12):767-770.
Not in our library10.1111/j.2042-7158.1977.tb11460.x
558.
Srisuma S, Bronstein AC, Hoyte CO. NBOMe and 2C substitute phenylethylamine exposures reported to the National Poison Data System. Clin Toxicol (Phila). 2015;53(7):624-628.
Not in our library10.3109/15563650.2015.1054502
559.
Srisung W, Jamal F, Prabhakar S. Synthetic cannabinoids and acute kidney injury. Proc (Bayl Univ Med Cent). 2015;28(4):475-477.
Not in our library10.1080/08998280.2015.11929313
560.
Staeheli SN, Baumgartner MR, Gauthier S, Gascho D, Jarmer J, Kraemer T, Steuer AE. Time-dependent postmortem redistribution of butyrfentanyl and its metabolites in blood and alternative matrices in a case of butyrfentanyl intoxication. Forensic Sci Int. 2016;266:170-177.
Not in our library10.1016/j.forsciint.2016.05.034
561.
Stanley TH. The fentanyl story. J Pain. 2014;15(12):1215-1226.
Not in our library10.1016/j.jpain.2014.08.010
562.
Stellpflug SJ, Kealey SE, Hegarty CB, Janis GC. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing. J Med Toxicol. 2014;10(1):45-50.
Not in our library10.1007/s13181-013-0314-y
563.
Sternbach LH. The benzodiazepine story. J Med Chem. 1979;22(1):1-7.
Not in our library10.1021/jm00187a001
564.
Stoller A, Dolder PC, Bodmer M, Hammann F, Rentsch KM, Exadaktylos AK, Liechti ME, Liakoni E. Mistaking 2C-P for 2C-B: what a difference a letter makes. J Anal Toxicol. 2017;41(1):77-79.
Not in our library10.1093/jat/bkw108
565.
Suyama JA, Banks ML, Negus SS. Effects of repeated treatment with methcathinone, mephedrone, and fenfluramine on intracranial self-stimulation in rats. Psychopharmacology. 2019;236(3):1057-1066.
Not in our library10.1007/s00213-018-5029-y
566.
Suzuki J, El-Haddad S. A review: fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend. 2017;171:107-116.
Not in our library10.1016/j.drugalcdep.2016.11.033
567.
Swanson DM, Hair LS, Strauch Rivers SR, Smyth BC, Brogan SC, Ventoso AD, Vaccaro SL, Pearson JM. Fatalities involving carfentanil and furanyl fentanyl: two case reports. J Anal Toxicol. 2017;41(6):498-502.
Not in our library10.1093/jat/bkx037
568.
Sweeney B, Talebi S, Toro D, Gonzalez K, Menoscal JP, Shaw R, Hassen GW. Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids. Am J Emerg Med. 2016;34(1):121.e1-2.
Not in our library10.1016/j.ajem.2015.05.052
569.
Sweet G, Kim S, Martin S, Washington NB, Brahm N. Psychiatric symptoms and synthetic cannabinoid use: information for clinicians. Ment Health Clin. 2017;7(4):156-159.
Not in our library10.9740/mhc.2017.07.156
570.
Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila). 2016;54(1):1-13.
Not in our library10.3109/15563650.2015.1110590
571.
Takase I, Koizumi T, Fujimoto I, Yanai A, Fujimiya T. An autopsy case of acetyl fentanyl intoxication caused by insufflation of 'designer drugs'. Leg Med (Tokyo). 2016;21:38-44.
Not in our library10.1016/j.legalmed.2016.05.006
572.
Takematsu M, Hoffman RS, Nelson LS, Schechter JM, Moran JH, Wiener SW. A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid. Clin Toxicol (Phila). 2014;52(9):973-975.
Not in our library10.3109/15563650.2014.958614
573.
Taljemark J, Johansson BA. Drug-induced acute psychosis in an adolescent first-time user of 4-HO-MET. Eur Child Adolesc Psychiatry. 2012;21(9):527-528.
Not in our library10.1007/s00787-012-0282-9
574.
Tanaka E, Kamata T, Katagi M, Tsuchihashi H, Honda K. A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine. Foxy Forensic Sci Int. 2006;163(1–2):152-154.
Not in our library10.1016/j.forsciint.2005.11.026
575.
Tanaka N, Kinoshita H, Jamal M, Ohkubo E, Kumihashi M, Ameno K. A case of drowning whilst under the influence of brotizolam, flunitrazepam and ethanol. Soud Lek. 2011;56(1):5-6.
Not in our library
576.
Tanaka N, Kinoshita H, Nishiguchi M, Jamal M, Kumihashi M, Takahashi M, Nishio H, Ameno K. An autopsy case of multiple psychotropic drug poisoning. Soud Lek. 2011;56(3):38-39.
Not in our library
577.
Tang MH, Ching CK, Tsui MS, Chu FK, Mak TW. Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe. Clin Toxicol (Phila). 2014;52(5):561-565.
Not in our library10.3109/15563650.2014.909932
578.
Thirakul P, Hair LS, Bergen KL, Pearson JM. Clinical presentation, autopsy results and toxicology findings in an acute N-ethylpentylone fatality. J Anal Toxicol. 2017;41(4):342-346.
Not in our library10.1093/jat/bkx004
579.
Thomas S, Bliss S, Malik M. Suicidal ideation and self-harm following K2 use. J Okla State Med Assoc. 2012;105(11):430-433.
Not in our library
580.
Thorlacius K, Borna C, Personne M (2008) Bromo-dragonfly–livsfarlig missbruksdrog. Kan ge vävnadsnekros, visar det första beskrivna fallet. Lakartidningen 105(16):1199–200
Not in our library
581.
Thornton SL, Wood C, Friesen MW, Gerona RR. Synthetic cannabinoid use associated with acute kidney injury. Clin Toxicol (Phila). 2013;51(3):189-190.
Not in our library10.3109/15563650.2013.770870
582.
Thornton S, Lisbon D, Lin T, Gerona R. Beyond ketamine and phencyclidine: analytically confirmed use of multiple novel arylcyclohexylamines. J Psychoactive Drugs. 2017;49(4):289-293.
Not in our library10.1080/02791072.2017.1333660
583.
Tofighi B, Lee JD. Internet highs–seizures after consumption of synthetic cannabinoids purchased online. J Addict Med. 2012;6(3):240-241.
Not in our library10.1097/adm.0b013e3182619004
584.
Topeff J, Ellsworth H, Willhite L, Bangh S, Edwards E, Cole J. A case series of symptomatic patients, including one fatality, following 2C-E exposure. Clin Toxicol (Phila). 2011;49:526.
Not in our library
585.
Trachsel D, Lehmann D, Enzensperger C. Phenethylamine: von der Struktur zur Funktion. 2013.
Not in our library
586.
Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid-related illnesses and deaths. N Engl J Med. 2015;373(2):103-107.
Not in our library10.1056/nejmp1505328
587.
Troxler F, Hofmann A. Substitutionen am Ringsystem der Lysergsäure. I Substitutionen am Indol-Stickstoff. 43. Mitteilung über Mutterkornalkaloide. Helv Chim Acta. 1957;40(6):1706-1720.
Not in our library10.1002/hlca.19570400619
588.
Tsai TH, Cha TL, Lin CM, Tsao CW, Tang SH, Chuang FP, Wu ST, Sun GH, Yu DS, Chang SY. Ketamine-associated bladder dysfunction. Int J Urol. 2009;16(10):826-829.
Not in our library10.1111/j.1442-2042.2009.02361.x
589.
Tse R, Kodur S, Squires B, Collins N. Sudden cardiac death complicating acute myocardial infarction following synthetic cannabinoid use. Intern Med J. 2014;44(9):934-936.
Not in our library10.1111/imj.12521
590.
Tyndall JA, Gerona R, De Portu G, Trecki J, Elie MC, Lucas J, Slish J, Rand K, Bazydlo L, Holder M, Ryan MF, Myers P, Iovine N, Plourde M, Weeks E, Hanley JR, Endres G, St Germaine D, Dobrowolski PJ, Schwartz M. An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA. Clin Toxicol (Phila). 2015;53(10):950-956.
Not in our library10.3109/15563650.2015.1100306
591.
Ukaigwe A, Karmacharya P, Donato A. A gut gone to pot: a case of cannabinoid hyperemesis syndrome due to K2, a synthetic cannabinoid. Case Rep Emerg Med. 2014;2014:167098.
Not in our library10.1155/2014/167098
592.
Umebachi R, Aoki H, Sugita M, Taira T, Wakai S, Saito T, Inokuchi S. Clinical characteristics of α-pyrrolidinovalerophenone (α-PVP) poisoning. Clin Toxicol (Phila). 2016;54(7):563-567.
Not in our library10.3109/15563650.2016.1166508
593.
Usui K, Fujita Y, Kamijo Y, Kokaji T, Funayama M. Identification of 5-fluoro ADB in human whole blood in four death cases. J Anal Toxicol. 2018;42(2):e21-e25.
Not in our library10.1093/jat/bkx088
594.
Valente MJ, Guedes de Pinho P, De Lourdes BM, Carvalho F, Carvalho M. Khat and synthetic cathinones: a review. Arch Toxicol. 2014;88(1):15-45.
Not in our library10.1007/s00204-013-1163-9
595.
Valente MJ, Aráujo AM, Bastos Mde L, Fernandes E, Carvalho F, Guedes de Pinho P, Carvalho M. characterization of hepatotoxicity mechanisms triggered by designer cathinone drugs (β-keto amphetamines). Toxicol Sci. 2016;153(1):89-102.
Not in our library10.1093/toxsci/kfw105
596.
Valente MJ, Aráujo AM, Silva R, Bastos Mde L, Carvalho F, Guedes de Pinho P, Carvalho M. 3,4-Methylenedioxypyrovalerone (MDPV): in vitro mechanisms of hepatotoxicity under normothermic and hyperthermic conditions. Arch Toxicol. 2016;90(8):1959-1973.
Not in our library10.1007/s00204-015-1653-z
597.
Valente MJ, Amaral C, Correia-da-Silva G, Duarte JA, Bastos ML, Carvalho F, Guedes de Pinho P, Carvalho M. Methylone and MDPV activate autophagy in human dopaminergic SH-SY5Y cells: a new insight into the context of β-keto amphetamines-related neurotoxicity. Arch Toxicol. 2017;91(11):3663-3676.
Not in our library10.1007/s00204-017-1984-z
598.
Valente MJ, Bastos ML, Fernandes E, Carvalho F, Guedes de Pinho P, Carvalho M. Neurotoxicity of β-keto amphetamines: deathly mechanisms elicited by methylone and MDPV in human dopaminergic SH-SY5Y cells. ACS Chem Neurosci. 2017;8(4):850-859.
Not in our library10.1021/acschemneuro.6b00421
599.
Van Amsterdam J, Brunt T, Van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol. 2015;29(3):254-263.
Not in our library10.1177/0269881114565142
600.
Van Dijken GD, Blom RE, Hene RJ, Boer WH, Consortium N. High incidence of mild hyponatraemia in females using ecstasy at a rave party. Nephrol Dial Transplant. 2013;28(9):2277-2283.
Not in our library10.1093/ndt/gft023
601.
Vanden Eede H, Montenij LJ, Touw DJ, Norris EM. Rhabdomyolysis in MDMA intoxication: a rapid and underestimated killer. “Clean" ecstasy, a safe party drug? J Emerg Med. 2012;42(6):655-658.
Not in our library10.1016/j.jemermed.2009.04.057
602.
Vandewater SA, Creehan KM, Taffe MA. Intravenous self-administration of entactogen-class stimulants in male rats. Neuropharmacology. 2015;99:538-545.
Not in our library10.1016/j.neuropharm.2015.08.030
603.
Van der Veer N, Friday J. Persistent psychosis following the use of Spice. Schizophr Res. 2011;130(1–3):285-286.
Not in our library10.1016/j.schres.2011.04.022
604.
Venhuis BJ, Blok-Tip L, De Kaste D. Designer drugs in herbal aphrodisiacs. Forensic Sci Int. 2008;177(2–3):e25-e27.
Not in our library10.1016/j.forsciint.2007.11.007
605.
Vizeli P, Liechti ME. Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol. 2017;31(5):576-588.
Not in our library10.1177/0269881117691569
606.
Vogel M, Knöpfli B, Schmid O, Prica M, Strasser J, Prieto L, Wiesbeck GA, Dursteler-Macfarland KM. Treatment or "high": benzodiazepine use in patients on injectable heroin or oral opioids. Addict Behav. 2013;38(10):2477-2484.
Not in our library10.1016/j.addbeh.2013.05.008
607.
Vogel M, Bucher P, Strasser J, Liechti ME, Krähenbühl S, Dürsteler KM. Similar and different? Subjective effects of methylphenidate and cocaine in opioid-maintained patients. J Psychoactive Drugs. 2016;48(2):93-100.
Not in our library10.1080/02791072.2015.1130883
608.
Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport. 1998;9(17):3897-3902.
Not in our library10.1097/00001756-199812010-00024
609.
Volz TJ, Hanson GR, Fleckenstein AE. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits. J Neurochem. 2007;101(4):883-888.
Not in our library10.1111/j.1471-4159.2006.04419.x
610.
Vorce SP, Knittel JL, Holler JM, Magluilo J, Levine B, Berran P, Bosy TZ. A fatality involving AH-7921. J Anal Toxicol. 2014;38(4):226-230.
Not in our library10.1093/jat/bku011
611.
Wagmann L, Brandt SD, Stratford A, Maurer HH, Meyer MR. Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases. Drug Test Anal. 2019;11(2):318-324.
Not in our library10.1002/dta.2494
612.
Wagmann L, Richter LHJ, Kehl T, Wack F, Bergstrand MP, Brandt SD, Stratford A, Maurer HH, Meyer MR. In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. Anal Bioanal Chem. 2019;411(19):4751-4763.
Not in our library10.1007/s00216-018-1558-9
613.
Wallach J, Brandt SD. 1,2-diarylethylamine- and ketamine-based new psychoactive substances. Handb Exp Pharmacol. 2018;252:305-352.
Not in our library10.1007/164_2018_148
614.
Wallach J, Brandt SD. Phencyclidine-based new psychoactive substances. Handb Exp Pharmacol. 2018;252:261-303.
Not in our library10.1007/164_2018_124
615.
Wallach J, Kang H, Colestock T, Morris H, Bortolotto ZA, Collingridge GL, Lodge D, Halberstadt AL, Brandt SD, Adejare A. Pharmacological investigations of the dissociative ‘legal highs' diphenidine, methoxphenidine and analogues. PLoS ONE. 2016;11(6):e0157021.
Not in our library10.1371/journal.pone.0157021
616.
Walterscheid JP, Phillips GT, Lopez AE, Gonsoulin ML, Chen HH, Sanchez LA. Pathological findings in 2 cases of fatal 25I-NBOMe toxicity. Am J Forensic Med Pathol. 2014;35(1):20-25.
Not in our library10.1097/paf.0000000000000082
617.
Wang Q, Wu Q, Wang J, Chen Y, Zhang G, Chen J, Zhao J, Wu P. Ketamine analog methoxetamine induced inflammation and dysfunction of bladder in rats. Int J Mol Sci. 2017;18(1):1.
Not in our library10.3390/ijms18010117
618.
Ward J, Rhyee S, Plansky J, Boyer E. Methoxetamine: a novel ketamine analog and growing health-care concern. Clin Toxicol (Phila). 2011;49(9):874-875.
Not in our library10.3109/15563650.2011.617310
619.
Waters L, Manchester KR, Maskell PD, Haegeman C, Haider S. The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines. Sci Justice. 2018;58(3):219-225.
Not in our library10.1016/j.scijus.2017.12.004
620.
Weber C, Krug O, Kamber M, Thevis M. Qualitative and semiquantitative analysis of doping products seized at the Swiss border. Subst Use Misuse. 2017;52(6):742-753.
Not in our library10.1080/10826084.2016.1263665
621.
Wee S, Woolverton WL. Self-administration of mixtures of fenfluramine and amphetamine by rhesus monkeys. Pharmacol Biochem Behav. 2006;84(2):337-343.
Not in our library10.1016/j.pbb.2006.05.022
622.
Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL. Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther. 2005;313(2):848-854.
Not in our library10.1124/jpet.104.080101
623.
Welter S, Lücke C, Lam AP, Custal C, Moeller S, Sörös P, Thiel CM, Philipsen A, Müller HHO. Synthetic cannabinoid use in a psychiatric patient population: a pilot study. Eur Addict Res. 2017;23(4):182-193.
Not in our library10.1159/000479554
624.
Westin AA, Frost J, Brede WR, Gundersen PO, Einvik S, Aarset H, Slordal L. Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA. J Anal Toxicol. 2016;40(1):86-87.
Not in our library10.1093/jat/bkv110
625.
White JC, Wood DM, Hill SL, Eddleston M, Officer J, Dargan PI, Dunn M, Thomas SHL. Acute toxicity following analytically confirmed use of the novel psychoactive substance (NPS) methiopropamine. A report from the Identification of Novel psychoActive substances (IONA) study. Clin Toxicol (Phila). 2019;57(7):663-667.
Not in our library10.1080/15563650.2018.1538519
626.
Wiergowski M, Anand JS, Krzyzanowski M, Jankowski Z. Acute methoxetamine and amphetamine poisoning with fatal outcome: a case report. Int J Occup Med Environ Health. 2014;27(4):683-690.
Not in our library10.2478/s13382-014-0290-8
627.
Wijers CH, Van Litsenburg RT, Hondebrink L, Niesink RJ, Croes EA. Acute toxic effects related to 4-fluoroamphetamine. Lancet. 2017;389(10069):600.
Not in our library10.1016/s0140-6736(17)30281-7
628.
Wikström M, Thelander G, Dahlgren M, Kronstrand R. An accidental fatal intoxication with methoxetamine. J Anal Toxicol. 2013;37(1):43-46.
Not in our library10.1093/jat/bks086
629.
Wilde M, Sommer MJ, Auwärter V, Hermanns-Clausen M. Acute severe intoxication with cyclopropylfentanyl, a novel synthetic opioid. Toxicol Lett. 2020;320:109-112.
Not in our library10.1016/j.toxlet.2019.11.025
630.
Wiley JL, Lefever TW, Marusich JA, Grabenauer M, Moore KN, Huffman JW, Thomas BF. Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice. Neuropharmacology. 2016;110(Pt A):143-153.
Not in our library10.1016/j.neuropharm.2016.07.016
631.
Wilkins C, Sweetsur P, Girling M. Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand. Drug Alcohol Rev. 2008;27(6):633-639.
Not in our library10.1080/09595230801956140
632.
Winstock AR, Barratt MJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend. 2013;131(1–2):106-111.
Not in our library10.1016/j.drugalcdep.2012.12.011
633.
Winter JC, Filipink RA, Timineri D, Helsley SE, Rabin RA. The paradox of 5-methoxy-N, N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors. Pharmacol Biochem Behav. 2000;65(1):75-82.
Not in our library10.1016/s0091-3057(99)00178-1
634.
Wolff V, Jouanjus E. Strokes are possible complications of cannabinoids use. Epilepsy Behav. 2017;70(Pt B):355-363.
Not in our library10.1016/j.yebeh.2017.01.031
635.
Wood DM, Button J, Lidder S, Ramsey J, Holt DW, Dargan PI. Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP). J Med Toxicol. 2008;4(4):254-257.
Not in our library10.1007/bf03161209
636.
Wood DM, Looker JJ, Shaikh L, Button J, Puchnarewicz M, Davies S, Lidder S, Ramsey J, Holt DW, Dargan PI. Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragonFLY. J Med Toxicol. 2009;5(4):226-229.
Not in our library10.1007/bf03178273
637.
Wood DM, Davies S, Greene SL, Button J, Holt DW, Ramsey J, Dargan PI. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol (Phila). 2010;48(9):924-927.
Not in our library10.3109/15563650.2010.531021
638.
Wood DM, Brailsford AD, Dargan PI. Acute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD). Drug Test Anal. 2011;3(7–8):417-425.
Not in our library10.1002/dta.292
639.
Wood DM, Davies S, Puchnarewicz M, Johnston A, Dargan PI. Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur J Clin Pharmacol. 2012;68(5):853-856.
Not in our library10.1007/s00228-011-1199-9
640.
Wood DM, Sedefov R, Cunningham A, Dargan PI. Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin Toxicol (Phila). 2015;53(2):85-92.
Not in our library10.3109/15563650.2015.1004179
641.
Wright TH, Cline-Parhamovich K, Lajoie D, Parsons L, Dunn M, Ferslew KE. Deaths involving methylenedioxypyrovalerone (MDPV) in Upper East Tennessee. J Forensic Sci. 2013;58(6):1558-1562.
Not in our library10.1111/1556-4029.12260
642.
Wyman JF, Lavins ES, Engelhart D, Armstrong EJ, Snell KD, Boggs PD, Taylor SM, Norris RN, Miller FP. Postmortem tissue distribution of MDPV following lethal intoxication by "bath salts". J Anal Toxicol. 2013;37(3):182-185.
Not in our library10.1093/jat/bkt001
643.
Yazici AB, Yazici E, Erol A. Delirium and high creatine kinase and myoglobin levels related to synthetic cannabinoid withdrawal. Case Rep Med. 2017;2017:3894749.
Not in our library10.1155/2017/3894749
644.
Yeruva RR, Mekala HM, Sidhu M, Lippmann S. Synthetic cannabinoids–“Spice" can induce a psychosis: a brief review. Innov Clin Neurosci. 2019;16(1–2):31-32.
Not in our library
645.
Yirgin G, Ates I, Katipoglu B, Demir BF, Yilmaz N. Pulmonary embolism due to synthetic cannabinoid use: case report. Turk Kardiyol Dern Ars. 2018;46(5):411-413.
Not in our library10.5543/tkda.2018.84425
646.
Yonemitsu K, Sasao A, Mishima S, Ohtsu Y, Nishitani Y. A fatal poisoning case by intravenous injection of "bath salts" containing acetyl fentanyl and 4-methoxy PV8. Forensic Sci Int. 2016;267:e6-e9.
Not in our library10.1016/j.forsciint.2016.08.025
647.
Young AC, Schwarz E, Medina G, Obafemi A, Feng SY, Kane C, Kleinschmidt K. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med. 2012;30(7):1320.e5-7.
Not in our library10.1016/j.ajem.2011.05.013
648.
Zaami S, Giorgetti R, Pichini S, Pantano F, Marinelli E, Busardo FP. Synthetic cathinones related fatalities: an update. Eur Rev Med Pharmacol Sci. 2018;22(1):268-274.
Not in our library10.26355/eurrev_201801_14129
649.
Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23(4):801-811.
Not in our library10.1038/mp.2017.255
650.
Zarifi C, Vyas S. Spice-y kidney failure: a case report and systematic review of acute kidney injury attributable to the use of synthetic cannabis. Perm J. 2017.
Not in our library10.7812/tpp/16-160
651.
Zawilska JB. Methoxetamine—a novel recreational drug with potent hallucinogenic properties. Toxicol Lett. 2014;230(3):402-407.
Not in our library10.1016/j.toxlet.2014.08.011
652.
Zawilska JB, Wojcieszak J. An expanding world of new psychoactive substances-designer benzodiazepines. Neurotoxicology. 2019;73:8-16.
Not in our library10.1016/j.neuro.2019.02.015
653.
Zhao A, Tan M, Maung A, Salifu M, Mallappallil M. Rhabdomyolysis and acute kidney injury requiring dialysis as a result of concomitant use of atypical neuroleptics and synthetic cannabinoids. Case Rep Nephrol. 2015;2015:235982.
Not in our library10.1155/2015/235982
654.
Zhou X, Luethi D, Sanvee GM, Bouitbir J, Liechti ME, Krähenbühl S. Molecular toxicological mechanisms of synthetic cathinones on C2C12 myoblasts. Int J Mol Sci. 2019;20(7):1.
Not in our library10.3390/ijms20071561
655.
Zidkova M, Hlozek T, Balik M, Kopecky O, Tesinsky P, Svanda J, Balikova MA. Two cases of non-fatal intoxication with a novel street hallucinogen: 3-methoxy-phencyclidine. J Anal Toxicol. 2017;41(4):350-354.
Not in our library10.1093/jat/bkx009
656.
Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch Arztebl Int. 2009;106(27):464-467.
Not in our library10.3238/arztebl.2009.0464
657.
Zvosec DL, Smith SW. Agitation is common in γ-hydroxybutyrate toxicity. Am J Emerg Med. 2005;23(3):316-320.
Not in our library10.1016/j.ajem.2005.02.003
658.
Zvosec DL, Smith SW, Porrata T, Strobl AQ, Dyer JE. Case series of 226 γ-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am J Emerg Med. 2011;29(3):319-332.
Not in our library10.1016/j.ajem.2009.11.008

Cited by papers we hold 2

Association of designer drug use and sudden cardiac death: a systematic review · 2025
Not checked
Etazene induces developmental toxicity in vivo Danio rerio and in silico studies of new synthetic opioid derivative · 2021
Not checked

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.